<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vaccines for preventing herpes zoster in older adults - de Oliveira Gomes, J - 2023 | Cochrane Library</title> <meta content="Vaccines for preventing herpes zoster in older adults - de Oliveira Gomes, J - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008858.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vaccines for preventing herpes zoster in older adults - de Oliveira Gomes, J - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008858.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008858.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Vaccines for preventing herpes zoster in older adults" name="citation_title"/> <meta content="Juliana de Oliveira Gomes" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="jumed34@yahoo.com.br" name="citation_author_email"/> <meta content="Anna MZ Gagliardi" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Brenda NG Andriolo" name="citation_author"/> <meta content="Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde" name="citation_author_institution"/> <meta content="Maria Regina Torloni" name="citation_author"/> <meta content="Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde" name="citation_author_institution"/> <meta content="Regis B Andriolo" name="citation_author"/> <meta content="Universidade do Estado do Pará" name="citation_author_institution"/> <meta content="Maria Eduarda dos Santos Puga" name="citation_author"/> <meta content="Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde" name="citation_author_institution"/> <meta content="Eduardo Canteiro Cruz" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD008858.pub5" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/10/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008858.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008858.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008858.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Chickenpox [chemically induced, drug therapy]; *Herpes Zoster [chemically induced, drug therapy, prevention &amp; control]; *Herpes Zoster Vaccine [adverse effects]; Herpesvirus 3, Human; Vaccines, Attenuated [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008858.pub5&amp;doi=10.1002/14651858.CD008858.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008858\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008858\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","pt","ko","ms","hr","fr","zh_HANS","zh_HANT","th","ja","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008858.pub5",title:"Vaccines for preventing herpes zoster in older adults",firstPublishedDate:"Oct 2, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008858.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008858.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008858.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008858.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008858.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008858.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008858.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008858.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008858.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008858.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6022 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008858.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-sec-0076"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/appendices#CD008858-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/supinfo/CD008858-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/supinfo/CD008858-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vaccines for preventing herpes zoster in older adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information#CD008858-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Juliana de Oliveira Gomes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information#CD008858-cr-0005">Anna MZ Gagliardi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information#CD008858-cr-0006">Brenda NG Andriolo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information#CD008858-cr-0007">Maria Regina Torloni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information#CD008858-cr-0008">Regis B Andriolo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information#CD008858-cr-0009">Maria Eduarda dos Santos Puga</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information#CD008858-cr-0010">Eduardo Canteiro Cruz</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information/en#CD008858-sec-0102">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 October 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008858.pub5">https://doi.org/10.1002/14651858.CD008858.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008858-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008858-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008858-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008858-abs-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008858-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008858-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008858-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD008858-abs-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008858-abs-0015">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008858-abs-0001" lang="en"> <section id="CD008858-sec-0001"> <h3 class="title" id="CD008858-sec-0001">Background</h3> <p>Herpes zoster, commonly known as shingles, is a neurocutaneous disease caused by the reactivation of the virus that causes varicella (chickenpox). After resolution of the varicella episode, the virus can remain latent in the sensitive dorsal ganglia of the spine. Years later, with declining immunity, the varicella zoster virus (VZV) can reactivate and cause herpes zoster, an extremely painful condition that can last many weeks or months and significantly compromise the quality of life of the affected person. The natural process of ageing is associated with a reduction in cellular immunity, and this predisposes older adults to herpes zoster. Vaccination with an attenuated form of the VZV activates specific T‐cell production avoiding viral reactivation. Two types of herpes zoster vaccines are currently available. One of them is the single‐dose live attenuated zoster vaccine (LZV), which contains the same live attenuated virus used in the chickenpox vaccine, but it has over 14‐fold more plaque‐forming units of the attenuated virus per dose. The other is the recombinant zoster vaccine (RZV) which does not contain the live attenuated virus, but rather a small fraction of the virus that cannot replicate but can boost immunogenicity. The recommended schedule for the RZV is two doses two months apart. </p> <p>This is an update of a Cochrane Review first published in 2010, and updated in 2012, 2016, and 2019. </p> </section> <section id="CD008858-sec-0002"> <h3 class="title" id="CD008858-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of vaccination for preventing herpes zoster in older adults. </p> </section> <section id="CD008858-sec-0003"> <h3 class="title" id="CD008858-sec-0003">Search methods</h3> <p>For this 2022 update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2022, Issue 10), MEDLINE (1948 to October 2022), Embase (2010 to October 2022), CINAHL (1981 to October 2022), LILACS (1982 to October 2022), and three trial registries. </p> </section> <section id="CD008858-sec-0004"> <h3 class="title" id="CD008858-sec-0004">Selection criteria</h3> <p>We included studies involving healthy older adults (mean age 60 years or older). We included randomised controlled trials (RCTs) or quasi‐RCTs comparing zoster vaccine (any dose and potency) versus any other type of intervention (e.g. varicella vaccine, antiviral medication), placebo, or no intervention (no vaccine). Outcomes were cumulative incidence of herpes zoster, adverse events (death, serious adverse events, systemic reactions, or local reaction occurring at any time after vaccination), and dropouts. </p> </section> <section id="CD008858-sec-0005"> <h3 class="title" id="CD008858-sec-0005">Data collection and analysis</h3> <p>We used the standard methodological procedures expected by Cochrane.</p> </section> <section id="CD008858-sec-0006"> <h3 class="title" id="CD008858-sec-0006">Main results</h3> <p>We included two new studies involving 1736 participants in this update. The review now includes a total of 26 studies involving 90,259 healthy older adults with a mean age of 63.7 years. Only three studies assessed the cumulative incidence of herpes zoster in groups that received vaccines versus placebo. Most studies were conducted in high‐income countries in Europe and North America and included healthy Caucasians (understood to be white participants) aged 60 years or over with no immunosuppressive comorbidities. Two studies were conducted in Japan and one study was conducted in the Republic of Korea. Sixteen studies used LZV. Ten studies tested an RZV. </p> <p>The overall certainty of the evidence was moderate, which indicates that the intervention probably works. Most data for the primary outcome (cumulative incidence of herpes zoster) and secondary outcomes (adverse events and dropouts) came from studies that had a low risk of bias and included a large number of participants. </p> <p>The cumulative incidence of herpes zoster at up to three years of follow‐up was lower in participants who received the LZV (one dose subcutaneously) than in those who received placebo (risk ratio (RR) 0.49, 95% confidence interval (CI) 0.43 to 0.56; risk difference (RD) 2%; number needed to treat for an additional beneficial outcome (NNTB) 50; moderate‐certainty evidence) in the largest study, which included 38,546 participants. There were no differences between the vaccinated and placebo groups for serious adverse events (RR 1.08, 95% CI 0.95 to 1.21) or deaths (RR 1.01, 95% CI 0.92 to 1.11; moderate‐certainty evidence). The vaccinated group had a higher cumulative incidence of one or more adverse events (RR 1.71, 95% CI 1.38 to 2.11; RD 23%; number needed to treat for an additional harmful outcome (NNTH) 4.3) and injection site adverse events (RR 3.73, 95% CI 1.93 to 7.21; RD 28%; NNTH 3.6; moderate‐certainty evidence) of mild to moderate intensity. These data came from four studies with 6980 participants aged 60 years or older. </p> <p>Two studies (29,311 participants for safety evaluation and 22,022 participants for efficacy evaluation) compared RZV (two doses intramuscularly, two months apart) versus placebo. Participants who received the new vaccine had a lower cumulative incidence of herpes zoster at 3.2 years follow‐up (RR 0.08, 95% CI 0.03 to 0.23; RD 3%; NNTB 33; moderate‐certainty evidence), probably indicating a favourable profile of the intervention. There were no differences between the vaccinated and placebo groups in cumulative incidence of serious adverse events (RR 0.97, 95% CI 0.91 to 1.03) or deaths (RR 0.94, 95% CI 0.84 to 1.04; moderate‐certainty evidence). The vaccinated group had a higher cumulative incidence of adverse events, any systemic symptom (RR 2.23, 95% CI 2.12 to 2.34; RD 33%; NNTH 3.0), and any local symptom (RR 6.89, 95% CI 6.37 to 7.45; RD 67%; NNTH 1.5). Although most participants reported that their symptoms were of mild to moderate intensity, the risk of dropouts (participants not returning for the second dose, two months after the first dose) was higher in the vaccine group than in the placebo group (RR 1.25, 95% CI 1.13 to 1.39; RD 1%; NNTH 100, moderate‐certainty evidence). </p> <p>Only one study reported funding from a non‐commercial source (a university research foundation). All other included studies received funding from pharmaceutical companies. </p> <p>We did not conduct subgroup and sensitivity analyses</p> </section> <section id="CD008858-sec-0007"> <h3 class="title" id="CD008858-sec-0007">Authors' conclusions</h3> <p>LZV (single dose) and RZV (two doses) are probably effective in preventing shingles disease for at least three years. To date, there are no data to recommend revaccination after receiving the basic schedule for each type of vaccine. Both vaccines produce systemic and injection site adverse events of mild to moderate intensity. The conclusions did not change in relation to the previous version of the systematic review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008858-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008858-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008858-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008858-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008858-abs-0022">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008858-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008858-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008858-abs-0020">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008858-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008858-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008858-abs-0023">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008858-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008858-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD008858-abs-0019">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008858-abs-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008858-abs-0017">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008858-abs-0002" lang="en"> <h3>Vaccines for preventing shingles in older adults</h3> <p><b>Key messages</b><br/>Vaccines can prevent shingles in healthy older adults. </p> <p><b>What is herpes zoster?</b><br/>Herpes zoster is a reactivation of the varicella zoster virus. Varicella zoster virus causes chickenpox and can remain inactive in nerve cells for many years. The virus can reactivate, travel through the nerve to the skin, and produce blisters along the nerve path. This condition is called shingles (herpes zoster), and mostly affects people with low immunity, such as older people. Before blisters appear, symptoms may include itching, numbness, tingling, or local pain. Shingles causes nerve inflammation and severe pain that can affect quality of life. The incidence rate of herpes zoster ranges from 2.08 cases to 6.20 cases per 1000 person‐years (i.e. the number of new cases per population at risk, in a given time period). This number is increasing, due in part to people living longer. </p> <p><b>What did we want to find out?</b><br/>We wanted to find out whether healthy older adults who receive the herpes zoster virus vaccine are less likely to develop this disease compared to healthy older adults who receive a 'fake vaccine' (i.e. a placebo, which is an injection that does not cause any effect related to herpes zoster). We also wanted to know if the vaccine, compared to the fake vaccine, caused any undesirable effects. </p> <p><b>What did we do?</b><br/>We looked for studies that investigated and compared healthy older adults (mean age of participants 60 years and older) who received the vaccine to protect against herpes zoster, to healthy older adults who received the fake vaccine. </p> <p>We compared and summarised the findings, and assessed our confidence in the evidence based on study size, on how the data were presented, and on the risks of bias (the likelihood that features of the study design or conduct of the study will lead to wrong results). </p> <p><b>What did we find?</b><br/>This is an update of the systematic review, and we found two new studies, bringing the total to 26 included studies (90,259 participants). These studies tested two types of vaccines that have already been approved for use. Sixteen studies tested the live attenuated virus vaccine (LZV) and included 55,975 participants (single dose); 10 studies tested the recombinant zoster vaccine (RZV), and included 34,284 participants (two doses with one two‐month interval between them). </p> <p>All studies involved people who were outpatients. Most study participants were Caucasian (White race). </p> <p><b>Main results</b> </p> <p><b>Vaccine effectiveness</b> </p> <p>LZV (single dose)<br/>The participants who received LZV had a lower rate of shingles compared to those who received the fake vaccine. Therefore, LZV is probably effective since the certainty of the evidence was moderate. It would be necessary to vaccinate 50 healthy older adults with LVZ to prevent one episode of shingles. </p> <p>RZV (two doses)<br/>Vaccination with RZV is also probably effective (moderate‐certainty evidence), and perhaps more effective than vaccination with LZV, since results show that it would be necessary to vaccinate 33 healthy older adults to prevent one episode of shingles. </p> <p><b>Safety</b><br/>Both vaccines are probably safe (moderate‐certainty evidence) for unwanted effects. </p> <p>In studies that tested RZV, which requires a second dose two months later, the dropout rate (number of persons who did not receive the second dose) was higher in the group that received the real vaccine than in the group that received the fake vaccine. This can be quantified in such a way that for every 100 healthy older adults vaccinated with two doses of the real vaccine, one older adult who received the first dose of this vaccine did not receive the second dose. The reactogenicity (side effects) of the first dose of the vaccine may have contributed to this behaviour. </p> <p><b>Conclusion</b><br/>LZV (single dose) and RZV (two doses) are probably effective in preventing shingles disease for at least three years. For both vaccines, the certainty of evidence was moderate in terms of efficacy and safety for at least three years. </p> <p><b>What are the limitations of the evidence?</b><br/>We have moderate‐certainty evidence for all effectiveness and safety endpoints, based on studies that included a large number of healthy older adults aged 60 years or older. </p> <p><b>How up‐to‐date is this evidence?</b><br/>The evidence is current to 21 October 2022. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008858-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008858-sec-0084"></div> <h3 class="title" id="CD008858-sec-0085">Implications for practice</h3> <section id="CD008858-sec-0085"> <p>It is probably beneficial to vaccinate older adults against herpes zoster (HZ) with either the attenuated live zoster vaccine (LVZ) or the recombinant zoster vaccine (RZV), with no major safety or tolerance concerns. Herpes zoster is more frequent amongst older adults, and its main clinical feature is pain, therefore preventing herpes zoster is desirable. Moderate‐certainty evidence suggests that amongst older adults aged 60 years and over, zoster vaccines probably reduce the incidence of herpes zoster for at least three years after vaccination. </p> </section> <h3 class="title" id="CD008858-sec-0086">Implications for research</h3> <section id="CD008858-sec-0086"> <p>We suggest that future studies follow participants for more than three years to assess the effectiveness of vaccines in preventing herpes zoster over longer periods of time. </p> <p>There is a need for more studies involving participants from different ethnicities in order to broaden the range of applicability of herpes vaccines to other populations. There is an ongoing study testing LZV versus placebo in participants of Asian ethnicity (<a href="./references#CD008858-bbs2-0043" title="NCT02526745. Safety and immunogenicity study of live attenuated vaccine against herpes zoster in Chinese adults aged 50 years and older. clinicaltrials.gov/ct2/show/NCT02526745 (first received 18 August 2015). ">NCT02526745</a>; <a href="./references#CD008858-bbs2-0047" title="NCT04869982. A phase IV, randomized, observer-blind, placebo-controlled, multi-center study to assess the prophylactic efficacy against herpes zoster, immunogenicity and safety of Shingrix when administered intramuscularly on a 2-dose schedule in Chinese adults aged 50 years and older. clinicaltrials.gov/study/NCT04869982 (first received 3 May 2021). ">NCT04869982</a>; <a href="./references#CD008858-bbs2-0050" title="NCT05219253. A phase 3, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the immune response and safety of the herpes zoster subunit vaccine when administered intramuscularly on a 2-dose schedule in adults aged 50 years and older in India. clinicaltrials.gov/ct2/show/NCT05219253 (first received 2 February 2018). ">NCT05219253</a>). </p> <p>One study was withdrawn prior to enrolment (<a href="./references#CD008858-bbs2-0042" title="NCT02180295. A lot-to-lot consistency study to evaluate safety, tolerability, and immunogenicity of inactivated varicella zoster virus (VZV) vaccine in healthy adults (V212-014). clinicaltrials.gov/ct2/show/NCT02180295 (first received 2 July 2014). ">NCT02180295</a>). </p> <p>Instead of relying on indirect comparisons, it is important to conduct randomised, double‐blind trials comparing the effects of the two available vaccines (LZV versus RZV) on clinical outcomes (herpes zoster cumulative incidence, adverse events) and dropouts. The findings of these trials will help to determine which intervention provides the most benefits and least harms for healthy adults aged 60 years or over. </p> <p>Two studies were classified as awaiting classification due to the age inclusion criterion. One compared LZV versus placebo (<a href="./references#CD008858-bbs2-0041" title="NCT04334577. Evaluation of the efficacy of attenuated zoster vaccine, live from herpes zoster in adults aged 40 years or older a multicenter, randomized, double-blinded, placebo-controlled trial phase III. clinicaltrials.gov/ct2/show/NCT04334577 (first received 6 April 2020). ">NCT04334577</a>). The other is about different amounts of LZV (<a href="./references#CD008858-bbs2-0040" title="NCT03314103. A multi-center, randomized, double-blinded, phase 3 trial to evaluate the efficacy against herpes zoster of a live attenuated varicella-zoster virus vaccine in adults over 40 years of age. clinicaltrials.gov/ct2/show/NCT03314103 (first received 19 October 2017). ">NCT03314103</a>). </p> <p>One ongoing study is testing the safety of different amounts of LZV (<a href="./references#CD008858-bbs2-0044" title="NCT03116594. Immunogenicity and safety of two lots of NBP608 compared to Zostavax in healthy adult aged 50 and over. clinicaltrials.gov/ct2/show/NCT03116594 (first received 17 April 2017). ">NCT03116594</a>). </p> <p>There are several ongoing RZV studies: RZV versus placebo in adults ≥ 50 years with a prior episode of herpes zoster (<a href="./references#CD008858-bbs2-0045" title="NCT04091451. A safety and immunogenicity study of GSK Biologicals' herpes zoster subunit vaccine (HZ/su) GSK1437173A on a two-dose schedule in adults ≥ 50 years of age with a prior episode of herpes zoster. clinicaltrials.gov (first received 19 April 2017). ">NCT04091451</a>), two studies on a new vaccine (<a href="./references#CD008858-bbs2-0046" title="NCT04210752. A phase 1, randomised, activator-controlled, double-blind, parallel study to assess the safety, tolerability and explore the immunogenicity of EG-HZ in healthy adult volunteers. clinicaltrials.gov/ct2/show/NCT04210752 (first received 24 February 2020). ">NCT04210752</a>; <a href="./references#CD008858-bbs2-0051" title="NCT05245838. A phase 1 randomized, subject-blinded, active-controlled, dose escalation, multicenter trial to evaluate the safety, tolerability, and immunogenicity of an investigational herpes zoster vaccine (Z-1018) compared to Shingrix® in healthy adult volunteers between the ages of 50 and 69 years. clinicaltrials.gov/ct2/show/NCT05245838 (first received 18 February 2022). ">NCT05245838</a>), and two studies on RZV given simultaneously with other vaccines (<a href="./references#CD008858-bbs2-0048" title="NCT05007041. Safety of simultaneous vaccination with zoster vaccine recombinant (RZV) and quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). clinicaltrials.gov/ct2/show/NCT05007041 (first received 21 September 2021). ">NCT05007041</a>; <a href="./references#CD008858-bbs2-0049" title="NCT05047770. A phase III, randomized, open-label, controlled, multicenter study to evaluate the immune response and safety of both herpes zoster subunit vaccine in healthy adults aged 50 years and older AND the influenza virus vaccine in healthy adults aged 18 years and older when administered sequentially or coadministered with mRNA-1273 booster vaccination. clinicaltrials.gov/ct2/show/NCT05047770 (first received 17 September 2021). ">NCT05047770</a>). </p> <p>The effectiveness of vaccines with different concentrations of varicella zoster virus could be tested in future studies. </p> <p>The effectiveness and safety of different adjuvants or formulations of RZV could also be tested in future studies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008858-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008858-sec-0008"></div> <div class="table" id="CD008858-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Live zoster vaccine versus placebo for preventing herpes zoster in older adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Live zoster vaccine versus placebo for preventing herpes zoster in older adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> healthy older adults aged ≥ 60 years<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> live zoster vaccine versus placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Live zoster vaccine versus placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cumulative incidence of herpes zoster, 3.1 years follow‐up (Incidence per 1000 person‐years at risk)</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/>(14 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b> <br/>(0.43 to 0.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,546<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB = 50</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>584 per 1000</b><br/>(553 to 615) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b> <br/>(1.38 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7119<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH = 4.3</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b><br/>Clinical criteria<br/>Follow‐up: mean 3.1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b><br/>(29 to 35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/>(0.92 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50,820<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(21 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/>(0.95 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51,029<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ systemic adverse events</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 42 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b><br/>(222 to 263) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b> (0.82 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7119<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ injection site adverse events</b><br/>Clinical criteria<br/>Follow‐up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>161 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b><br/>(441 to 522) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.73</b> (1.93 to 7.21<b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7040<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH = 3.6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b><br/>(43 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> <br/>(0.90 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,916<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Most data came from a large study, and we downgraded the certainty of the evidence because the trial did not describe the method used for random sequence generation. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008858-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Recombinant zoster vaccine versus placebo for preventing herpes zoster in older adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Recombinant zoster vaccine versus placebo for preventing herpes zoster in older adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> healthy older adults aged ≥ 60 years<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> recombinant zoster vaccine<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Recombinant zoster vaccine versus placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cumulative incidence of herpes zoster at least 3.2 years follow‐up</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/>(2 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.08</b> <br/>(0.03 to 0.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,022<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB = 33</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ death</b><br/>Clinical criteria<br/>Follow‐up: mean 3.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b><br/>(36 to 45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.84 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,311<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ serious adverse events</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b><br/>(118 to 133) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> <br/>(0.91 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,311<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ any systemic symptom</b><br/>Clinical criteria<br/>Follow‐up: mean 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>291 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>648 per 1000</b><br/>(617 to 680) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.23</b> <br/>(2.12 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9762<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH = 3.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ potential immune‐mediated disease</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b><br/>(9 to 14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/>(0.71 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,311<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ any local symptom</b><br/>Clinical criteria<br/>Follow‐up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>807 per 1000</b><br/>(746 to 873) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 6.89</b> <br/>(6.37 to 7.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9769<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH = 1.5</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts ‐ did not receive second dose</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b><br/>(50 to 50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> <br/>(1.13 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,311<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH = 100</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Both studies had limitations in study design or execution (allocation concealment, attrition, or detection bias). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008858-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008858-sec-0009"></div> <section id="CD008858-sec-0010"> <h3 class="title" id="CD008858-sec-0010">Description of the condition</h3> <p>Herpes zoster, or shingles, is a neurocutaneous disease that can be extremely painful. Symptoms often last for many weeks or months after complete healing of the lesions (<a href="./references#CD008858-bbs2-0072" title="GildenDH , Kleinschmidt-DeMastersBK , LaGuardiaJJ , MahalingamR , CohrsRJ . Neurologic complications of the reactivation of varicella zoster virus. New England Journal of Medicine2000;342(9):635–45. [PMID: 10699164]">Gilden 2000</a>). </p> <p>Herpes zoster is caused by the reactivation of the varicella zoster virus (VZV), the same virus which causes chickenpox, when immunity to that virus declines (<a href="./references#CD008858-bbs2-0103" title="MoffatJ , KuCC , ZerboniL , SommerM , ArvinA . Pathogenesis and the disease consequences of primary infection. In: ArvinA , Campadelli-FiumeG , MocarskiE , MoorePS , RoizmanB , WhitleyR , et al, editors(s). Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press, 2007. [PMID: 21348076]">Moffat 2007</a>). </p> <p>The geographical distribution of VZV indicates that it is a common human pathogen which occurs worldwide (<a href="./references#CD008858-bbs2-0088" title="JohnsonRW , LevinMJ . Vaccines for older adults: current practices and future opportunities. In: WeinbergerB , editors(s). Interdisciplinary Topics in Gerontology and Geriatrics. Herpes Zoster and Its Prevention by Vaccination edition. Vol. 43. Basel: Current Vaccines for the Older Population, 2020:131–45. [DOI: DOI:10.1159/000504484]">Johnson 2020</a>; <a href="./references#CD008858-bbs2-0107" title="PatilA , GoldustM , WollinaU . Herpes zoster: a review of clinical manifestations and management. Viruses2022;14(192):1-13. [DOI: doi.org/10.3390/v14020192]">Patil 2022</a>). Although chickenpox occurs worldwide, the epidemiology of the disease is markedly different in tropical and temperate countries. In temperate countries such as the UK and US, most people seroconvert to VZV in their teens (meaning they have had previous contact with the virus and developed antibodies). Serological studies of tropical resident populations indicate that seroconversion generally occurs later or in adulthood (<a href="./references#CD008858-bbs2-0124" title="Varicella and herpes zoster vaccines: WHO position paper, June 2014. C:/Users/acer/Downloads/WER8925_265-287WHO.pdf:265-87.">WHO 2014</a>). Since most young adults have had chickenpox, more than 90% of people worldwide can develop herpes zoster (<a href="./references#CD008858-bbs2-0119" title="SenguptaN , BooyR , SchmittHJ , PeltolaH , van-DammeP , SchumacherRF , et al. Varicella vaccination in Europe: are we ready for a universal childhood programme?European Journal of Pediatrics2008;167:47–55. [DOI: https://doi.org/10.1007/s00431-007-0424-0]">Sengupta 2008</a>). </p> <p>The incidence of herpes zoster varies greatly. In a systematic review based on data from prospective surveillance, medical record or administrative record with medical record review, the incidence rate of herpes zoster ranged between 3 and 5/1000 person‐years in North America, Europe and Asia‐Pacific (<a href="./references#CD008858-bbs2-0089" title="KawaiK , GebremeskelBG , AcostaCJ . Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ2014;4(6):e004833. [DOI: 10.1136/bmjopen-2014-004833]">Kawai 2014</a>). In the US, the crude incidence of HZ increased from 4.0 per 1000 persons in 1998 to 6.3 per 1000 persons in 2019 (<a href="./references#CD008858-bbs2-0097" title="LeungJ , DoolingK , MarinM , AndersonTC , HarpazR . The impact of universal varicella vaccination on herpes zoster incidence in the United States: comparison of birth cohorts preceding and following varicella vaccination program launch. Journal of Infectious Diseases2022;226(Suppl 4):470–7. [DOI: doi.org/10.1093/infdis/jiac255]">Leung 2022</a>). The crude incidence of HZ was 2.2 to 4.9 per 1000 in people aged 30 to 49 years, reaching 8.2 to 11.2 per 1000 in adults ≥ 70 years (<a href="./references#CD008858-bbs2-0097" title="LeungJ , DoolingK , MarinM , AndersonTC , HarpazR . The impact of universal varicella vaccination on herpes zoster incidence in the United States: comparison of birth cohorts preceding and following varicella vaccination program launch. Journal of Infectious Diseases2022;226(Suppl 4):470–7. [DOI: doi.org/10.1093/infdis/jiac255]">Leung 2022</a>). Another recent systematic review conducted in Spain reported an incidence rate of 2.08 to 5.46/1000 person‐years (<a href="./references#CD008858-bbs2-0099" title="MarequeM , OyagüezI , MoranoR , CasadoMA . Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. Public Health2019;167(February):136-46. [DOI: 10.1016/j.puhe.2018.10.015]">Mareque 2019</a>). In a cohort study conducted in Taiwan (66,453 participants), the incidence was 4.72 per 1000 person‐years (<a href="./references#CD008858-bbs2-0064" title="ChungWS , LinHH , ChengNC . The incidence and risk of herpes zoster in patients with sleep disorders: a population-based cohort study. Medicine2016;95(11):e2195. [DOI: 10.1097/MD.0000000000002195]">Chung 2016</a>). In a study conducted in Germany involving 4751 participants mostly aged 60 to 69 years, the annual self‐reported incidence rate of herpes zoster was of 6.2 per 1000 person‐years (<a href="./references#CD008858-bbs2-0062" title="CaputoM , HornJ , KarchA , AkmatovMK , BecherH , BraunB , et al. Herpes zoster incidence in Germany - an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort. BMC Infectious Diseases2019;19(1):99. [DOI: 10.1186/s12879-019-3691-2]">Caputo 2019</a>). Older adults (aged 60 years or older) are at increased risk of developing herpes zoster (<a href="./references#CD008858-bbs2-0063" title="ChoJW , ShinDH , LeeKS . Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea. Journal of Dermatological Science2007;45(3):213-5. [PMID: 17204399]">Cho 2007</a>; <a href="./references#CD008858-bbs2-0080" title="HeymannAD , ChodickG , KarpatiT , KamerL , KremerE , GreenMS , et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection2008;36(3):226-30. [PMID: 18454342]">Heymann 2008</a>; <a href="./references#CD008858-bbs2-0086" title="JihJS , ChenYJ , LinMW , ChenYC , ChenTJ , HuangYL , et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Dermato-Venereologica2009;89(6):612-6. [PMID: 19997693]">Jih 2009</a>; <a href="./references#CD008858-bbs2-0121" title="ThomasSL , HallAJ . What does epidemiology tell us about risk factors for herpes zoster?Lancet Infectious Diseases2004;4(1):26-33. [PMID: 14720565]">Thomas 2004</a>). A recent systematic review reported that the incidence of herpes zoster increased with age, from 5 to 8/1000 in people aged 50 years or over to 11/1000 in those aged 75 years and over (five studies) (<a href="./references#CD008858-bbs2-0099" title="MarequeM , OyagüezI , MoranoR , CasadoMA . Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. Public Health2019;167(February):136-46. [DOI: 10.1016/j.puhe.2018.10.015]">Mareque 2019</a>). A Canadian cohort study reported incidence of 8.2/1000 in adults aged 50 years or over (<a href="./references#CD008858-bbs2-0100" title="MarraF , ChongM , NajafzadehM . Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infectious Diseases2016;16(1):589. [DOI: 10.1186/s12879-016-1898-z]">Marra 2016</a>). <a href="./references#CD008858-bbs2-0089" title="KawaiK , GebremeskelBG , AcostaCJ . Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ2014;4(6):e004833. [DOI: 10.1136/bmjopen-2014-004833]">Kawai 2014</a> reported herpes zoster incidence of 6 to 8/1000 person‐years at 60 years and 8 to 12/1000 person‐years at 80 years of age. </p> <p>Several studies indicate that incidence is also increasing over time. <a href="./references#CD008858-bbs2-0100" title="MarraF , ChongM , NajafzadehM . Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infectious Diseases2016;16(1):589. [DOI: 10.1186/s12879-016-1898-z]">Marra 2016</a> reported that in Canada, the incidence of herpes zoster increased from 2.9 per 1000 inhabitants in 1997 to 4.7 per 1000 inhabitants in 2012. In a cohort study in the USA (<a href="./references#CD008858-bbs2-0090" title="KawaiK , YawnBP , WollanP , HarpazR . Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clinical Infectious Diseases2016;63(2):221–6. [DOI: 10.1093/cid/ciw296]">Kawai 2016</a>), the incidence rate of herpes zoster adjusted by age and sex increased from 0.76 (95% confidence interval (CI) 0.63 to 0.89) per 1000 person‐years in 1945 to 1949 to 3.15 (95% CI 3.04 to 3.26) per 1000 person‐years in 2000 to 2007, which corresponds to a more than four‐fold increase over the 60‐year period. In the USA, the annual incidence of herpes zoster increased from 3.10 episodes per 1000 in older adults in 2000 to 5.22 in 2007 (<a href="./references#CD008858-bbs2-0112" title="RimlandD , MoannaA . Increasing incidence of herpes zoster among veterans. Clinical Infectious Diseases2010;50(7):1000-5. [PMID: 20178416]">Rimland 2010</a>). Incidence rates are higher in women (<a href="./references#CD008858-bbs2-0062" title="CaputoM , HornJ , KarchA , AkmatovMK , BecherH , BraunB , et al. Herpes zoster incidence in Germany - an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort. BMC Infectious Diseases2019;19(1):99. [DOI: 10.1186/s12879-019-3691-2]">Caputo 2019</a>; <a href="./references#CD008858-bbs2-0099" title="MarequeM , OyagüezI , MoranoR , CasadoMA . Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. Public Health2019;167(February):136-46. [DOI: 10.1016/j.puhe.2018.10.015]">Mareque 2019</a>; <a href="./references#CD008858-bbs2-0100" title="MarraF , ChongM , NajafzadehM . Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infectious Diseases2016;16(1):589. [DOI: 10.1186/s12879-016-1898-z]">Marra 2016</a>). Although family history of shingles suggests a possible genetic predisposition to the disease (<a href="./references#CD008858-bbs2-0063" title="ChoJW , ShinDH , LeeKS . Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea. Journal of Dermatological Science2007;45(3):213-5. [PMID: 17204399]">Cho 2007</a>; <a href="./references#CD008858-bbs2-0078" title="HaanpääM , NurmikkoT , HurmeM . Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scandinavian Journal of Infectious Diseases2002;34(2):112-4. [PMID: 11928840]">Haanpää 2002</a>), results from available case‐control studies are conflicting (<a href="./references#CD008858-bbs2-0071" title="GattiA , PicaF , BocciaMT , De AntoniF , SabatoAF , VolpiA . No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia. Journal of Medical Virology2010;82(6):1007-11. [PMID: 20419815]">Gatti 2010</a>; <a href="./references#CD008858-bbs2-0081" title="HicksLD , Cook-NorrisRH , MendozaN , MadkanV , AroraA , TyringSK . Family history as a risk factor for herpes zoster: a case-control study. Archives of Dermatology2008;144(5):603-8. [PMID: 18490586]">Hicks 2008</a>). Due to lengthening lifespans, there are increasing concerns about quality of life for older adults, who are a growing segment of the population (<a href="./references#CD008858-bbs2-0088" title="JohnsonRW , LevinMJ . Vaccines for older adults: current practices and future opportunities. In: WeinbergerB , editors(s). Interdisciplinary Topics in Gerontology and Geriatrics. Herpes Zoster and Its Prevention by Vaccination edition. Vol. 43. Basel: Current Vaccines for the Older Population, 2020:131–45. [DOI: DOI:10.1159/000504484]">Johnson 2020</a>). </p> <p>The most common risk factors for varicella‐zoster virus reactivation are increasing age (≥ 50 years) and immunocompromised status (<a href="./references#CD008858-bbs2-0107" title="PatilA , GoldustM , WollinaU . Herpes zoster: a review of clinical manifestations and management. Viruses2022;14(192):1-13. [DOI: doi.org/10.3390/v14020192]">Patil 2022</a>). </p> <p>VZV is highly contagious. The first contact with the virus is usually in childhood and the individual develops chickenpox (varicella). VZV can remain dormant for years in the dorsal sensory ganglia of the spinal cord. The latency of the virus is maintained by cellular immunity, which inhibits viral replication. Years later, during periods of decreased cell‐mediated immunity or simply because of ageing, the virus can replicate in the dorsal sensory ganglia of the spinal cord and migrate along sensory nerves. Prodromal symptoms of viral reactivation include itching, numbness, tingling, or severe localised pain, which precede the appearance of skin lesions by one to five days. The typical cutaneous manifestations of an acute herpes zoster episode include clusters of vesicles that spread in a linear pattern along the path of nerves and do not cross the midline of the body. Within three to five days, these lesions progress to pustules, ulcerations, and crusting and go on to heal spontaneously within two to four weeks (<a href="./references#CD008858-bbs2-0103" title="MoffatJ , KuCC , ZerboniL , SommerM , ArvinA . Pathogenesis and the disease consequences of primary infection. In: ArvinA , Campadelli-FiumeG , MocarskiE , MoorePS , RoizmanB , WhitleyR , et al, editors(s). Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press, 2007. [PMID: 21348076]">Moffat 2007</a>; <a href="./references#CD008858-bbs2-0107" title="PatilA , GoldustM , WollinaU . Herpes zoster: a review of clinical manifestations and management. Viruses2022;14(192):1-13. [DOI: doi.org/10.3390/v14020192]">Patil 2022</a>). </p> <p>Herpes zoster causes substantial morbidity and has a significant impact on the quality of life (<a href="./references#CD008858-bbs2-0106" title="PartridgeDG , McKendrickMW . The treatment of varicella-zoster virus infection and its complications. Expert Opinion on Pharmacotherapy2009;10(5):797-812. [PMID: 19351229]">Partridge 2009</a>; <a href="./references#CD008858-bbs2-0113" title="SampathkumarP , DrageLA , MartinDP . Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clinic Proceedings2009;84(3):274-80. [PMID: 19252116]">Sampathkumar 2009</a>). <a href="./references#CD008858-bbs2-0115" title="SchmaderKE , SloaneR , PieperC , CoplanPM , NikasA , SaddierP , et al. Herpes zoster pain and discomfort on functional status and quality of life in older adults. Clinical Journal of Pain2007;23(6):490-6. [PMID: 17575488]">Schmader 2007</a> conducted a prospective observational study of 165 outpatients with acute herpes zoster who were enroled within 14 days of onset of rash. Pain was moderate to severe, and discomfort was common during the acute rash phase. Acute herpetic neuralgia was associated with sleep disruption, impaired general activities, and enjoyment of life, especially after the onset of the rash, and had significant impact on the quality of life. Although herpes zoster lesions and symptoms are transient in most individuals, some of those affected may develop postherpetic neuralgia that can last for months to years, which can cause substantial suffering and have a negative impact on the quality of life (<a href="./references#CD008858-bbs2-0065" title="CoplanPM , SchmaderK , NikasA , ChanISF , ChooP , LevinMJ , et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory. Journal of Pain2004;5(6):344-56. [DOI: 10.1016/j.jpain.2004.06.001]">Coplan 2004</a>; <a href="./references#CD008858-bbs2-0067" title="DworkinRH , SchmaderKE . Treatment and prevention of postherpetic neuralgia. Clinical Infectious Diseases2003;36(7):877-82. [DOI: 10.1086/368196]">Dworkin 2003</a>; <a href="./references#CD008858-bbs2-0087" title="JohnsonRW , RiceAS . Postherpetic neuralgia. New England Journal of Medicine2014;371(16):1526-33. [DOI: 10.1056/NEJMcp1403062]">Johnson 2014</a>; <a href="./references#CD008858-bbs2-0109" title="PickeringG , LeplegeA . Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Practice2011;11(4):397–402. [DOI: 10.1111/j.1533-2500.2010.00432.x]">Pickering 2011</a>). </p> </section> <section id="CD008858-sec-0011"> <h3 class="title" id="CD008858-sec-0011">Description of the intervention</h3> <p>Two different vaccines are currently available to prevent herpes zoster.</p> <p> <ol id="CD008858-list-0001"> <li> <p>Live attenuated VZV zoster vaccine (LZV): this vaccine contains the same live attenuated virus used in the chickenpox vaccine, but it has over 14‐fold more plaque‐forming units of the attenuated virus per dose. The two vaccines are therefore not interchangeable (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). This vaccine was approved by the US Food and Drug Administration (FDA) for older adults (aged 60 years and over) in May 2006 (<a href="./references#CD008858-bbs2-0068" title="USA FDA approval letter - Zostavax, 25 May 2006. https://wayback.archive-it.org/7993/20170723093336/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm132873.htm accessed 24 October 2019.">FDA 2006</a>), and was approved by the FDA for individuals aged 50 years or over in March 2011 (<a href="./references#CD008858-bbs2-0120" title="SunW . Summary basis for regulatory action. http://wayback.archive-it.org/7993/20170723093318/https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM249230.pdf2011.">Sun 2011</a>). LZV is one dose only. </p> </li> <li> <p>Adjuvanted recombinant subunit zoster vaccine (RZV) has also been tested (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>). It does not contain the live attenuated virus, but rather a small fraction of the virus that cannot replicate but can boost immunogenicity. This vaccine contains antigen gE (glycoprotein E), which is the most abundant glycoprotein on the surface of VZV and the most abundant antigen in VZV‐infected cells and the main target for VZV‐specific CD4 + T‐cell response (<a href="./references#CD008858-bbs2-0088" title="JohnsonRW , LevinMJ . Vaccines for older adults: current practices and future opportunities. In: WeinbergerB , editors(s). Interdisciplinary Topics in Gerontology and Geriatrics. Herpes Zoster and Its Prevention by Vaccination edition. Vol. 43. Basel: Current Vaccines for the Older Population, 2020:131–45. [DOI: DOI:10.1159/000504484]">Johnson 2020</a>). This vaccine also includes adjuvant AS01, which is a liposome‐based adjuvant system containing immunoenhancers 3‐O‐desacyl‐4′‐monophosphoryl lipid A (MPL) plus saponin QS‐21 (<i>Quillaja saponaria</i> Molina, fraction 21) (<a href="./references#CD008858-bbs2-0058" title="BaldridgeJR , McGowanP , EvansJT , CluffC , MossmanS , JohnsonD , el al. Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opinion on Biological Therapy2004;4(7):1129-38. [PMID: 15268679]">Baldridge 2004</a>; <a href="./references#CD008858-bbs2-0088" title="JohnsonRW , LevinMJ . Vaccines for older adults: current practices and future opportunities. In: WeinbergerB , editors(s). Interdisciplinary Topics in Gerontology and Geriatrics. Herpes Zoster and Its Prevention by Vaccination edition. Vol. 43. Basel: Current Vaccines for the Older Population, 2020:131–45. [DOI: DOI:10.1159/000504484]">Johnson 2020</a>). It was approved by the FDA for clinical use in October 2017 (<a href="./references#CD008858-bbs2-0069" title="USA FDA approval letter - zoster vaccine recombinant, adjuvanted. 20 October 2017. www.fda.gov/downloads/biologicsblood vaccines/vaccines/approvedproducts/ucm581750.pdf accessed 24 October 2019.">FDA 2017</a>). The approved vaccine schedule for RZV consists of two doses given two months apart. </p> </li> </ol> </p> </section> <section id="CD008858-sec-0012"> <h3 class="title" id="CD008858-sec-0012">How the intervention might work</h3> <p>Primary infection with VZV induces the production of specific memory T‐cells in sufficient numbers to keep the virus in its latent form. Host factors such as ageing, or other conditions that affect cellular immunity, may reduce T‐cells to levels that can no longer inhibit viral replication, thereby increasing the likelihood of clinical manifestations of the disease. </p> <p>Live attenuated VZV zoster vaccine (LZV) consists of live attenuated VZV that activates specific T‐cell production, thus increasing existing immunity and avoiding reactivation of viral replication (<a href="./references#CD008858-bbs2-0055" title="ArvinA . Ageing, immunity, and the varicella-zoster virus. New England Journal of Medicine2005;352(22):2266-7. [PMID: 15930416]">Arvin 2005</a>). Several randomised controlled trials (RCTs) have evaluated the efficacy and safety of LZV in preventing herpes zoster (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>). </p> <p>Adjuvanted recombinant VZV subunit zoster vaccine (RZV) is a newer vaccine that contains the most abundant glycoprotein on the surface of VZV and the most abundant antigen in VZV‐infected cells. The adjuvant component is important because it helps to elicit an early, high, and long‐lasting immune response with less antigen (<a href="./references#CD008858-bbs2-0110" title="RajeshK , GuptaRK , SiberGR . Adjuvants for human vaccines - current status, problems and future prospects. Vaccine1995;13(14):1263–76. [DOI: 10.1016/0264-410X(95)00011-O]">Rajesh 1995</a>). This leads to additional stimulation of the immune system. The RZV improves immune stimulation against VZV, and its efficacy and safety have been tested in several RCTs (<a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> </section> <section id="CD008858-sec-0013"> <h3 class="title" id="CD008858-sec-0013">Why it is important to do this review</h3> <p>Herpes zoster is a disease that can have an important effect on the quality of life of affected individuals (<a href="./references#CD008858-bbs2-0115" title="SchmaderKE , SloaneR , PieperC , CoplanPM , NikasA , SaddierP , et al. Herpes zoster pain and discomfort on functional status and quality of life in older adults. Clinical Journal of Pain2007;23(6):490-6. [PMID: 17575488]">Schmader 2007</a>). The incidence of herpes zoster is increasing over time (<a href="./references#CD008858-bbs2-0100" title="MarraF , ChongM , NajafzadehM . Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infectious Diseases2016;16(1):589. [DOI: 10.1186/s12879-016-1898-z]">Marra 2016</a>), and is higher in the elderly population (<a href="./references#CD008858-bbs2-0099" title="MarequeM , OyagüezI , MoranoR , CasadoMA . Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. Public Health2019;167(February):136-46. [DOI: 10.1016/j.puhe.2018.10.015]">Mareque 2019</a>). The vaccination of healthy individuals is a way of preventing the disease. In this context, it is important to critically assess the best available evidence on the effectiveness of these vaccines, as well as their safety profile, since they are given to healthy individuals. This review is also important to map the existing research gaps and to encourage scientists to pursue investigations in this area, including studies with longer follow‐ups of participants, and to test new types of vaccines. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008858-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008858-sec-0014"></div> <p>To evaluate the effectiveness and safety of vaccination for preventing herpes zoster in older adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008858-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008858-sec-0015"></div> <section id="CD008858-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008858-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs and quasi‐RCTs (studies in which participants are allocated to different arms of the trial using a method of allocation that is not truly random), regardless of publication date or language. </p> </section> <section id="CD008858-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies involving older adults (mean age 60 years and over). We excluded trials involving participants with immunosuppressive conditions. </p> </section> <section id="CD008858-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included clinical trials that compared herpes zoster vaccine, of any dose and potency, with at least one of the following comparison groups. </p> <p> <ol id="CD008858-list-0002"> <li> <p>Any other type of intervention (e.g. varicella vaccine, antiviral medication).</p> </li> <li> <p>Placebo.</p> </li> <li> <p>Nothing (no vaccine).</p> </li> </ol> </p> </section> <section id="CD008858-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD008858-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008858-list-0003"> <li> <p>Cumulative incidence of herpes zoster, diagnosed according to the criteria (clinical or laboratory, or both) established by the primary studies. </p> </li> </ol> </p> </section> <section id="CD008858-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008858-list-0004"> <li> <p>Adverse events (occurring at any time after vaccination):</p> <ul id="CD008858-list-0005"> <li> <p>death (death was specified as a serious adverse event because of its importance in clinical studies and clinical practice); </p> </li> <li> <p>serious adverse events (as defined by the Food and Drug Administration as: "Death, life‐threatening, hospitalisation (initial or prolonged), disability or permanent damage, congenital anomaly/birth defect, required intervention to prevent permanent impairment or damage (devices), other important medical events)" (<a href="https://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm" target="_blank">FDA definition</a>); </p> </li> <li> <p>systemic reactions (e.g. fatigue, fever, gastrointestinal symptoms, headache, myalgia, shivering, or other); and </p> </li> <li> <p>local reaction (e.g. pain, pruritus, swelling, or other).</p> </li> </ul> </li> <li> <p>Dropouts.</p> </li> </ol> </p> </section> </section> </section> <section id="CD008858-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008858-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2022, Issue 10), which includes the Cochrane Acute Respiratory Infections Specialised Register, in the Cochrane Library, MEDLINE (1948 to October 2022), Embase (2010 to October 2022), CINAHL (Cumulative Index to Nursing and Allied Health Literature) (1981 to October 2022), and LILACS (Latin American and Caribbean Health Science Information database) (1982 to October 2022). We conducted all searches for this update on 21 October 2022. </p> <p>We used the search strategy in <a href="./appendices#CD008858-sec-0090">Appendix 1</a> to search MEDLINE and CENTRAL. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximising version (2008 revision); Ovid format (<a href="./references#CD008858-bbs2-0096" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Lefebvre 2011</a>). We adapted the search strategy to search Embase (<a href="./appendices#CD008858-sec-0091">Appendix 2</a>), LILACS (<a href="./appendices#CD008858-sec-0092">Appendix 3</a>), and CINAHL (<a href="./appendices#CD008858-sec-0093">Appendix 4</a>). We imposed no language or publication restrictions. </p> </section> <section id="CD008858-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched three trial registries, the WHO ICTRP (World Health Organization ‐ International Clinical Trials Registry Platform) (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (on 21 October 2022), ClinicalTrials.gov (on 21 October 2022), and the US National Institutes of Health Ongoing Trials Register (<a href="http://clinicaltrials.gov/" target="_blank">ClinialTrials.gov</a>) (21 October 2022), for completed and ongoing studies. </p> <p>We checked the reference lists of relevant studies. We contacted trial authors for additional information and unpublished studies. We checked conference proceedings and thesis banks for unpublished studies. We also contacted vaccine manufacturers for unpublished data. </p> </section> </section> <section id="CD008858-sec-0026"> <h3 class="title" id="CD008858-sec-0026">Data collection and analysis</h3> <p>The aim of intention‐to‐treat (ITT) analysis is to include all participants randomised into a trial irrespective of what subsequently occurred (<a href="./references#CD008858-bbs2-0098" title="LewisJA , MachinD . Intention to treat – who should use ITT?British Journal of Cancer1993;68(4):647-50. [PMID: 8398686]">Lewis 1993</a>; <a href="./references#CD008858-bbs2-0105" title="NewellDJ . Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology1992;21(5):837-41. [DOI: 10.1093/ije/21.5.837]">Newell 1992</a>). ITT analyses are generally preferred as they are unbiased, and also because they address a more pragmatic and clinically relevant question. We attempted to consider ITT when this was possible or available. </p> <section id="CD008858-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AG, BNGA) independently assessed the titles and abstracts of all retrieved records against our inclusion criteria. We used the Kappa coefficient to test concordance amongst review authors (<a href="./references#CD008858-bbs2-0093" title="LatourJ , AbrairaV , CabelloJB , López SánchezJ . Investigation methods in clinical cardiology (IV) clinical measurements in cardiology: validity and errors of measurement. Revista Española de Cardiología1997;50(2):117-28. [PMID: 9091999]">Latour 1997</a>). Any discrepancies were resolved through consensus or by consulting a third review author (MRT) when necessary. </p> </section> <section id="CD008858-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We created a data extraction form specifically for this review to collect relevant information such as study methods, participants, intervention group, control group, and outcomes. </p> </section> <section id="CD008858-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We evaluated the methodological quality of each included study in accordance with the criteria for judging risk of bias in the Cochrane risk of bias assessment tool (<a href="./references#CD008858-bbs2-0083" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We evaluated the following domains. </p> <p> <ol id="CD008858-list-0006"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding (performance bias and detection).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We classified each of these domains as 'low risk of bias', 'unclear risk of bias', or 'high risk of bias'. </p> </section> <section id="CD008858-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <section id="CD008858-sec-0031"> <h5 class="title">Dichotomous data</h5> <p>For binary data, we calculated the results for each study using the risk ratio (RR) with 95% confidence interval (CI) and number needed to treat for an additional beneficial outcome (NNTB) for efficacy, and number needed to treat for an additional harmful outcome (NNTH) for adverse events, where there were statistically significant differences. </p> </section> <section id="CD008858-sec-0032"> <h5 class="title">Continuous data</h5> <p>For outcomes presented in other forms (e.g. reported as medians, quartiles, etc.) or without consistent statistical information (e.g. standard deviations (SDs), or number of participants), we inserted these data into an additional table. </p> </section> </section> <section id="CD008858-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the unit of analysis, including participants undergoing more than one intervention in cross‐over trials. We used data from cross‐over studies (separated or grouped) when this information was available. </p> </section> <section id="CD008858-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>For dichotomous data, we performed ITT analyses to include all participants randomised to the study groups. We contacted trial authors in order to obtain any missing data from the included studies. In studies for which reasons for withdrawal were not provided, we analysed data assuming the worst possible outcome, since imputation of data is a matter of personal judgement (<a href="./references#CD008858-bbs2-0083" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> </section> <section id="CD008858-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the consistency of results through visual inspection of the forest plots and by calculating the I² statistic (<a href="./references#CD008858-bbs2-0082" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.)2003;327(7414):557-60. [PMID: 12958120]">Higgins 2003</a>), which estimates the proportion of variation in point estimates that is due to heterogeneity rather than sampling error. We assumed substantial (significant) heterogeneity when the I² statistic was &gt; 50%. We analysed data using a random‐effects model. </p> </section> <section id="CD008858-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>It was not necessary to prepare a funnel plot since we included fewer than 10 studies in the meta‐analysis. </p> </section> <section id="CD008858-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We calculated the RR for dichotomous variables and the mean difference (MD) for continuous variables, when studies reported their results in the same units of measurement. When continuous data were reported in different units, we pooled the data through standardised mean differences (SMDs). We used 95% CIs for all statistical methods employed to pool data. We entered data into Cochrane Review Manager 5 software (<a href="./references#CD008858-bbs2-0111" title="Review Manager 5 (RevMan). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>), and conducted meta‐analyses using a random‐effects model. </p> </section> <section id="CD008858-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We grouped results from studies according to methodological and clinical aspects such as vaccine dosage (plaque‐forming units per dose), vaccine conservation method (refrigerated or frozen), participant age, previous episode of herpes zoster, and simultaneous administration of other vaccines. </p> </section> <section id="CD008858-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses where this was possible. We investigated the impact of quasi‐RCTs, studies with lower methodological quality, cross‐over studies, and unpublished data on the results of the review. </p> </section> <section id="CD008858-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a summary of findings table using the following outcomes: cumulative incidence of herpes zoster, adverse events (i.e. death, serious, systemic, potential immune‐mediated disease, and local symptoms), and dropouts. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) (<a href="./references#CD008858-bbs2-0057" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Atkins 2004</a>), to assess the certainty of evidence as it relates to the studies that contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD008858-bbs2-0076" title="GuyattG , GuttermanD , BaumannMH , Addrizzo-HarrisD , HylekEM , PhillipsB , et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest2006;129(1):174-81. [PMID: 16424429]">Guyatt 2006a</a>; <a href="./references#CD008858-bbs2-0077" title="GuyattG , VistG , Falck-YtterY , KunzR , MagriniN , SchünemannH . An emerging consensus on grading recommendations?ACP Journal Club2006;144(1):A8-9. [PMID: 16388549]">Guyatt 2006b</a>). We used the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008858-bbs2-0083" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), using GRADEpro GDT software (<a href="./references#CD008858-bbs2-0074" title="GRADEpro GDT. Version accessed 1 December 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD008858-bbs2-0118" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Schünemann 2021</a>). We justified all decisions to downgrade or upgrade the certainty of studies using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> <p>Factors that can reduce the certainty of the evidence (downgrade) include:</p> <p> <ol id="CD008858-list-0007"> <li> <p>limitations in study design or execution (risk of bias): lower by one or two levels;</p> </li> <li> <p>inconsistency of results: lower by one or two levels;</p> </li> <li> <p>indirectness of evidence: lower by one or two levels;</p> </li> <li> <p>imprecision: lower by one or two levels; and</p> </li> <li> <p>publication bias: lower by one or two levels.</p> </li> </ol> </p> <p>Factors that can increase the certainty of the evidence (upgrade) include:</p> <p> <ol id="CD008858-list-0008"> <li> <p>large magnitude of effect: upgrade by one or two levels;</p> </li> <li> <p>all plausible confounding that would reduce the demonstrated the effect or increase the effect if no effect was observed: upgrade by one level; and </p> </li> <li> <p>dose‐response gradient: upgrade by one level.</p> </li> </ol> </p> <p>Based on these factors, we classified the certainty of evidence for each outcome as high, moderate, low, or very low (<a href="./references#CD008858-bbs2-0117" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Schünemann 2011</a>): </p> <p> <ol id="CD008858-list-0009"> <li> <p>high‐certainty evidence: RCTs or double‐upgraded observational studies;</p> </li> <li> <p>moderate‐certainty evidence: downgraded RCTs or upgraded observational studies;</p> </li> <li> <p>low‐certainty evidence: double‐downgraded RCTs or observational studies; and</p> </li> <li> <p>very low‐certainty evidence: triple‐downgraded RCTs or downgraded observational studies; or case series/case reports. </p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008858-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008858-sec-0041"></div> <section id="CD008858-sec-0042"> <h3 class="title">Description of studies</h3> <p>In this 2022 updated review, we included two new studies (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>), bringing the total number of included randomised controlled trials (RCTs) to 26 (38 published reports) (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>; <a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> <p><a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a> presented efficacy data by age; data for participants aged 60 years or over were included. However, in response to our enquiry, the study authors replied that safety data ordered by age were not available; therefore we used safety data provided for participants aged 50 years or over. </p> <p>We excluded two new studies (<a href="./references#CD008858-bbs2-0030" title="JohnsonMJ , LiuC , GhoshD , LangN , LevinMJ , WeinbergA . Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: 5-year persistence. Journal of Infectious Diseases2022;225(8):1477-81. [DOI: 10.1093/infdis/jiab580]">Johnson 2022</a>; <a href="./references#CD008858-bbs2-0036" title="Investigators: Study Director - GSK Clinical Trials - GlaxoSmithKline. Immunogenicity and safety study of GSK's investigational vaccine (GSK3277511A) when administered in healthy smokers and ex-smokers following receipt of shingrix vaccine. clinicaltrials.gov2022. [CLINICALTRILAS.GOV: NCT03894969]">NCT03894969</a>), bringing the total number of excluded studies to 13. We classified two studies as awaiting classification due to the age criterion of above 40 years (<a href="./references#CD008858-bbs2-0040" title="NCT03314103. A multi-center, randomized, double-blinded, phase 3 trial to evaluate the efficacy against herpes zoster of a live attenuated varicella-zoster virus vaccine in adults over 40 years of age. clinicaltrials.gov/ct2/show/NCT03314103 (first received 19 October 2017). ">NCT03314103</a>; <a href="./references#CD008858-bbs2-0041" title="NCT04334577. Evaluation of the efficacy of attenuated zoster vaccine, live from herpes zoster in adults aged 40 years or older a multicenter, randomized, double-blinded, placebo-controlled trial phase III. clinicaltrials.gov/ct2/show/NCT04334577 (first received 6 April 2020). ">NCT04334577</a>). </p> <section id="CD008858-sec-0043"> <h4 class="title">Results of the search</h4> <p>We included two new studies in this update. The process of study identification and selection for this update is shown in <a href="#CD008858-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD008858-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram 2022 update." data-id="CD008858-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram 2022 update.</p> </div> </div> </div> </section> <section id="CD008858-sec-0044"> <h4 class="title">Included studies</h4> <p>The 26 included studies enroled a total of 90,259 participants (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>; <a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). Sixteen studies involving 55,975 participants tested the live attenuated virus vaccine (LZV). Ten studies involving 34,284 participants tested the recombinant zoster vaccine (RZV). </p> <section id="CD008858-sec-0045"> <h5 class="title">Design</h5> <p>All included studies were RCTs. Of the 26 studies, 15 were double‐blinded (<a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>; <a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); two were partially blinded (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>); and nine were open‐label studies (<a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). Trial duration varied from 28 days to 7.0 years postvaccination. </p> <p>Only <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a> used a cross‐over design. We included this study because the cross‐over was design appropriate; it is clear that the order of receiving treatments was randomised ("subjects were enroled and randomised in a 1:1 ratio to one of two vaccination groups"); it can be assumed that the trial was not biased from carry‐over effects; and unbiased data were available. This study reported outcome data (for adverse events and dropouts) separately for participants aged 50 to 59 years and 60 years or over. For this review, we only included data from these older participants who received zoster vaccines versus placebo. </p> </section> <section id="CD008858-sec-0046"> <h5 class="title">Location</h5> <p>Seven studies were conducted in the USA (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>); 15 studies were multicentre: France, Switzerland, and Ireland (<a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>); the Czech Republic, Spain, and the USA (<a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>); the Czech Republic, Germany, the Netherlands, and Sweden (<a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>); 18 countries in Europe, North America, Latin America, Asia, and Australia (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>); Germany and Spain (<a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>); 18 countries in Europe, North America, Latin America, Asia, and Australia (<a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>); the USA and Estonia (<a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>); the USA, Canada, and Estonia (<a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>); Canada, Germany, Spain, the UK, and the USA (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>); Canada, Germany, and the USA (<a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>); the USA, Canada, the UK, Germany, and Belgium (<a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>); the USA and the Netherlands (<a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); Finland, Germany, Italy, Spain, and the Netherlands (<a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>). One study was conducted in Canada, Estonia, Germany, and the USA (<a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>). Two studies were conducted in Japan (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). One study was conducted in the Republic of Korea (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>). Location was not provided for two studies (<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>). </p> </section> <section id="CD008858-sec-0047"> <h5 class="title">Setting</h5> <p>All studies were conducted in outpatient settings.</p> </section> <section id="CD008858-sec-0048"> <h5 class="title">Sample sizes</h5> <p>The mean sample size was 3472 participants and ranged from 54 to 38,546 participants. Four studies included more than 10,000 participants (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> </section> <section id="CD008858-sec-0049"> <h5 class="title">Participants</h5> <p>Participants were healthy adults, with a mean age of 63.7 years. Most participants (&gt; 88%) in the primary studies were Caucasian (understood to be white) and female (58%). </p> <p>With one exception, all included studies enroled healthy older adults with previous varicella zoster virus (VZV) contact, but without a history of herpes zoster (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>). <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a> enroled participants with a history of herpes zoster. Two studies included participants aged 70 or older (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>). <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a> included participants with diabetes and good glycaemic control. One study was carried out in the Republic of Korea and included only Asian participants (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>). </p> </section> <section id="CD008858-sec-0050"> <h5 class="title">Interventions</h5> <p>As there were several types of interventions, we grouped them as follows.</p> <p> <ol id="CD008858-list-0010"> <li> <p>Vaccine versus placebo: LZV versus placebo (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); RZV versus placebo (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>). </p> </li> <li> <p>Different routes of administration: LZV intramuscular (IM) route versus LZV subcutaneous (SC) route (<a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>); LZV intradermal route (ID) versus LZV SC route (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>); RZV IM route versus RZV SC route (<a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> </li> <li> <p>Different storage modes: refrigerated versus frozen LZV (<a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>). </p> </li> <li> <p>Different processing or composition: high‐potency LZV versus low‐potency LZV (<a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>); <a href="./references#CD008858-bbs2-0104" title="SK Chemicals receives permission to market shingles vaccine. http://english.hani.co.kr/arti/english_edition/e_business/813943.html accessed 24 October 2019.">NBP608</a> LZV versus LZV (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>); LZV AMP (alternative manufacturing process) versus LZV (<a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>); heat‐treated LZV versus LZV or placebo (<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>). </p> </li> <li> <p>Different administration intervals: two doses of a LZV versus a single dose and two doses given at different intervals (<a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>); adjuvanted recombinant VZV subunit zoster vaccine: lower or higher quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline (<a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>); adjuvanted recombinant VZV subunit zoster vaccine: three groups of VZV subunit gE in three different quantities versus unadjuvanted gE or saline (<a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>); RZV two doses given at three different intervals (<a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>). </p> </li> <li> <p>Comparison with other vaccines or concomitant versus non‐concomitant administration: LZV versus 23‐valent pneumococcal polysaccharide vaccine (<a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a><a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>); RZV versus 23‐valent pneumococcal polysaccharide vaccine (<a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>); PCV13 (13‐valent pneumococcal vaccine ‐ conjugated) concomitant with RZV versus PCV13 sequential RZV (<a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>); LZV + inactivated quadrivalent influenza vaccines (IIV4) concomitant administration versus LZV + IIV4 sequential administration (<a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>); RZV + IIV4 co‐administration group versus non‐co‐administration group (<a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>); RZV + tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (TDaPV) co‐administration group versus RZV + TDaPV non‐co‐administration group (<a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>). </p> </li> </ol> </p> </section> <section id="CD008858-sec-0051"> <h5 class="title">Subgroup and sensitivity analyses</h5> <p>We did not conduct subgroup analyses due to differences between study interventions.</p> <p>We did not conduct sensitivity analyses because there were no quasi‐randomised studies or studies with lower methodological quality. We found only one small cross‐over study that had no impact on the results of the review. </p> </section> <section id="CD008858-sec-0052"> <h5 class="title">Outcomes</h5> <p>Seven included studies reported incidence of herpes zoster (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> <p>All 26 included studies reported adverse events. These included or were defined as death, serious adverse events, unsolicited reports of adverse events, systemic adverse events, and injection site reactions (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>; <a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> </section> </section> <section id="CD008858-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 13 RCTs (<a href="./references#CD008858-bbs2-0027" title="HaywardAR , BudaK , LevinMJ . Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunology1994;7(1):31-6. [PMID: 7986334]">Hayward 1994</a>; <a href="./references#CD008858-bbs2-0028" title="HaywardAR , BudaK , JonesM , WhiteCJ , LevinMJ . Varicella zoster virus specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunology1996;9(4):241-5. [PMID: 8978020]">Hayward 1996</a>; <a href="./references#CD008858-bbs2-0029" title="IrwinMR , OlmsteadR , OxmanMN . Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of tai chi. Journal of the American Geriatrics Society2007;55(4):511-7. [DOI: 10.1111/j.532-5415.2007.01109.x]">Irwin 2007</a>; <a href="./references#CD008858-bbs2-0030" title="JohnsonMJ , LiuC , GhoshD , LangN , LevinMJ , WeinbergA . Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: 5-year persistence. Journal of Infectious Diseases2022;225(8):1477-81. [DOI: 10.1093/infdis/jiab580]">Johnson 2022</a>; <a href="./references#CD008858-bbs2-0031" title="KerznerB , MurrayAV , GhengE , IfleR , HarveyPR , TomlinsonM , et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. Journal of the American Geriatrics Society2007;55(10):1499-507. [DOI: 10.1111/j.1532-5415.2007.01397.x]">Kerzner 2007</a>; <a href="./references#CD008858-bbs2-0032" title="KovacM , LalH , CunninghamAL , LevinMJ , JohnsonRW , CamporaL , et al, ZOE-50/70 Study Group. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine2018;36(12):1537-41. [DOI: 10.1016/j.vaccine.2018.02.029]">Kovac 2018</a>; <a href="./references#CD008858-bbs2-0033" title="Leroux-RoelsI , Leroux-RoelsG , Frédéric ClementF , VandepapelièreP , VassilevV , LedentE , et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults. Journal of Infectious Diseases2012;206(8):1280-90. [DOI: 10.1093/infdis/jis497]">Leroux‐Roels 2012</a>; <a href="./references#CD008858-bbs2-0034" title="MacaladadN , MarcanoT , GuzmanM , MoyaJ , JuradoF , ThompsonM , et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine2007;25(11):2139-44. [DOI: 10.1016/j.vaccine.2006.11.011]">Macaladad 2007</a>; <a href="./references#CD008858-bbs2-0035" title="MacIntyreCR , EgertonT , McCaugheyM , ParrinoJ , CampbellBV , SuSC , et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥ 60 years old. Human Vaccines2010;6(11):894-902. [PMID: 20980796]">MacIntyre 2010</a>; <a href="./references#CD008858-bbs2-0036" title="Investigators: Study Director - GSK Clinical Trials - GlaxoSmithKline. Immunogenicity and safety study of GSK's investigational vaccine (GSK3277511A) when administered in healthy smokers and ex-smokers following receipt of shingrix vaccine. clinicaltrials.gov2022. [CLINICALTRILAS.GOV: NCT03894969]">NCT03894969</a>; <a href="./references#CD008858-bbs2-0037" title="Patterson-BartlettJ , LevinMJ , LangN , SchödelFP , VesseyR , WeingergA . Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine2007;25(41):7087-93. [PMID: 17766015]">Patterson‐Bartlett 2007</a>; <a href="./references#CD008858-bbs2-0038" title="StrezovaA , GodeauxO , AggarwalN , Leroux-RoelsG , Lopez-FauquedM , DammePV , et al. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. Vaccine2017;35(48 Part B):6700-6. [DOI: 10.1016/j.vaccine.2017.10.017]">Strezova 2017</a>; <a href="./references#CD008858-bbs2-0039" title="WeinbergA , KroehlME , JohnsonMJ , HammesA , ReinholdD , LangN , et al. Comparative immune responses to licensed herpes zoster vaccines. Journal of Infectious Diseases2018;218(Suppl 2):81-7. [DOI: 10.1093/infdis/jiy383]">Weinberg 2018</a>). Four of these studies evaluated LZV focusing on immunogenicity, but did not report clinical outcomes (<a href="./references#CD008858-bbs2-0027" title="HaywardAR , BudaK , LevinMJ . Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunology1994;7(1):31-6. [PMID: 7986334]">Hayward 1994</a>; <a href="./references#CD008858-bbs2-0028" title="HaywardAR , BudaK , JonesM , WhiteCJ , LevinMJ . Varicella zoster virus specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunology1996;9(4):241-5. [PMID: 8978020]">Hayward 1996</a>; <a href="./references#CD008858-bbs2-0030" title="JohnsonMJ , LiuC , GhoshD , LangN , LevinMJ , WeinbergA . Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: 5-year persistence. Journal of Infectious Diseases2022;225(8):1477-81. [DOI: 10.1093/infdis/jiab580]">Johnson 2022</a>; <a href="./references#CD008858-bbs2-0037" title="Patterson-BartlettJ , LevinMJ , LangN , SchödelFP , VesseyR , WeingergA . Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine2007;25(41):7087-93. [PMID: 17766015]">Patterson‐Bartlett 2007</a>). <a href="./references#CD008858-bbs2-0039" title="WeinbergA , KroehlME , JohnsonMJ , HammesA , ReinholdD , LangN , et al. Comparative immune responses to licensed herpes zoster vaccines. Journal of Infectious Diseases2018;218(Suppl 2):81-7. [DOI: 10.1093/infdis/jiy383]">Weinberg 2018</a> compared LZV versus RZV, but focused only on immunogenicity. <a href="./references#CD008858-bbs2-0029" title="IrwinMR , OlmsteadR , OxmanMN . Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of tai chi. Journal of the American Geriatrics Society2007;55(4):511-7. [DOI: 10.1111/j.532-5415.2007.01109.x]">Irwin 2007</a> tested an intervention outside the scope of this review (Tai Chi). <a href="./references#CD008858-bbs2-0031" title="KerznerB , MurrayAV , GhengE , IfleR , HarveyPR , TomlinsonM , et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. Journal of the American Geriatrics Society2007;55(10):1499-507. [DOI: 10.1111/j.1532-5415.2007.01397.x]">Kerzner 2007</a> evaluated LZV administered concomitantly with influenza vaccine. <a href="./references#CD008858-bbs2-0032" title="KovacM , LalH , CunninghamAL , LevinMJ , JohnsonRW , CamporaL , et al, ZOE-50/70 Study Group. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine2018;36(12):1537-41. [DOI: 10.1016/j.vaccine.2018.02.029]">Kovac 2018</a> investigated RZV, but reported outcomes and clinical conditions in participants with herpes zoster (postherpetic neuropathy, autoimmune disease) that were not relevant for this review. <a href="./references#CD008858-bbs2-0033" title="Leroux-RoelsI , Leroux-RoelsG , Frédéric ClementF , VandepapelièreP , VassilevV , LedentE , et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults. Journal of Infectious Diseases2012;206(8):1280-90. [DOI: 10.1093/infdis/jis497]">Leroux‐Roels 2012</a> evaluated RZV, but included participants outside the age range of interest (55 to 57 years). <a href="./references#CD008858-bbs2-0034" title="MacaladadN , MarcanoT , GuzmanM , MoyaJ , JuradoF , ThompsonM , et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine2007;25(11):2139-44. [DOI: 10.1016/j.vaccine.2006.11.011]">Macaladad 2007</a> evaluated LZV, but included participants outside the age range of interest (adults aged up to 60 years). <a href="./references#CD008858-bbs2-0035" title="MacIntyreCR , EgertonT , McCaugheyM , ParrinoJ , CampbellBV , SuSC , et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥ 60 years old. Human Vaccines2010;6(11):894-902. [PMID: 20980796]">MacIntyre 2010</a> evaluated LZV, but the comparison arms did not match our inclusion criteria (antizoster + placebo versus antizoster + pneumo‐23 vaccine). <a href="./references#CD008858-bbs2-0038" title="StrezovaA , GodeauxO , AggarwalN , Leroux-RoelsG , Lopez-FauquedM , DammePV , et al. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. Vaccine2017;35(48 Part B):6700-6. [DOI: 10.1016/j.vaccine.2017.10.017]">Strezova 2017</a> conducted a multicentre, lot‐to‐lot consistency study (RZV), with no known systematic difference between comparison groups (Lot A versus Lot B versus Lot C). In <a href="./references#CD008858-bbs2-0036" title="Investigators: Study Director - GSK Clinical Trials - GlaxoSmithKline. Immunogenicity and safety study of GSK's investigational vaccine (GSK3277511A) when administered in healthy smokers and ex-smokers following receipt of shingrix vaccine. clinicaltrials.gov2022. [CLINICALTRILAS.GOV: NCT03894969]">NCT03894969</a>, the intervention was to prevent respiratory disorders. </p> </section> <section id="CD008858-sec-0054"> <h4 class="title">Studies awaiting classification</h4> <p>We classified two new studies as awaiting classification because the age inclusion criterion is 40 years or older, and there is still no information on participants' average age (<a href="./references#CD008858-bbs2-0040" title="NCT03314103. A multi-center, randomized, double-blinded, phase 3 trial to evaluate the efficacy against herpes zoster of a live attenuated varicella-zoster virus vaccine in adults over 40 years of age. clinicaltrials.gov/ct2/show/NCT03314103 (first received 19 October 2017). ">NCT03314103</a>; <a href="./references#CD008858-bbs2-0041" title="NCT04334577. Evaluation of the efficacy of attenuated zoster vaccine, live from herpes zoster in adults aged 40 years or older a multicenter, randomized, double-blinded, placebo-controlled trial phase III. clinicaltrials.gov/ct2/show/NCT04334577 (first received 6 April 2020). ">NCT04334577</a>). We contacted the trial authors to ascertain more details about their participants' age, and we are awaiting their response. </p> </section> <section id="CD008858-sec-0055"> <h4 class="title">Ongoing studies</h4> <p>In this 2022 update, three studies remain as ongoing (<a href="./references#CD008858-bbs2-0042" title="NCT02180295. A lot-to-lot consistency study to evaluate safety, tolerability, and immunogenicity of inactivated varicella zoster virus (VZV) vaccine in healthy adults (V212-014). clinicaltrials.gov/ct2/show/NCT02180295 (first received 2 July 2014). ">NCT02180295</a>; <a href="./references#CD008858-bbs2-0043" title="NCT02526745. Safety and immunogenicity study of live attenuated vaccine against herpes zoster in Chinese adults aged 50 years and older. clinicaltrials.gov/ct2/show/NCT02526745 (first received 18 August 2015). ">NCT02526745</a>; <a href="./references#CD008858-bbs2-0044" title="NCT03116594. Immunogenicity and safety of two lots of NBP608 compared to Zostavax in healthy adult aged 50 and over. clinicaltrials.gov/ct2/show/NCT03116594 (first received 17 April 2017). ">NCT03116594</a>), and two previously ongoing studies have now been published (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>). We identified seven new ongoing studies (<a href="./references#CD008858-bbs2-0045" title="NCT04091451. A safety and immunogenicity study of GSK Biologicals' herpes zoster subunit vaccine (HZ/su) GSK1437173A on a two-dose schedule in adults ≥ 50 years of age with a prior episode of herpes zoster. clinicaltrials.gov (first received 19 April 2017). ">NCT04091451</a>; <a href="./references#CD008858-bbs2-0046" title="NCT04210752. A phase 1, randomised, activator-controlled, double-blind, parallel study to assess the safety, tolerability and explore the immunogenicity of EG-HZ in healthy adult volunteers. clinicaltrials.gov/ct2/show/NCT04210752 (first received 24 February 2020). ">NCT04210752</a>; <a href="./references#CD008858-bbs2-0047" title="NCT04869982. A phase IV, randomized, observer-blind, placebo-controlled, multi-center study to assess the prophylactic efficacy against herpes zoster, immunogenicity and safety of Shingrix when administered intramuscularly on a 2-dose schedule in Chinese adults aged 50 years and older. clinicaltrials.gov/study/NCT04869982 (first received 3 May 2021). ">NCT04869982</a>; <a href="./references#CD008858-bbs2-0048" title="NCT05007041. Safety of simultaneous vaccination with zoster vaccine recombinant (RZV) and quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). clinicaltrials.gov/ct2/show/NCT05007041 (first received 21 September 2021). ">NCT05007041</a>; <a href="./references#CD008858-bbs2-0049" title="NCT05047770. A phase III, randomized, open-label, controlled, multicenter study to evaluate the immune response and safety of both herpes zoster subunit vaccine in healthy adults aged 50 years and older AND the influenza virus vaccine in healthy adults aged 18 years and older when administered sequentially or coadministered with mRNA-1273 booster vaccination. clinicaltrials.gov/ct2/show/NCT05047770 (first received 17 September 2021). ">NCT05047770</a>; <a href="./references#CD008858-bbs2-0050" title="NCT05219253. A phase 3, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the immune response and safety of the herpes zoster subunit vaccine when administered intramuscularly on a 2-dose schedule in adults aged 50 years and older in India. clinicaltrials.gov/ct2/show/NCT05219253 (first received 2 February 2018). ">NCT05219253</a>; <a href="./references#CD008858-bbs2-0051" title="NCT05245838. A phase 1 randomized, subject-blinded, active-controlled, dose escalation, multicenter trial to evaluate the safety, tolerability, and immunogenicity of an investigational herpes zoster vaccine (Z-1018) compared to Shingrix® in healthy adult volunteers between the ages of 50 and 69 years. clinicaltrials.gov/ct2/show/NCT05245838 (first received 18 February 2022). ">NCT05245838</a>). We will check for completion of these studies in future review updates. If complete, we will assess the reports for inclusion in the review. </p> </section> </section> <section id="CD008858-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>Details of the risk of bias assessment for each trial are provided in <a href="./references#CD008858-sec-0108" title="">Characteristics of included studies</a>. The overall risk of bias is presented graphically in <a href="#CD008858-fig-0002">Figure 2</a> and is summarised in <a href="#CD008858-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD008858-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008858-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008858-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008858-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008858-sec-0057"> <h4 class="title">Allocation</h4> <section id="CD008858-sec-0058"> <h5 class="title">Random sequence generation</h5> <p>We assessed 12 studies as at low risk of bias for random sequence generation (selection bias) because they described how randomisation was performed (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>). </p> <p>The other 14 included studies provided no details on the randomisation process and were thus classified as at unclear risk of bias for this domain (<a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> </section> <section id="CD008858-sec-0059"> <h5 class="title">Allocation concealment</h5> <p>We assessed seven studies as at low risk of bias because adequate allocation concealment was described in the study reports (<a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>: <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>). </p> <p>Seventeen studies did not report details of allocation concealment and were thus classified as at unclear risk of bias for this domain (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> </section> </section> <section id="CD008858-sec-0060"> <h4 class="title">Blinding</h4> <p>We assessed 10 studies as at low risk of bias for this domain because it was clear that trial personnel were blinded to assignments (<a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>; <a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>). </p> <p>We judged five studies as at unclear risk of bias because the study reports did not describe the blinding process (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>). </p> <p>We assessed 11 studies as at high risk for this domain as they did not describe how blinding was performed or were open‐label studies (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> </section> <section id="CD008858-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed 17 studies as at low risk of bias for this domain because the flow of participants was clear (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> <p>We classified <a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a> and <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a> as at unclear risk of attrition bias due to insufficient information related to this domain. </p> <p>We assessed the remaining seven studies as at high risk for attrition bias: the participant flow was unclear (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>); the study report provided no data from the first arm of this cross‐over study (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>); and data for many outcomes were presented graphically only (<a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>). </p> </section> <section id="CD008858-sec-0062"> <h4 class="title">Selective reporting</h4> <p>We classified 24 studies as at low risk of reporting bias because the outcomes originally defined by the authors were presented for all groups (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>; <a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> <p>We assessed <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a> as at unclear risk of bias due to insufficient information related to this domain. We judged <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a> as at high risk of reporting bias because not all adverse events proposed in the methods section were presented in the results. </p> </section> <section id="CD008858-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>We only assessed <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a> as having a high risk of bias for this domain because it used a cross‐over design. We classified all of the other included studies as having an unclear risk for other bias due to insufficient information for judgement. </p> </section> </section> <section id="CD008858-sec-0064"> <h3 class="title" id="CD008858-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD008858-tbl-0001"><b>Summary of findings 1</b> Live zoster vaccine versus placebo for preventing herpes zoster in older adults</a>; <a href="./full#CD008858-tbl-0002"><b>Summary of findings 2</b> Recombinant zoster vaccine versus placebo for preventing herpes zoster in older adults</a> </p> <section id="CD008858-sec-0065"> <h4 class="title">Primary outcome</h4> <section id="CD008858-sec-0066"> <h5 class="title">1. Cumulative incidence of herpes zoster</h5> <section id="CD008858-sec-0067"> <h6 class="title">Live attenuated varicella zoster virus (VZV) vaccine (LZV) versus placebo</h6> <p><a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a> evaluated the effectiveness of zoster vaccine versus placebo in reducing the incidence of herpes zoster with a median surveillance of 3.1 years and reported a significant reduction for this outcome in the vaccinated group (risk ratio (RR) 0.49, 95% confidence interval (CI) 0.43 to 0.56; 1 study; 38,546 participants; <a href="./references#CD008858-fig-0004" title="">Analysis 1.1</a>.1). Although this was a significant difference in favour of the intervention, the magnitude of this effect was a risk difference (RD) of 2%, and the number needed to treat for an additional beneficial outcome (NNTB) was 50. The certainty of evidence was moderate, downgraded due to risk of bias (no description of the randomisation process) (<a href="./full#CD008858-tbl-0001">summary of findings Table 1</a>). </p> <p>The vaccinated group had a reduced incidence of herpes zoster as early as 30 days postvaccination (RR 0.33, 95% CI 0.13 to 0.84; <a href="./references#CD008858-fig-0004" title="">Analysis 1.1</a>.2). These cases were excluded from the final intention‐to‐treat (ITT) analysis. At 42 days postvaccination, the benefits of vaccination are clear (RR 0.29, 95% CI 0.13 to 0.68; <a href="./references#CD008858-fig-0004" title="">Analysis 1.1</a>.3). </p> <p>The continuation of the <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a> study was published in 2012 (<a href="./references#CD008858-bbs2-0116" title="SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]">Schmader 2012</a>) (N = 14,270), and evaluated the effectiveness of the vaccine five years after participants had been vaccinated. However, the published data reported different dates for the collection of outcomes in the intervention and the placebo groups. The data from the zoster vaccine group were from December 2004 to March 2006 (16 months), whilst data from the placebo group were reported from December 2004 to September 2005 (10 months), since in October 2005 the zoster vaccine was also offered to participants in the placebo group, as stated by the authors: "Beginning in October 2005, open‐label zoster vaccine was offered without charge to Shingles Prevention Study placebo recipients". We contacted the study authors and asked for data corresponding to the period from December 2004 to September 2005 (10 months) for both groups (vaccine and placebo). The authors replied to our request but did not provide this information and suggested that we should instead assume a uniform rate of events and calculate the estimated number of cases from that. According to their suggestion, we calculated that the inferred rate of incidence of herpes zoster (from December 2004 to September 2005) would be 53 in the vaccine group at 10 months (the total number of herpes zoster cases in the vaccine group was 84 in 16 months, therefore 53 in 10 months), and the incidence of herpes zoster would be 95 cases in 10 months in the placebo group. The resulting RR was 0.53, 95% CI 0.38 to 0.74; risk difference (RD) −0.01, 95% CI −0.01 to −0.00; NNTB 100, in favour of the vaccinated group (<a href="./references#CD008858-fig-0004" title="">Analysis 1.1</a>.4). By the same reasoning, when considering the follow‐up period of five years, there was a significant decrease in the incidence of herpes zoster in the vaccine group compared to the placebo group (RR 0.50, 95% CI 0.44 to 0.56; RD −0.02, 95% CI −0.02 to −0.02; NNTB 50; <a href="./references#CD008858-fig-0004" title="">Analysis 1.1</a>.5). We did not include these data in <a href="./full#CD008858-tbl-0001">summary of findings Table 1</a> as these data were inferred. <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a> did not present any cases of herpes zoster (<a href="./references#CD008858-fig-0004" title="">Analysis 1.1</a>.6). See <a href="./full#CD008858-tbl-0001">summary of findings Table 1</a>. </p> <p><a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a> compared LZV versus placebo in people with controlled diabetes and did not report any confirmed cases of herpes zoster in the one year of follow‐up. However, this study was small (54 participants). </p> <p>The overall certainty of evidence for the primary effectiveness outcome (incidence of herpes zoster) up to three years of follow‐up was moderate for the comparison LZV versus placebo (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). We downgraded the certainty of the evidence due to insufficient information about random sequence generation (<a href="./full#CD008858-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD008858-sec-0068"> <h6 class="title">Higher‐potency LZV versus lower‐potency LZV</h6> <p><a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a> compared higher‐potency LZV versus lower‐potency LZV and reported a higher incidence of herpes zoster (the polymerase chain reaction was positive for wild‐type VZV in two cases) in the first group, but this difference was not significant (RR 2.55, 95% CI 0.12 to 52.99). </p> </section> <section id="CD008858-sec-0069"> <h6 class="title">Live versus inactivated zoster vaccine</h6> <p><a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a> compared LZV versus an inactivated zoster vaccine and reported no difference in the incidence of herpes zoster (RR 0.96, 95% CI 0.06 to 15.17). </p> </section> <section id="CD008858-sec-0070"> <h6 class="title">Adjuvanted recombinant zoster vaccine (RZV) versus placebo</h6> <p><a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a> and <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a> (N = 22,022) tested RZV efficacy. For a follow‐up period of at least 3.2 years, the pooled data showed a decrease in the incidence of herpes zoster in vaccinated participants compared to those who received placebo (RR 0.08, 95% CI 0.03 to 0.23; RD 3%; NNTB 33; <a href="./references#CD008858-fig-0009" title="">Analysis 2.1</a>). Heterogeneity (I² statistic) for this meta‐analysis was 82% (<a href="./references#CD008858-fig-0009" title="">Analysis 2.1</a>). The RR for herpes zoster from data provided by <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a> for the follow‐up period of at least four years was 0.11, 95% CI 0.04 to 0.31; RD 6%; NNTB 16.7 (<a href="./references#CD008858-fig-0010" title="">Analysis 2.2</a>). </p> <p>We assessed certainty of evidence as moderate, downgrading due to insufficient information on allocation concealment and the flow of participants (<a href="./full#CD008858-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> </section> <section id="CD008858-sec-0071"> <h4 class="title">Secondary outcomes</h4> <section id="CD008858-sec-0072"> <h5 class="title">1. Adverse events</h5> <p>A summary of adverse events associated with the use of different types of herpes zoster vaccines compared with placebo or other interventions is presented in <a href="#CD008858-tbl-0003">Table 1</a>. </p> <div class="table" id="CD008858-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of adverse events for LZV versus placebo and RZV versus placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Summary of adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The incidence of the following AEs did not differ significantly between the groups receiving LZV or placebo: 1 or more SAEs (including death), vaccine‐related SAEs, systemic AEs, AEs not related to vaccine, and haematoma at inoculation site. </p> <p>Participants of the vaccinated group had a higher incidence of vaccine‐related AEs and vaccine‐related systemic AEs beyond AEs at the injection site (erythema, pain, swelling, warmth, pruritus, rash, mass, and varicella‐like rash). </p> <p>The injection site AEs were erythema, pruritus, swelling, which lasted longer in the LZV group, and duration of rash, which lasted longer in the placebo group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The incidence of the following AEs did not differ significantly between the groups receiving RZV or placebo: SAEs (including death), SAEs (including death) related to vaccination, and potential immune‐mediated disease. </p> <p>Systemic AEs (myalgia, fatigue, headache, fever, shivering, and gastrointestinal symptom) as well as local AEs (redness, pain, and swelling) occurred more frequently in the RZV group than in the placebo group. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AEs: adverse events<br/>LZV: live zoster vaccine<br/>RZV: recombinant zoster vaccine<br/>SAEs: serious adverse events </p> </div> </div> <section id="CD008858-sec-0073"> <h6 class="title">LZV versus placebo</h6> <p>Details of the adverse events for this comparison are provided in <a href="#CD008858-tbl-0004">Table 2</a>. </p> <div class="table" id="CD008858-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events live zoster vaccine (LZV)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV versus placebo</b> </p> <p>(<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The following adverse events did not differ significantly between groups receiving LZV or placebo: death (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), 1 or more SAE regardless of type of storage of the vaccine (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), vaccine‐related serious adverse events (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), hospitalisation (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), hospitalisation related to HZ (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), systemic adverse events (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>), systemic pruritus (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>), general malaise (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>), headache (<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>), varicella‐like rash not at injection site (from day of vaccination to day 42) (<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>), rash unrelated to HZ (from day of vaccination to day 42) (<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), haematoma at inoculation site (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), and adverse events not related to vaccine (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>). </p> <p>Participants in the vaccinated group had a higher incidence of the following: 1 or more adverse events (RR 1.71, 95% CI 1.38 to 2.11; RD 0.23, 95% CI 0.14 to 0.32; NNTH 4.3, 95% CI 3.1 to 7.1) (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.6) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); vaccine‐related adverse events (RR 2.64, 95% CI 1.21 to 5.75; RD 0.26, 95% CI 0.03 to 0.55; NNTH 3.8, 95% CI 1.8 to 33.3) (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.7) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); and vaccine‐related systemic adverse events (RR 1.30, 95% CI 1.07 to 1.58; RD 0.01, 95% CI 0.00 to 0.03; NNTH 100.0 95% CI 33.3 to 100.00) (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.9) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> <p>The vaccinated group had a higher incidence of adverse events at the injection site (RR 3.73, 95% CI 1.93 to 7.21; RD 0.28, 95% CI 0.15 to 0.41; NNTH 3.6, 95% CI 2.4 to 6.7) (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.15) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>). </p> <p>Specific injection site adverse events also occurred more frequently in the vaccinated group: </p> <p> <ul id="CD008858-list-0011"> <li> <p>participants with erythema: RR 4.30, 95% CI 2.66 to 6.94; RD 0.22, 95% CI 0.05 to 0.38; NNTH 4.5, 95% CI 2.6 to 20.0 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.16) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); </p> </li> <li> <p>participants with pain: RR 6.47, 95% CI 2.67 to 15.68; RD 0.27, 95% CI 0.15 to 0.40; NNTH 3.7, 95% CI 2.5 to 6.7 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.17) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); </p> </li> <li> <p>participants with pruritus: RR 4.32, 95% CI 1.49 to 12.48; RD 0.05, 95% CI 0.01 to 0.09; NNTH 20.0, 95% CI 11.1 to 100.0 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.18) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); </p> </li> <li> <p>participants with swelling: RR 5.84, 95% CI 4.95 to 6.89; RD 0.18, 95% CI 0.07 to 0.29; NNTH 5.6, 95% CI 3.4 to 14.3 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.19) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); </p> </li> <li> <p>participants with warmth: RR 4.73, 95% CI 2.57 to 8.74; RD 0.01, 95% CI 0.01 to 0.02; NNTH 100.0, 95% CI 50.0 to 100.0 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.20) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); </p> </li> <li> <p>participants with rash: RR 3.26, 95% CI 1.31 to 8.11, but no significant RD (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.21) (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>); </p> </li> <li> <p>participants with mass: RR 7.05, 95% CI 1.91 to 26.05; RD 0.15, 95% CI −0.20 to 0.50; NNTH 6.7 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.23) (<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> </li> </ul> </p> <p>Varicella‐like rash at injection site (up to day 42) also occurred more frequently in the vaccinated group: RR 2.86, 95% CI 1.21 to 6.76, but without a significant RD due to the small number of events (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.24) (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> <p>The risk of herpes zoster‐like rash up to 42 days postvaccination was lower in the vaccinated group (RR 0.47, 95% CI 0.27 to 0.84) than in the placebo group, but without a significant RD (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.26) (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> <p><b>Duration of injection site adverse events</b> </p> <p>Injection site adverse events generally lasted longer in the zoster vaccine group. There were significant differences with respect to the duration of the following local adverse events: erythema MD 2.40 days (95% CI 1.56 to 3.24) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.1); pruritus MD 2.40 days (95% CI 1.32 to 3.48) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.3); and swelling MD 1.90 days (95% CI 1.35 to 2.45) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.4). </p> <p>The duration of pain and haematoma did not differ significantly between the groups: MD 1.00 (95% CI −0.10 to 2.10) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.2) and MD −0.50 (95% CI −5.52 to 4.52) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.6), respectively. </p> <p>The duration of rash was longer in the placebo group than in the vaccine group: RR −16.60 (95% CI −33.68 to 0.48) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.5). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High‐potency (∼207,000 pfu/0.65 mL) versus low‐potency (∼58,000 pfu/0.65 mL) zoster vaccine</b> (<a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The comparison of high‐ versus low‐potency zoster vaccine yielded no significant differences between groups for the following adverse events: vaccine‐related adverse events, systemic vaccine‐related adverse events, and vaccine‐related serious adverse events (death). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NBP608 (minimum 27,400 pfu/0.5 ml) versus LZV (minimum 19,400 pfu/0.65 ml)</b> (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For the AEs evaluated, there were no statistical significances. The AEs were: solicited local AEs, pain, redness/erythema, induration/swelling, solicited systemic AEs, fever, fatigue/malaise, myalgia, headache, vomiting, diarrhoea, unsolicited AEs infections and infestations, musculoskeletal and connective tissue disorders, gastrointestinal disorders, skin and subcutaneous tissue disorders, nervous system disorders, immune system disorders, injury, poisoning, and procedural complications, other disorders, SAE within 6 weeks postvaccination, SAE within 26 weeks postvaccination. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Refrigerated versus frozen zoster vaccine</b> </p> <p>(<a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between the refrigerated versus the frozen zoster vaccine for the following adverse events: 1 or more adverse events, vaccine‐related adverse events, systemic adverse events, systemic vaccine‐related adverse events, serious adverse events, vaccine‐related serious adverse events or death. However, there were more injection site adverse events in the group receiving frozen vaccines (RR 0.77, 95% CI 0.60 to 0.98). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 doses versus a single dose of LZV and 2 doses given at different intervals</b> </p> <p>(<a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zoster vaccine 1‐month schedule versus zoster vaccine 3‐month schedule</b> </p> <p>There was no statistical difference between participants who received the doses of zoster vaccine 2 months apart compared to those receiving them 3 months apart: SAE (RR 0.95, 0.14 to 6.70); withdrawal due to AE (RR 2.86, 95% CI 0.12 to 69.80); AE (RR 1.10, 95% CI 0.91 to 1.31); vaccine‐related AE (RR 1.00, 95% CI 0.81 to 1.24); systemic AE (RR 1.34, 95% CI 0.90 to 2.00); vaccine‐related systemic AE (RR 1.27, 95% CI 0.45 to 3.60); rash of interest non‐injection site rashes (RR 0.95, 95% CI 0.06 to 15.14); varicella/varicella‐like rash (RR 0.95, 95% CI 0.06 to 15.14); injection site reaction (RR 0.99, 95% CI 0.80 to 1.23); solicited injection site reaction (RR 1.00, 95% CI 0.81 to 1.25); unsolicited injection site reaction (RR 0.41, 95% CI 0.11 to 1.56); erythema injection site (RR 1.01, 95% CI 0.80 to 1.27); pain injection site (RR 0.84, 95% CI 0.57 to 1.25); swelling injection site (RR 1.05, 95% CI 0.75 to 1.47). </p> <p>No participants from either group reported the following AEs: vaccine‐related SAE; vaccine‐related withdrawal due to AE; non‐serious vaccine‐related withdrawal due to AE; and herpes zoster/zoster‐like rash. </p> <p><b>Zoster vaccine 1‐month schedule versus zoster vaccine single dose</b> </p> <p>Only participants with systemic AE: there were significant differences in favour of the 2 doses 1 month apart, with a higher incidence in the single‐dose group: RR 0.74, 95% CI 0.56 to 0.97; RD −0.07, 95% CI −0.13 to −0.01; NNTH 14.3, 95% CI 7.6 to 100. </p> <p>There was no statistical difference for most adverse events: SAE (RR 0.72, 95% CI 0.16 to 3.30); withdrawal due to AE (RR 0.36, 95% CI 0.05 to 2.82); vaccine‐related withdrawal due to AE (RR 0.21, 95% CI 0.01 to 3.74); non‐serious vaccine‐related withdrawal due to AE (RR 0.21, 95% CI 0.01 to 3.74); AE (RR 0.92, 95% CI 0.80 to 1.05); vaccine‐related AE (RR 0.91, 95% CI 0.77 to 1.08); vaccine‐related systemic AE (RR 0.54, 95% CI 0.26 to 1.12); rash of interest non‐injection site rashes (RR 1.61, 95% CI 0.15 to 17.72); varicella/varicella‐like rash (RR 9.66, 95% CI 0.39 to 236.25); herpes zoster/zoster‐like rash (RR 0.64, 95% CI 0.03 to 13.36); injection site reaction (RR 0.93, 95% CI 0.78 to 1.10); solicited injection site reaction (RR 0.94, 95% CI 0.79 to 1.11); unsolicited injection site reaction (RR 0.35, 95% CI 0.11 to 1.13); injection site erythema (RR 0.98, 95% CI 0.81 to 1.17); injection site pain (RR 0.74, 95% CI 0.54 to 1.01); injection site swelling (RR 1.08, 95% CI 0.82 to 1.41). </p> <p>There were no participants with vaccine‐related SAEs in either group.</p> <p><b>Zoster vaccine 3‐month schedule versus zoster vaccine single dose</b> </p> <p>Participants in the single‐dose group had a higher incidence of the following AEs in comparison to the group that received 2 doses, 3 months apart: AE (RR 0.84, 95% CI 0.72 to 0.97; RD −0.09; 95% CI −0.17 to −0.02; NNTH 11.1, 95% CI 5.9 to 50); systemic AE (RR 0.55, 95% CI 0.39 to 0.76; RD −0.13, 95% CI −0.18 to −0.07; NNTH 7.6, 95% CI 5.6 to 14.3); vaccine‐related systemic AE (RR 0.42, 95% CI 0.18 to 0.98; RD −0.04, 95% CI −0.06 to −0.01; NNTH 25.0, 95% CI 16.6 to 100). There were no significant differences between groups for the following adverse events: SAE (RR 0.75, 95% CI 0.16 to 3.46); withdrawal due to AE (RR 0.18, 95% CI 0.01 to 3.04); vaccine‐related withdrawal due to AE (RR 0.23, 95% CI 0.01 to 3.93); non‐serious vaccine‐related withdrawal due to AE (RR 0.23, 95% CI 0.01 to 3.93); vaccine‐related AE (RR 0.91, 95% CI 0.77 to 1.08); rash of interest non‐injection site rashes (RR 1.69, 95% CI 0.15 to 18.60); varicella/varicella‐like rash (RR 10.14, 95% CI 0.41 to 247.92); herpes zoster/zoster‐like rash (RR 0.68, 95% CI 0.03 to 14.02); injection site reaction (RR 0.93, 95% CI 0.79 to 1.11); solicited injection site reaction (RR 0.93, 95% CI 0.78 to 1.11); unsolicited injection site reaction (RR 0.85, 95% CI 0.38 to 1.91); injection site erythema (RR 0.97, 95% CI 0.80 to 1.17); injection site pain (RR 0.87, 95% CI 0.65 to 1.17); injection site swelling (RR 1.03, 95% CI 0.77 to 1.36). </p> <p>There were no participants with vaccine‐related SAE in either group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV AMP versus LZV</b> (<a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between LZV AMP versus LZV for the following adverse events: participants with 1 or more adverse events; injection site adverse events; injection site erythema; injection site pain; injection site pruritus; and injection site swelling. It is important to note that there was a significant difference for participants with 1 or more serious adverse events (RR 0.25, 95% CI 0.08 to 0.82; RD −0.04, 95% CI −0.07 to −0.00; NNTH 25.0, and no RD favourable to LZV). There were no deaths in this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heat‐treated LZV versus LZV or placebo</b> </p> <p>(<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heat LZV versus LZV</b> </p> <p>There was no SAE in this comparison. There were no significant differences between groups for the following adverse events: 1 or more AE, 1 or more vaccine‐related AE, 1 or more systemic AE, 1 or more vaccine‐related systemic AE, headache, injection site erythema, and injection site pruritus. On the other hand, for 1 or more injection site AE (RR 0.40, 95% CI 0.23 to 0.70; RD −0.40, 95% CI −0.60 to −0.20; NNTH 2.5, 95% CI 1.17 to 5.0); vaccine‐related 1 or more injection site AE (RR 0.48, 95% CI 0.27 to 0.85; RD −0.30, 95% CI −0.50 to −0.09; NNTH 3.3, 95% CI 2 to 11.1); injection site induration (RR 0.36, 95% CI 0.16 to 0.82; RD −0.26, 95% CI −0.45 to −0.08; NNTH 3.8, 95% CI 2.2 to 12.5); injection site pain (RR 0.18, 95% CI 0.07 to 0.48; RD −0.44, 95% CI −0.62 to −0.26; NNTH 2.3, 95% CI 1.6 to 3.8). All significant differences were favourable to heat LZV. </p> <p><b>Heat LZV versus placebo</b> </p> <p>There was no SAE in this comparison. There was no significant difference between heat LZV and placebo for all adverse events reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV IM route versus LZV SC route</b> </p> <p>(<a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The participants who received SC vaccines had a significantly higher incidence of the following adverse events: </p> <p> <ul id="CD008858-list-0012"> <li> <p>at least 1 AE: RR 0.68, 95% CI 0.56 to 0.82; RD −0.22, 95% CI −0.32 to −0.12; NNTH 4.5, 95% CI 3.1 to 8.33; </p> </li> <li> <p>vaccine‐related AE: RR 0.58, 95% CI 0.47 to 0.72; RD −0.28, 95% CI −0.38 to −0.18; NNTH 3.6, 95% CI 2.6 to 5.55; </p> </li> <li> <p>solicited injection site reaction: RR 0.53, 95% CI 0.42 to 0.67; RD −0.30, 95% CI −0.40 to −0.20; NNTH 1.8, 95% CI 2.5 to 5; </p> </li> <li> <p>injection site erythema: RR 0.30, 95% CI 0.21 to 0.44; RD −0.37, 95% CI −0.46 to −0.28; NNTH 2.7, 95% CI 2.1 to 3.5; </p> </li> <li> <p>injection site pain: RR 0.65, 95% CI 0.47 to 0.88; RD −0.14, 95% CI −0.24 to −0.04; NNTH 7.1, 95% CI 4.2 to 25; </p> </li> <li> <p>injection site swelling: RR 0.37, 95% CI 0.24 to 0.56; RD −0.24, 95% CI −0.32 to −0.15; NNTH 4.2, 95% CI 3.1 to 6.7; </p> </li> <li> <p>injection site pruritus: RR 0.27, 95% CI 0.08 to 0.97; RD −0.05, 95% CI −0.09 to −0.00; NNTH 20.0, 95% CI 0 to 11.0. </p> </li> </ul> </p> <p>There were no significant differences between groups for the following adverse events: all systemic adverse events: RR 1.03, 95% CI 0.70 to 1.51; vaccine‐related systemic AE: RR 0.93, 95% CI 0.44 to 1.98; headache considered as vaccine‐related by the investigator: RR 0.75, 95% CI 0.17 to 3.32; unsolicited injection site reaction: RR 0.65, 95% CI 0.29 to 1.45; severe injection site erythema (&gt; 10 cm): RR 0.67, 95% CI 0.11 to 3.96; severe injection site pain (inability to work or perform usual activity): RR 1.01, 95% CI 0.14 to 7.06; severe injection site swelling (&gt; 10 cm): RR 0.25, 95% CI 0.03 to 2.23. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV intradermal route versus LZV SC route</b> (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Full‐dose intradermal versus full‐dose subcutaneous</b> </p> <p>There were significant differences in favour of LZV SC for 2 AEs: 1 or more injection site AEs (RR 1.53, 95% CI 1.12 to 2.09; RD 0.27, 95% CI 0.08 to 0.47; NNTH 3.7, 95% CI 2.1 to 12.5) and erythema (RR 2.49, 95% CI 1.59 to 3.89; RD 0.46, 95% CI 0.27 to 0.65; NNTH 2.2, 95% CI 1.5 to 3.7). There were no significant differences between groups for the following adverse events: pain, swelling, induration, pruritus, haematoma, anaesthesia, or rash. </p> <p><b>1/3 dose intradermal versus full‐dose subcutaneous</b> </p> <p>There were significant differences in favour of full‐dose LZV SC for the following AEs: erythema (RR 1.95, 95% CI 1.20 to 3.18; RD 0.29, 95% CI 0.09 to 0.50; NNTH 3.4, 95% CI 2.0 to 11.1) and induration (RR 3.57, 95% CI 1.38 to 9.23; RD 0.25, 95% CI 0.07 to 0.42; NNTH 4.0, 95% CI 2.4 to 14.3). There was no significant difference between groups for the other adverse events. </p> <p><b>1/10 dose intradermal versus full‐dose subcutaneous</b> </p> <p>There was no significant difference between groups for any adverse events.</p> <p><b>1/27 dose intradermal versus full‐dose subcutaneous</b> </p> <p>Erythema (RR 1.72, 95% CI 1.03 to 2.88; RD 0.22, 95% CI 0.01 to 0.43; NNTH 4.5, 95% CI 2.30 to 100.0) and induration (RR 3.06, 95% CI 1.14 to 8.17; RD 0.20, 95% CI 0.03 to 0.37; NNTH 5.0, 95% CI 2.7.0 to 3.3). There was no significant difference between groups for the other adverse events. </p> <p><b>Full‐dose intradermal versus 1/3 dose subcutaneous</b> </p> <p>There was a difference between the groups favourable to the subcutaneous 1/3 dose group, which had a significantly lower incidence of the following AEs: 1 or more injection site adverse events (RR 3.86, 95% CI 1.95 to 7.63; RD 0.59, 95% CI 0.40 to 0.77; NNTH 1.7, 95% CI 1.3 to 2.5); erythema (RR 5.20, 95% CI 2.27 to 11.93; RD 0.62, 95% CI 0.43 to 0.80; NNTH 1.6, 95% CI 1.2 to 2.3); and induration (RR 6.00, 95% CI 1.45 to 24.81; RD 0.29, 95% CI 0.12 to 0.47; NNTH 3.4, 95% CI 2.1 to 8.3). There was no significant difference between groups for the other adverse events. </p> <p><b>1/3 dose intradermal versus 1/3 dose subcutaneous</b> </p> <p>There was no significant difference between groups for all adverse events reported.</p> <p><b>1/10 dose intradermal versus 1/3 dose subcutaneous</b> </p> <p>There were significant differences in favour of 1/3 dose SC for the following AEs: 1 or more injection site adverse events (RR 2.71, 95% CI 1.32 to 5.60; RD 0.35, 95% CI 0.14 to 0.57; NNTH 2.9, 95% CI 1.8 to 7.1); erythema (RR 3.20, 95% CI 1.32 to 7.75; RD 0.32, 95% CI 0.12 to 0.53; NNTH 3.1, 95% CI 1.9 to 8.3); and induration (RR 5.50, 95% CI 1.32 to 22.98; RD 0.26, 95% CI 0.09 to 0.44; NNTH 3.8, 95% CI 2.3 to 11.1). There was no significant difference between groups for the other adverse events. </p> <p><b>1/27 dose intradermal versus 1/3 dose subcutaneous</b> </p> <p>There were significant differences in favour of 1/3 dose SC for the following AEs: 1 or more injection site adverse events (RR 2.71, 95% CI 1.32 to 5.60; RD 0.35, 95% CI 0.14 to 0.57; NNTH 2.9, 95% CI 1.8 to 7.1); erythema (RR 3.60, 95% CI 1.51 to 8.59; RD 0.38, 95% CI 0.18 to 0.59; NNTH 2.6, 95% CI 1.7 to 5.6); and induration (RR 5.00, 95% CI 1.18 to 21.14; RD 0.24, 95% CI 0.06 to 0.41; NNTH 4.2, 95% CI 2.4 to 16.7). There was no significant difference between groups for the other adverse events. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV versus pneumo‐23 vaccine</b> </p> <p>(<a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study compared 3 different concentrations of plaque‐forming units (pfu) of live attenuated VZV and reported the following adverse events: </p> <p><b>3200 pfu VZV/dose versus pneumo‐23</b> </p> <p>There was a lower incidence of 1 or more injection site reactions in the group vaccinated with the 3200 pfu/dose zoster vaccine (RR 0.61, 95% CI 0.41 to 0.91) as well as pain at the injection site (RR 0.49, 95% CI 0.30 to 0.81). </p> <p>There were no significant differences between the 3200 pfu/dose zoster vaccine and the pneumo‐23 vaccine for the following local adverse events: induration (≥ 2 cm diameter injection site), probably vaccine‐related injection site pain, redness (≥ 2 cm diameter injection site), pruritus or vesicles (no patients had vesicles in the 3200 pfu/dose zoster vaccine nor the pneumo‐23 groups). </p> <p><b>8500 pfu VZV/dose versus pneumo‐23</b> </p> <p>There was a lower incidence of 1 or more injection site reaction in the group vaccinated with the 8500 pfu/dose zoster vaccine (RR 0.63, 95% CI 0.43 to 0.93). </p> <p>There were no significant differences for the following injection site adverse events between participants who received the 8500 pfu/dose VZV vaccine and those who received the pneumo‐23 vaccine: induration (≥ 2 cm diameter injection site), pain (injection site), probably vaccine‐related injection site pain, redness, pruritus, and vesicles. </p> <p><b>41,650 pfu VZV/dose VZV versus pneumo‐23</b> </p> <p>Participants receiving the 41,650 pfu/dose zoster vaccine had significantly lower rates of one or more injection site reaction (RR 0.41, 95% CI 0.24 to 0.68) and pain at injection site (RR 0.43, 95% CI 0.25 to 0.74) than those receiving the pneumo‐23 vaccine. </p> <p>There were no significant differences between the groups for the following injection site adverse events: induration (≥ 2 cm diameter injection site), probably vaccine‐related injection site pain, redness (≥ 2 cm diameter injection site), pruritus, and vesicles (no patients had vesicles in the 41,650 pfu/dose zoster vaccine nor the pneumo‐23 vaccine groups). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV + IIV4 concomitant administration versus LZV + IIV4 sequential administration</b> (<a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between groups for the following: death, serious adverse events, one or more adverse events, non injection‐site adverse events, non injection site vaccine‐related AE, injection‐site adverse events. </p> <p>There were no vaccine‐related adverse events.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse event or adverse experiences<br/>AMP: alternative manufacturing process<br/>CI: confidence interval<br/>Elderly or older adults: aged ≥ 60 years old<br/>Frozen: −15 °C or colder<br/>gE: recombinant subunit VZV composed of glycoprotein E<br/>gE/saline: unadjuvanted gE<br/>Heat LZV: heat‐treated LZV<br/>HZ: herpes zoster<br/>ID: identification<br/>IIV4: inactivated quadrivalent influenza vaccines<br/>IM: intramuscular<br/>ISRs: injection site adverse reactions<br/>ITT: intention‐to‐treat<br/>LZV or ZV: live zoster vaccine (live attenuated Oka varicella zoster virus vaccine) minimum of 19,400 pfu (0.65 mL)<br/>MD: mean difference<br/>mL: millilitres<br/>NBP608 LZV: live zoster vaccine (live attenuated Oka varicella zoster virus vaccine) with a minimum of 27,400 pfu (0.50 mL)<br/>NNTB: number needed to treat for an additional beneficial outcome<br/>NNTH: number needed to treat for an additional harmful outcome<br/>pfu: plaque‐forming units<br/>pIMDs: potential immune‐mediated diseases<br/>pneumo‐23 vaccine: 23–valent pneumococcal polysaccharide vaccine<br/>RD: risk difference<br/>Refrigerated: 2 °C to 8 °C<br/>RR: risk ratio<br/>SAEs: serious adverse events<br/>SC: subcutaneously or subcutaneous<br/>VZV: varicella zoster virus </p> </div> </div> <p>Seven studies (N = 51,952) compared herpes zoster vaccine versus placebo and presented safety data that could be pooled into a meta‐analysis (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>). <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a> presented a more detailed assessment of safety for a subgroup of participants (zoster vaccine N = 3345; placebo N = 3271). <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a> assessed only serious adverse events. </p> <p>There were no significant differences between groups receiving LZV or placebo for death (RR 1.01, 95% CI 0.92 to 1.11; 50,820 participants; <a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.1) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>); one or more serious adverse events (RR 1.08, 95% CI 0.95 to 1.21; 51,029 participants; <a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.2) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); vaccine‐related serious adverse events (RR 0.99, 95% CI 0.24 to 4.15; 50,766 participants; <a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.3) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>); hospitalised (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.4) or hospitalisation related to herpes zoster (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.5). </p> <p>Participants who received the active agent had a higher risk of adverse events than those in the placebo group. When we pooled data from studies reporting the number of participants with one or more adverse event (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>), we observed an increased risk in the vaccine group (RR 1.71, 95% CI 1.38 to 2.11; RD 0.23, 95% CI 0.14 to 0.32; number needed to treat for an additional harmful outcome (NNTH) 4.3, 95% CI 3.1 to 7.1; 7119 participants; <a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.6). </p> <p>Vaccine‐related adverse events occurred more frequently in the vaccinated group than in the placebo group (RR 2.64, 95% CI 1.21 to 5.75; RD 0.26, 95% CI −0.03 to 0.55; NNTH 3.8, 95% CI 1.8 to 33.3; 342 participants; <a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.7) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>). </p> <p>Systemic adverse events were more frequent in the vaccinated groups (RR 1.24, 95% CI 0.82 to 1.87; 7119 participants; <a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.8) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>). Regarding systemic adverse events (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.8), there was a discrepancy between <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a> and the other studies. When we were reviewing data collection, we noted at the bottom of the table with this information, the authors clarified that the vaccine‐related systemic events were also included in "systemic events". This may have led to the assumption that the outcome systemic adverse events favoured the placebo group. However, the pooled data showed no differences between groups for this adverse event. </p> <p>Vaccine‐related systemic adverse events occurred more frequently in the vaccinated group than in the placebo group (pooled data RR 1.30, 95% CI 1.07 to 1.58; RD 0.01, 95% CI 0.00 to 0.03; NNTH 100.0, 95% CI 33.3 to 100.00; 6856 participants; <a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.9) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> <p>The vaccinated group had a higher risk of injection site adverse events than the placebo group (pooled RR 3.73, 95% CI 1.93 to 7.21; RD 0.28, 95% CI 0.15 to 0.41; NNTH 3.6, 95% CI 2.4 to 6.7; 7040 participants; <a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.15) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>). </p> <p>Specific injection site adverse events occurred more frequently in the vaccinated group but were mild to moderate in intensity. </p> <p>The most important adverse events (serious adverse events, hospitalisation, injection site adverse events, and death) are presented in <a href="./full#CD008858-tbl-0001">summary of findings Table 1</a>. Although the vaccinated groups had a higher rate of injection site adverse events, this higher rate was not detected for serious adverse events, hospitalisation, or deaths. </p> <p>For the safety studies with different formulations of LZV (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>), or LZV compared to pneumo‐23 (<a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>), or LZV + IIV4 co‐administration concomitant versus sequential administration (<a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>), there were no significant differences between comparison groups. The administration of LZV using the subcutaneous (SC) route was associated with a higher incidence of adverse events compared to intramuscular (IM) administration of the same vaccine (<a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>). There were fewer adverse events in participants who received the LZV using the SC route than the intradermal (ID) route (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>). </p> <p>We judged the certainty of evidence for safety outcomes up to three years of follow‐up (hospital admissions or participants with injection site adverse events) as moderate, downgrading by one level due to risk of bias related to insufficient information on random sequence generation (<a href="./full#CD008858-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD008858-sec-0074"> <h6 class="title">RZV versus placebo</h6> <p>Details of the adverse events for this comparison are provided in <a href="#CD008858-tbl-0005">Table 3</a>. </p> <div class="table" id="CD008858-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: adjuvanted recombinant varicella zoster virus subunit zoster vaccine (RZV)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV versus placebo</b> (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The adverse events related to RZV versus placebo were:</p> <p> <ul id="CD008858-list-0013"> <li> <p>deaths: RR 0.94, 95% CI 0.84 to 1.04 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.1); </p> </li> <li> <p>deaths within 30 days after vaccination: RR 1.15, 95% CI 0.42 to 3.16 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.2); </p> </li> <li> <p>serious adverse events: RR 0.97, 95% CI 0.91 to 1.03 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.3); </p> </li> <li> <p>with serious adverse events within 30 days after vaccination: RR 0.90, 95% CI 0.67 to 1.20 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.4); </p> </li> <li> <p>serious adverse events within 30 days after vaccination related to vaccination: RR 0.33, 95% CI 0.03 to 3.21 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.5); </p> </li> <li> <p>any symptom: RR 2.41, 95% CI 2.02 to 2.88; RD 0.47, 95% CI 0.45 to 0.49; NNTH 2.1, 95% CI 2.0 to 2.2 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.6); </p> </li> <li> <p>any symptom grade 3: RR 5.29, 95% CI 4.48 to 6.26; RD 0.12, 95% CI 0.08 to 0.16; NNTH 8.3, 95% CI 6.3 to 12.5 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.7); </p> </li> <li> <p>any symptom grade 3 related to vaccination: RR 8.37, 95% CI 6.69 to 10.47; RD 0.14, 95% CI 0.13 to 0.15; NNTH 7.1, 95% CI 6.7 to 7.7 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.8); </p> </li> <li> <p>any systemic symptom: RR 2.23, 95% CI 2.12 to 2.34; RD 0.33, 95% CI 0.24 to 0.41; NNTH 3.0, 95% CI 2.4 to 4.2 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.9); </p> </li> <li> <p>any systemic symptom grade 3: RR 4.29, 95% CI 3.01 to 6.11; RD 0.07, 95% CI 0.02 to 0.12; NNTH 14.3, 95% CI 8.3.0 to 50.0 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.10); </p> </li> <li> <p>potential immune‐mediated disease: RR 0.88, 95% CI 0.71 to 1.08 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.11); </p> </li> <li> <p>myalgia: RR 3.82, 95% CI 3.52 to 4.16; RD 0.33, 95% CI 0.31 to 0.35; NNTH 3.0, 95% CI 2.9 to 3.3 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.12); </p> </li> <li> <p>fatigue: RR 2.51, 95% CI 1.99 to 3.17; RD 0.24, 95% CI 0.12 to 0.35; NNTH 4.2, 95% CI 2.9 to 8.3 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.13); </p> </li> <li> <p>headache: RR 2.44, 95% CI 2.26 to 2.63; RD 0.22, 95% CI 0.21 to 0.24; NNTH 4.5, 95% CI 4.1 to 4.8 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.14); </p> </li> <li> <p>fever: RR 6.45, 95% CI 4.61 to 9.04; RD 0.14, 95% CI 0.06 to 0.23; NNTH 7.1, 95% CI 4.3 to 16.7 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.15); </p> </li> <li> <p>shivering: RR 4.35, 95% CI 3.26 to 5.81; RD 0.16, 95% CI 0.05 to 0.28; NNTH 6.3, 95% CI 3.6 to 20.0 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.16); </p> </li> <li> <p>gastrointestinal symptom: RR 1.75, 95% CI 1.21 to 2.55; RD 0.06, 95% CI 0.00 to 0.12 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.17); </p> </li> <li> <p>any local symptom: RR 6.89, 95% CI 6.37 to 7.45; RD 0.67, 95% CI 0.62 to 0.73; NNTH 1.5, 95% CI 1.4 to 1.6 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.18); </p> </li> <li> <p>any local symptom grade 3: RR 12.69, 95% CI 2.87 to 56.06; RD 0.09, 95% CI 0.08 to 0.10; NNTH 11.1, 95% CI 10 to 12.5 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.19); </p> </li> <li> <p>local redness: RR 28.93, 95% CI 22.62 to 37.00; RD 0.37, 95% CI 0.35 to 0.38; NNTH 2.7, 95% CI 2.6 to 2.9 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.20); </p> </li> <li> <p>local pain: RR 7.14, 95% CI 6.58 to 7.74; RD 0.64, 95% CI 0.57 to 0.72; NNTH 1.6, 95% CI 1.4 to 1.8 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.21); </p> </li> <li> <p>local swelling: RR 28.26, 95% CI 15.91 to 50.20; RD 0.24, 95% CI 0.21 to 0.27; NNTH 4.2, 95% CI 3.7 to 4.8 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.22); </p> </li> <li> <p>unsolicited report of adverse events: RR 1.07, 95% CI 1.00 to 1.14; RD 0.02, 95% CI 0.00 to 0.04 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.23); </p> </li> <li> <p>unsolicited report of adverse events grade 3: RR 1.38, 95% CI 1.12 to 1.69; RD 0.01, 95% CI 0.00 to 0.02 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.24). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV: lower or higher quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline</b> </p> <p>(<a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The incidence of adverse events in participants randomised to 4 different groups was compared as follows: </p> <p> <ol id="CD008858-list-0014"> <li> <p>Participants who received smaller amounts of adjuvant (AS01E) plus gE subunit VZV injection </p> </li> <li> <p>Participants who received larger amounts of adjuvant (AS01B) plus gE subunit VZV injection</p> </li> <li> <p>Participants who received unadjuvanted gE subunit VZV injection</p> </li> <li> <p>Participants who received saline injections</p> </li> </ol> </p> <p>We compared each of the groups with all of the other groups (total of 6 comparisons) as follows: </p> <p><b>50 μg gE/AS01<sub>E</sub> versus 50 μg gE/AS01<sub>B</sub> </b> </p> <p>There was a significantly higher incidence of adverse events in participants who received a higher quantity of adjuvant (AS01<sub>B</sub>): </p> <p> <ul id="CD008858-list-0015"> <li> <p>any symptom: RR 0.89, 95% CI 0.80 to 0.99; RD −0.09, 95% CI −0.18 to −0.01; NNTH 11.1, 95% CI 5.6 to 100.0; </p> </li> <li> <p>fatigue: RR 0.73, 95% CI 0.55 to 0.96; RD −0.13, 95% CI −0.24 to −0.02; NNTH 7.7, 95% CI 4.2 to 50.0; </p> </li> <li> <p>headache: RR 0.67, 95% CI 0.47 to 0.94; RD −0.13, 95% CI −0.23 to −0.02; NNTH 7.7, 95% CI 4.3 to 50.0; </p> </li> <li> <p>any local symptom: RR 0.85, 95% CI 0.75 to 0.96; RD −0.13, 95% CI −0.22 to −0.04; NNTH 7.7, 95% CI 4.5 to 25.0; </p> </li> <li> <p>local redness: RR 0.59, 95% CI 0.39 to 0.91; RD −0.12, 95% CI −0.21 to −0.02; NNTH 8.3, 95% CI 4.7 to 50.0; </p> </li> <li> <p>local pain: RR 0.84, 95% CI 0.74 to 0.95; RD −0.14, 95% CI −0.23 to −0.04; NNTH 7.1, 95% CI 4.3 to 25.0. </p> </li> </ul> </p> <p>There were no significant differences between groups for all other adverse events: any grade 3 symptom, any general symptom, any general grade 3 symptom, grade 3 fatigue, fever, gastrointestinal symptoms, grade 3 gastrointestinal symptoms, grade 3 headache, myalgia, grade 3 myalgia, any grade 3 local symptom, local grade 3 pain, local grade 3 redness, local swelling and local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>50 μg gE/AS01<sub>E</sub> versus 50 μg gE/saline (unadjuvanted)</b> </p> <p> <ul id="CD008858-list-0016"> <li> <p>any symptom: RR 1.76, 95% CI 1.34 to 2.32; RD 0.33, 95% CI 0.20 to 0.47; NNTH 3.0, 95% CI 2.1 to 5.0; </p> </li> <li> <p>any general symptom: RR 1.67, 95% CI 1.17 to 2.40; RD 0.22, 95% CI 0.09 to 0.36; NNTH 4.5, 95% CI 2.7 to 11.1; </p> </li> <li> <p>myalgia: RR 2.00, 95% CI 1.14 to 3.52; RD 0.16, 95% CI 0.05 to 0.28; NNTH 6.25, 95% CI 3.5 to 20.0; </p> </li> <li> <p>fever: RR 18.25, 95% CI 1.12 to 298.73; RD 0.12, 95% CI 0.06 to 0.18; NNTH 8.3, 95% CI 5.5 to 16.6; </p> </li> <li> <p>any local symptom: RR 3.05, 95% CI 1.99 to 4.69; RD 0.48, 95% CI 0.36 to 0.60; NNTH 2.0, 95% CI 1.6 to 2.7; </p> </li> <li> <p>local redness: RR 4.25, 95% CI 1.33 to 13.57; RD 0.13, 95% CI 0.06 to 0.21; NNTH 7.6, 95% CI 4.7 to 16.6; </p> </li> <li> <p>local pain: RR 3.64, 95% CI 2.25 to 5.90; RD 0.51, 95% CI 0.39 to 0.62; NNTH 1.9, 95% CI 1.6 to 2.5; </p> </li> <li> <p>local swelling: RR 4.08, 95% CI 1.27 to 13.08; RD 0.13, 95% CI 0.05 to 0.20; NNTH 7.6, 95% CI 5.0 to 20. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured the unadjuvanted gE group. </p> <p>There were no significant differences between groups for the following adverse events: any grade 3 symptom, any general grade 3 symptom, fatigue, grade 3 fatigue, gastrointestinal symptoms, grade 3 gastrointestinal symptoms, headache, grade 3 myalgia, any local grade 3 symptom, local grade 3 pain, local grade 3 redness and local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever or grade 3 headache in either group.</p> <p><b>50 μg gE/AS01<sub>B</sub> versus 50 μg gE/saline (unadjuvanted)</b> </p> <p> <ul id="CD008858-list-0017"> <li> <p>any symptom: RR 1.98, 95% CI 1.51 to 2.58; RD 0.43, 95% CI 0.30 to 0.55; NNTH 2.3, 95% CI 1.8 to 3.3; </p> </li> <li> <p>any general symptom: RR 1.93, 95% CI 1.36 to 2.73; RD 0.30, 95% CI 0.17 to 0.44; NNTH 3.3, 95% CI 2.2 to 5.8; </p> </li> <li> <p>myalgia: RR 2.51, 95% CI 1.45 to 4.36; RD 0.25, 95% CI 0.13 to 0.36; NNTH 4.0, 95% CI 2.7 to 7.6; </p> </li> <li> <p>fatigue: RR 2.19, 95% CI 1.38 to 3.48; RD 0.26, 95% CI 0.14 to 0.38; NNTH 3.8, 95% CI 2.6 to 7.1; </p> </li> <li> <p>headache: RR 2.73, 95% CI 1.48 to 5.03; RD 0.24, 95% CI 0.13 to 0.35; NNTH 4.1, 95% CI 2.8 to 7.6; </p> </li> <li> <p>fever: RR 24.99, 95% CI 1.54 to 404.89; RD 0.17, 95% CI 0.10 to 0.23; NNTH 5.8, 95% CI 4.3 to 10.0; </p> </li> <li> <p>any local symptom: RR 3.61, 95% CI 2.36 to 5.50; RD 0.61, 95% CI 0.49 to 0.72; NNTH 1.6, 95% CI 1.3 to 2.0; </p> </li> <li> <p>local redness: RR 7.14, 95% CI 2.29 to 22.22; RD 0.25, 95% CI 0.17 to 0.34; NNTH 4.0, 95% CI 2.9 to 5.8; </p> </li> <li> <p>local pain: RR 4.35, 95% CI 2.70 to 7.00; RD 0.64, 95% CI 0.53 to 0.75; NNTH 1.5, 95% CI 1.3 to 1.8; </p> </li> <li> <p>local swelling: RR 3.73, 95% CI 1.16 to 12.02; RD 0.11, 95% CI 0.04 to 0.19; NNTH 9.0, 95% CI 5.2 to 25. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured unadjuvanted gE.</p> <p>There were no significant differences between groups for the following adverse events: any grade 3 symptom, any general grade 3 symptom, grade 3 fatigue, gastrointestinal symptoms, grade 3 headache, grade 3 myalgia, any local grade 3 symptom, local grade 3 pain, local grade 3 redness and local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever or grade 3 gastrointestinal symptoms in either group.</p> <p><b>50 μg gE/AS01<sub>E</sub> versus saline</b> </p> <p> <ul id="CD008858-list-0018"> <li> <p>any symptom: RR 3.67, 95% CI 1.97 to 6.83; RD 0.56, 95% CI 0.42 to 0.71; NNTH 1.7, 95% CI 1.4 to 2.3; </p> </li> <li> <p>any general symptom: RR 2.99, 95% CI 1.51 to 5.92; RD 0.37, 95% CI 0.22 to 0.51; NNTH 9.1, 95% CI 1.9 to 4.5; </p> </li> <li> <p>myalgia: RR 6.25, 95% CI 1.59 to 24.55; RD 0.28, 95% CI 0.17 to 0.38; NNTH 3.5, 95% CI 2.6 to 5.8; </p> </li> <li> <p>any local symptom: RR 9.01, 95% CI 3.03 to 26.82; RD 0.63, 95% CI 0.52 to 0.74; NNTH 1.5, 95% CI 1.3 to 1.9; </p> </li> <li> <p>local pain: RR 8.84, 95% CI 2.97 to 26.33; RD 0.62, 95% CI 0.51 to 0.73; NNTH 1.6, 95% CI 1.3 to 1.9. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured the saline group.</p> <p>There were no significant differences between groups for the following adverse events: any grade 3 symptom, any general grade 3 symptom, fatigue, grade 3 fatigue, fever, gastrointestinal symptoms, grade 3 gastrointestinal symptoms, headache, grade 3 headache, grade 3 myalgia, any local grade 3 symptom, local grade 3 pain, local redness, local grade 3 redness, local swelling and local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever or grade 3 headache in either group.</p> <p><b>50 μg gE/AS01<sub>B</sub> versus saline</b> </p> <p> <ul id="CD008858-list-0019"> <li> <p>any symptom: RR 4.12, 95% CI 2.22 to 7.64; RD 0.66, 95% CI 0.52 to 0.80; NNTH 1.5, 95% CI 1.2 to 1.9; </p> </li> <li> <p>any general symptom: RR 3.44, 95% CI 1.74 to 6.79; RD 0.45, 95% CI 0.30 to 0.59; NNTH 2.2, 95% CI 1.6 to 3.3; </p> </li> <li> <p>myalgia: RR 7.85, 95% CI 2.01 to 30.67; RD 0.36, 95% CI 0.25 to 0.47; NNTH 2.7, 95% CI 2.1 to 4.0; </p> </li> <li> <p>fatigue: RR 2.61, 95% CI 1.31 to 5.19; RD 0.30, 95% CI 0.15 to 0.44; NNTH 1.3, 95% CI 2.2 to 6.6; </p> </li> <li> <p>headache: RR 3.55, 95% CI 1.37 to 9.17; RD 0.27, 95% CI 0.14 to 0.39; NNTH 3.7, 95% CI 2.5 to 7.1; </p> </li> <li> <p>any local symptom: RR 10.64, 95% CI 3.58 to 31.59; RD 0.76, 95% CI 0.66 to 0.86; NNTH 1.3, 95% CI 1.1 to 1.5; </p> </li> <li> <p>local redness: RR 22.99, 95% CI 1.45 to 365.01; RD 0.29, 95% CI 0.21 to 0.37; NNTH 3.4, 95% CI 2.7 to 4.7; </p> </li> <li> <p>local pain: RR 10.56, 95% CI 3.55 to 31.34; RD 0.75, 95% CI 0.65 to 0.86; NNTH 1.3, 95% CI 1.1 to 1.5. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured the saline group.</p> <p>There were no significant differences between groups for the following adverse events: any grade 3 symptom, any general grade 3 symptom, grade 3 fatigue, fever, gastrointestinal symptoms, grade 3 gastrointestinal symptoms, grade 3 headache, grade 3 myalgia, any local grade 3 symptom, local grade 3 pain, local grade 3 redness, local swelling and local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>50 μg gE/saline (unadjuvanted) versus saline</b> </p> <p> <ul id="CD008858-list-0020"> <li> <p>any symptom: RR 2.08, 95% CI 1.07 to 4.06; RD 0.23, 95% CI 0.06 to 0.40; NNTH 4.3, 95% CI 2.5 to 16.6 (favouring saline). </p> </li> </ul> </p> <p>There were no significant differences between groups for the following adverse events: any grade 3 symptom, any general symptom, any general grade 3 symptom, fatigue, grade 3 fatigue, fever, gastrointestinal symptoms, grade 3 gastrointestinal symptoms, headache, myalgia, grade 3 myalgia, any local symptom, local pain, local redness and local swelling, or consent withdrawal. </p> <p>No participants in either group had grade 3 fever, grade 3 headache, any local grade 3 symptom, local grade 3 pain, local grade 3 redness, local grade 3 swelling, loss to follow‐up, and serious adverse events. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline</b> (<a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The incidence of adverse events in participants randomised to 5 different groups was compared as follows: </p> <p> <ol id="CD008858-list-0021"> <li> <p>Participants receiving 25 µg adjuvanted gE/AS01<sub>B</sub> injection </p> </li> <li> <p>Participants receiving 50 µg adjuvanted gE/AS01<sub>B</sub> injection </p> </li> <li> <p>Participants receiving 100 µg adjuvanted gE/AS01<sub>B</sub> injection </p> </li> <li> <p>Participants receiving 1 dose saline injection + 1 dose 100 µg gE 2 months later injection</p> </li> <li> <p>Participants receiving 100 µg gE/saline</p> </li> </ol> </p> <p>We compared each of the groups to all other groups (total of 10 comparisons) as follows:</p> <p><b>25 µg gE/AS01<sub>B</sub> versus 50 µg gE/AS01<sub>B</sub> </b> </p> <p>There were no differences between groups in the incidence of the following adverse events: any fatigue, grade 3 fatigue, any fever, grade 3 fever, any headache, grade 3 headache, any myalgia, grade 3 myalgia, local pain, local grade 3 pain, local redness, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p><b>25 µg gE/AS01<sub>B</sub> versus 100 µg gE/AS01<sub>B</sub> </b> </p> <p>There were no differences between groups in the incidence of the following adverse events: any fatigue, grade 3 fatigue, any fever, any headache, grade 3 headache, any myalgia, grade 3 myalgia, local pain, grade 3 local pain, local redness, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p><b>50 µg gE/AS01<sub>B</sub> versus 100 µg gE/AS01<sub>B</sub> </b> </p> <p> <ul id="CD008858-list-0022"> <li> <p>any myalgia: RR 1.26, 95% CI 1.01 to 1.59; RD 0.11, 95% CI 0.00 to 0.22; NNTH 9.0, 95% CI 0 to 4.5 (favouring 100 µg gE/AS01<sub>B</sub>). </p> </li> </ul> </p> <p>There were no differences between groups in the incidence of other adverse events: any fatigue, grade 3 fatigue, any fever, grade 3 fever, any headache, grade 3 headache, grade 3 myalgia, local pain, local grade 3 pain, local redness, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, and serious adverse events. </p> <p><b>25 µg gE/AS01<sub>B</sub> versus 100 µg gE/saline (unadjuvanted gE)</b> </p> <p> <ul id="CD008858-list-0023"> <li> <p>any myalgia: RR 2.71, 95% CI 1.46 to 5.03; RD 0.28, 95% CI 0.16 to 0.41; NNTH 3.5, 95% CI 2.4 to 6.2; </p> </li> <li> <p>any fatigue: RR 1.89, 95% CI 1.11 to 3.22; RD 0.20, 95% CI 0.06 to 0.33; NNTH 5.0, 95% CI 3.0 to 16.6; </p> </li> <li> <p>local redness: RR 11.20, 95% CI 2.84 to 44.15; RD 0.38, 95% CI 0.29 to 0.47; NNTH 2.6, 95% CI 2.1 to 3.4; </p> </li> <li> <p>local pain: RR 4.21, 95% CI 2.30 to 7.70; RD 0.53, 95% CI 0.41 to 0.66; NNTH 1.8, 95% CI 1.5 to 2.4; </p> </li> <li> <p>local swelling: RR 14.49, 95% CI 2.04 to 102.66; RD 0.25, 95% CI 0.17 to 0.33; NNTH 4.0, 95% CI 3.0 to 5.8. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured unadjuvanted gE.</p> <p>There were no differences in the incidence of the following adverse events: grade 3 fatigue, any fever, any headache, grade 3 headache, grade 3 myalgia, local grade 3 pain, local grade 3 redness, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>50 µg gE/AS01<sub>B</sub> versus 100 µg gE/saline (unadjuvanted gE)</b> </p> <p> <ul id="CD008858-list-0024"> <li> <p>any myalgia: RR 3.22, 95% CI 1.74 to 5.94; RD 0.37, 95% CI 0.24 to 0.49; NNTH 2.7, 95% CI 2.0 to 4.1; </p> </li> <li> <p>any fatigue: RR 2.30, 95% CI 1.37 to 3.88; RD 0.29, 95% CI 0.16 to 0.42; NNTH 3.4, 95% CI 2.3 to 6.2; </p> </li> <li> <p>any headache: RR 2.13, 95% CI 1.14 to 4.01; RD 0.19, 95% CI 0.07 to 0.31; NNTH 5.2, 95% CI 3.2 to 14.2; </p> </li> <li> <p>local redness: RR 10.73, 95% CI 2.72 to 42.37; RD 0.36, 95% CI 0.27 to 0.45; NNTH 2.7, 95% CI 2.2 to 3.7; </p> </li> <li> <p>local pain: RR 4.37, 95% CI 2.39 to 8.00; RD 0.56, 95% CI 0.44 to 0.68; NNTH 1.7, 95% CI 1.4 to 2.2; </p> </li> <li> <p>local swelling: RR 10.73, 95% CI 1.50 to 76.64; RD 0.18, 95% CI 0.11 to 0.25; NNTH 5.5, 95% CI 4.0 to 9.0. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured unadjuvanted gE.</p> <p>There were no differences in the incidence of the following adverse events: grade 3 fatigue, any fever, grade 3 headache, grade 3 myalgia, local grade 3 pain, local grade 3 redness, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>100 µg gE/AS01<sub>B</sub> versus 100 µg gE/saline (unadjuvanted gE)</b> </p> <p> <ul id="CD008858-list-0025"> <li> <p>any myalgia: RR 2.55, 95% CI 1.37 to 4.74; RD 0.26, 95% CI 0.13 to 0.38; NNTH 3.8, 95% CI 2.6 to 7.6; </p> </li> <li> <p>any fatigue: RR 1.99, 95% CI 1.17 to 3.37; RD 0.22, 95% CI 0.09 to 0.35; NNTH 4.5, 95% CI 2.8 to 11.1; </p> </li> <li> <p>any headache: RR 1.85, 95% CI 0.98 to 3.51; RD 0.14, 95% CI 0.02 to 0.26; NNTH 7.1, 95% CI 3.8 to 50.0; </p> </li> <li> <p>local redness: RR 11.13, 95% CI 2.82 to 43.88; RD 0.38, 95% CI 0.28 to 0.47; NNTH 2.6, 95% CI 2.1 to 3.5; </p> </li> <li> <p>local pain: RR 4.44, 95% CI 2.43 to 8.11; RD 0.57, 95% CI 0.45 to 0.69; NNTH 1.7, 95% CI 1.4 to 2.2; </p> </li> <li> <p>local swelling: RR 14.73, 95% CI 2.08 to 104.31; RD 0.25, 95% CI 0.18 to 0.33; NNTH 4.0, 95% CI 3.0 to 5.5. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured unadjuvanted gE.</p> <p>There were no differences in the incidence of the following adverse events: grade 3 fatigue, any fever, grade 3 headache, grade 3 myalgia, local grade 3 pain, local grade 3 redness, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>25 µg gE/AS01<sub>B</sub> versus saline + 100 µg gE/AS01<sub>B</sub> </b> </p> <p> <ul id="CD008858-list-0026"> <li> <p>any myalgia: RR 1.52, 95% CI 1.14 to 2.03; RD 0.15, 95% CI 0.05 to 0.26; NNTH 6.6, 95% CI 3.8 to 20; </p> </li> <li> <p>any fatigue: RR 1.48, 95% CI 1.09 to 2.00; RD 0.14, 95% CI 0.03 to 0.24; NNTH 7.1, 95% CI 4.1 to 33.3; </p> </li> <li> <p>local redness: RR 1.40, 95% CI 1.04 to 1.88; RD 0.12, 95% CI 0.01 to 0.22; NNTH 8.3, 95% CI 4.5 to 100.0; </p> </li> <li> <p>local pain: RR 1.24, 95% CI 1.05 to 1.47; RD 0.14, 95% CI 0.03 to 0.24; NNTH 7.1, 95% CI 4.1 to 33.3. </p> </li> </ul> </p> <p>All differences in incidence of adverse events favoured saline + 100 µg gE/AS01<sub>B</sub>. </p> <p>There were no differences in the incidence of the following adverse events: any fatigue, grade 3 fever, any headache, grade 3 headache, grade 3 myalgia, local grade 3 pain, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>50 µg gE/AS01<sub>B</sub> versus saline + 100 µg gE/AS01<sub>B</sub> </b> </p> <p> <ul id="CD008858-list-0027"> <li> <p>any myalgia: RR 1.81, 95% CI 1.37 to 2.37; RD 0.24, 95% CI 0.14 to 0.34; NNTH 4.1, 95% CI 2.9 to 7.1; </p> </li> <li> <p>any fatigue: RR 1.80, 95% CI 1.35 to 2.39; RD 0.23, 95% CI 0.12 to 0.33; NNTH 4.3, 95% CI 3.0 to 8.3; </p> </li> <li> <p>any headache: RR 1.63, 95% CI 1.14 to 2.32; RD 0.14, 95% CI 0.04 to 0.23; NNTH 7.1, 95% CI 4.3 to 25; </p> </li> <li> <p>local pain: RR 1.29, 95% CI 1.10 to 1.52; RD 0.17, 95% CI 0.06 to 0.27; NNTH 5.8, 95% CI 3.7 to 16.6. </p> </li> </ul> </p> <p>All differences in incidence of adverse events favoured saline + 100 µg gE/AS01<sub>B</sub>. </p> <p>There were no differences in the incidence of the following adverse events: grade 3 fatigue, any fever, grade 3 fever, grade 3 headache, grade 3 myalgia, local grade 3 pain, local redness, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p><b>100 µg gE/AS01<sub>B</sub> versus saline + 100 µg gE/AS01<sub>B</sub> </b> </p> <p> <ul id="CD008858-list-0028"> <li> <p>any myalgia: RR 1.43, 95% CI 1.06 to 1.92; RD 0.13, 95% CI 0.02 to 0.23; NNTH 7.6, 95% CI 4.3 to 50.0; </p> </li> <li> <p>any fatigue: RR 1.55, 95% CI 1.15 to 2.09; RD 0.16, 95% CI 0.06 to 0.26; NNTH 6.2, 95% CI 3.8 to 16.6; </p> </li> <li> <p>any fever: RR 2.44, 95% CI 1.16 to 5.15; RD 0.08, 95% CI 0.02 to 0.14; NNTH 12.5, 95% CI 7.1 to 50; </p> </li> <li> <p>local redness: RR 1.39, 95% CI 1.03 to 1.87; RD 0.12, 95% CI 0.01 to 0.22; NNTH 8.3, 95% CI 4.5 to 100.0; </p> </li> <li> <p>local pain: RR 1.31, 95% CI 1.12 to 1.54; RD 0.18, 95% CI 0.07 to 0.28; NNTH 5.5, 95% CI 3.5 to 14.2. </p> </li> </ul> </p> <p>All differences in incidence of adverse events favoured saline + 100 µg gE/AS01<sub>B</sub>. </p> <p>There were no differences in the incidence of the following adverse events: grade 3 fatigue, headache, grade 3 headache, grade 3 myalgia, local grade 3 pain, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>Saline + 100 µg gE/AS01<sub>B</sub> versus 100 µg gE/saline (unadjuvanted gE)</b> </p> <p> <ul id="CD008858-list-0029"> <li> <p>local redness: RR 8.02, 95% CI 2.02 to 31.88; RD 0.26, 95% CI 0.17 to 0.35; NNTH 3.8, 95% CI 2.8 to 5.8; </p> </li> <li> <p>local pain: RR 3.38, 95% CI 1.84 to 6.23; RD 0.40, 95% CI 0.27 to 0.52; NNTH 2.5, 95% CI 1.9 to 3.7; </p> </li> <li> <p>local swelling: RR 9.82, 95% CI 1.37 to 70.30; RD 0.16, 95% CI 0.09 to 0.23; NNTH 6.2, 95% CI 4.3 to 11.1. </p> </li> </ul> </p> <p>All differences in incidence of adverse events favoured 100 µg gE/saline.</p> <p>There were no differences in the incidence of the following adverse events: any fatigue, grade 3 fatigue, any fever, any headache, any myalgia, grade 3 myalgia, local grade 3 pain, local grade 3 redness, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever, grade 3 headache, or local grade 3 swelling in either group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV: 2 doses given at 3 different intervals</b> (<a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no statistically significant differences between groups for any of the 3 comparisons (<b>RZV 2 doses 2 months apart versus RZV 2 doses 6 months apart; RZV 2 doses 2 months apart versus RZV 2 doses 12 months apart; and RZV 2 doses 6 months apart versus RZV 2 doses 12 months apart</b>) in incidence of the following adverse events: at least 1 unsolicited AE symptom, at least 1 unsolicited AE symptom related to vaccination. </p> <p>There were no significant differences between groups for the following general symptoms: fatigue, grade 3 fatigue, fever, grade 3 fever, headache, grade 3 headache, myalgia, grade 3 myalgia, gastrointestinal symptom, grade 3 gastrointestinal symptom. The average duration of solicited general symptoms was ≤ 2 days. </p> <p>There were no significant differences between groups for the following local symptoms: local pain, grade 3 local pain, local redness, grade 3 redness, local swelling, grade 3 local swelling. The average duration of local symptoms was ≤ 3 days. There were no significant differences between groups for the following: SAE, withdrawn due to an SAE, consent withdrawal, lost to follow‐up. There were no cases of suspected zoster or autoimmune disease throughout the study in any of the groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV IM route versus RZV SC route</b> (<a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a significant difference between groups favouring the IM route for the following adverse events: injection site redness (RR 1.73, 95% CI 1.18 to 2.55; RD 0.37, 95% CI 0.15 to 0.58; NNTH 2.7, 95% CI 1.7 to 6.7); injection site swelling (RR 2.00, 95% CI 1.25 to 3.21; RD 0.40, 95% CI 0.17 to 0.63; NNTH 2.5, 95% CI 1.6 to 5.9); grade 3 injection site swelling (RR 5.00, 95% CI 1.19 to 20.92; RD 0.27, 95% CI 0.08 to 0.46; NNTH 3.7, 95% CI 2.2 to 12.5); injection site pruritus (RR 2.10, 95% CI 1.20 to 3.67; RD 0.37, 95% CI 0.13 to 0.60; NNTH 2.7, 95% CI 1.7 to 7.7). There were no differences between groups for all other adverse events. </p> <p>There were no deaths or autoimmune diseases.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV versus pneumo‐23</b> (<a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events within 30 days after vaccination</b> </p> <p> <ul id="CD008858-list-0030"> <li> <p>any serious adverse event: RR 0.78, 95% CI 0.29 to 2.07 and no RD;</p> </li> <li> <p>potential immune‐mediated disease: RR 0.33, 95% CI 0.01 to 8.18 and no RD;</p> </li> </ul> </p> <p>There were no serious adverse events or pIMDs that were considered vaccine‐related.</p> <p><b>Serious adverse events from 30 days after last vaccination up to the end of study</b> </p> <p> <ul id="CD008858-list-0031"> <li> <p>any serious adverse event: RR 1.00, 95% CI 0.32 to 2.38 and no RD;</p> </li> <li> <p>potential immune‐mediated disease: RR 3.01, 95% CI 0.12 to 73.71 and no RD;</p> </li> </ul> </p> <p>There were no serious adverse events or pIMDs that were considered vaccine‐related.</p> <p>When comparing the group that received RZV + pneumo‐23 versus the group that received only pneumo‐23, the following systemic adverse events occurred within 7 days after vaccination: </p> <p> <ul id="CD008858-list-0032"> <li> <p>any general symptom: RR 1.74, 95% CI 1.51 to 2.01; RD 0.27, 95% CI 0.21 to 0.34; NNTH 3.7, 95% CI 2.9 to 4.8; </p> </li> <li> <p>any general symptom grade 3: RR 5.90, 95% CI 2.95 to 11.81; RD 0.10, 95% CI 0.07 to 0.14; NNTH 10.0, 95% CI 7.1 to 14.3; </p> </li> <li> <p>myalgia: RR 2.18, 95% CI 1.75 to 2.70; RD 0.24, 95% CI 0.18 to 0.30; NNTH 4.2, 95% CI 3.3 to 5.6; </p> </li> <li> <p>myalgia grade 3: RR 2.78, 95% CI 1.31 to 5.90; RD 0.04, 95% CI 0.01 to 0.06; NNTH 25.0, 95% CI 16.7 to 100.0; </p> </li> <li> <p>pain local: RR 1.93, 95% CI 1.70 to 2.19; RD 0.37, 95% CI 0.31 to 0.43; NNTH 2.7, 95% CI 2.3 to 3.2; </p> </li> <li> <p>fatigue grade 3: RR 7.52, 95% CI 2.67 to 21.16; RD 0.06, 95% CI 0.03 to 0.09; NNTH 16.7, 95% CI 11.1 to 33.3; </p> </li> <li> <p>headache: RR 2.23, 95% CI 1.74 to 2.85; RD 0.20, 95% CI 0.14 to 0.26; NNTH 5.0, 95% CI 3.8 to 7.1; </p> </li> <li> <p>headache grade 3: RR 4.26, 95% CI 1.45 to 12.56; RD 0.03, 95% CI 0.01 to 0.05; NNTH 33.3, 95% CI 20.0 to 100.0; </p> </li> <li> <p>fever: RR 5.32, 95% CI 2.99 to 9.48; RD 0.13, 95% CI 0.09 to 0.17; NNTH 7.7, 95% CI 5.9 to 11.1; </p> </li> <li> <p>fever grade 3: RR 2.00, 95% CI 0.37 to 10.89; RD 0.00, 95% CI −0.01 to 0.02;</p> </li> <li> <p>shivering: RR 3.17, 95% CI 2.15 to 4.68; RD 0.02, 95% CI 0.00 to 0.04; NNTH 50.0; and no RD; </p> </li> <li> <p>shivering grade 3: RR 3.26, 95% CI 1.07 to 9.91; RD 0.32, 95% CI 0.30 to 0.34; NNTH 3.1, 95% CI 2.9 to 3.3; </p> </li> <li> <p>gastrointestinal symptom: RR 2.54, 95% CI 1.70 to 3.79; RD 0.11, 95% CI 0.06 to 0.15; NNTH 9.0, 95% CI 6.7 to 16.7; </p> </li> <li> <p>gastrointestinal symptom grade 3: RR 3.01, 95% CI 0.61 to 14.82; RD 0.01, 95% CI −0.00 to 0.02; and no RD. </p> </li> </ul> </p> <p><b>Injection site AE</b> </p> <p> <ul id="CD008858-list-0033"> <li> <p>any local symptom: RR 1.05, 95% CI 1.00 to 1.11; and no RD;</p> </li> <li> <p>any local symptom grade 3: RR 1.49, 95% CI 1.10 to 2.03; RD 0.07, 95% CI 0.02 to 0.11; NNTH 14.3, 95% CI 9.1 to 50.0; </p> </li> <li> <p>redness local: RR 5.61, 95% CI 3.90 to 8.08; RD 0.32, 95% CI 0.27 to 0.37; NNTH 3.1, 95% CI 2.7 to 3.7; </p> </li> <li> <p>redness local grade 3: RR 6.52, 95% CI 1.48 to 28.70; RD 0.03, 95% CI 0.01 to 0.04; NNTH 33.3, 95% CI 25.0 to 100.0; </p> </li> <li> <p>pain local: RR 1.93, 95% CI 1.70 to 2.19; RD 0.37, 95% CI 0.31 to 0.43; NNTH 2.7, 95% CI 2.3 to 3.2; </p> </li> <li> <p>pain local grade 3: RR 10.77, 95% CI 3.90 to 29.76; RD 0.09, 95% CI 0.06 to 0.12; NNTH 11.1, 95% CI 8.3 to 16.7; </p> </li> <li> <p>swelling local: RR 4.15, 95% CI 2.65 to 6.48; RD 0.16, 95% CI 0.12 to 0.20; NNTH 6.25, 95% CI 5.0 to 8.3; </p> </li> <li> <p>swelling local grade 3: RR 2.00, 95% CI 0.18 to 22.03; and no RD.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV + TDaPV co‐administration group versus RZV + TDaPV not co‐administration group</b> (<a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between groups for the following: death, serious adverse events, systemic adverse events, injection site adverse events, unsolicited vaccine‐related adverse events. There were no pIMDs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV + IIV4 co‐administration group versus not co‐administration group</b> (<a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no deaths.</p> <p>There were no significant differences between groups except for the following AEs:</p> <p> <ul id="CD008858-list-0034"> <li> <p>fatigue: RR 1.21, 95% CI 1.05 to 1.39; RD 0.09, 95% CI 0.03 to 0.16; NNTH 11.1, 95% CI 6.3 to 33.3; </p> </li> <li> <p>pain local: RR 1.09, 95% CI 1.02 to 1.16; RD 0.07, 95% CI 0.01 to 0.12; NNTH 14.3, 95% CI 8.3 to 100.0. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PCV13 vaccine + RZV concomitant administration (Co‐Ad) versus PCV13 vaccine + RZV sequential administration (Se‐Ad)</b> (<a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between groups for the following: death, serious adverse events, systemic adverse events, injection site adverse events, unsolicited vaccine‐related adverse events and pIMDs. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse event or adverse experiences<br/>AS01: liposome‐based adjuvant system containing the immunoenhancers 3‐O‐desacyl‐4′‐monophosphoryl lipid A (MPL) and the saponin QS‐21 (<i>Quillaja saponaria</i> Molina, fraction 21)<br/>Adjuvanted gE/AS01<sub>B</sub>: 50 μg purified gE with adjuvant B (1 mg dioleoyl phosphatidylcholine, 250 μg cholesterol, 50 μg MPL, and 50 μg QS‐21)<br/>Adjuvanted gE/AS01<sub>E</sub>: 50 μg purified gE with adjuvant E (500 μg dioleoyl phosphatidylcholine, 125 μg cholesterol, 25 μg MPL, and 25 μg QS‐21)<br/>AS01<sub>B</sub>: adjuvant B composed of 1 mg dioleoyl phosphatidylcholine, 250 μg cholesterol, 50 μg MPL, and 50 μg QS‐21<br/>AS01<sub>E</sub>: adjuvant E composed of 500 μg dioleoyl phosphatidylcholine, 125 μg cholesterol, 25 μg MPL, and 25 μg QS‐21<br/>CI: confidence interval<br/>Elderly or older adults: aged ≥ 60 years old<br/>gE: recombinant subunit VZV composed of glycoprotein E<br/>gE/saline: unadjuvanted gE<br/>ID: identification<br/>IIV4: inactivated quadrivalent influenza vaccines<br/>IM: intramuscular<br/>MPL: immunoenhancer 3‐O‐desacyl‐4′‐monophosphoryl lipid A<br/>NNTB: number needed to treat for an additional beneficial outcome<br/>NNTH: number needed to treat for an additional harmful outcome<br/>pIMDs: potential immune‐mediated diseases<br/>PCV13 vaccine: 13‐valent pneumococcal polysaccharide vaccine<br/>pneumo‐23 vaccine: 23–valent pneumococcal polysaccharide vaccine<br/>QS‐21: immunoenhancer saponin <i>Quillaja saponaria</i> Molina, fraction 21<br/>RD: risk difference<br/>RR: risk ratio<br/>RZV: adjuvanted recombinant zoster vaccine (contains 50 µg of recombinant VZV glycoprotein E, and the liposome‐based AS01<sub>B</sub> adjuvant system contains 50 µg of 3‐O‐desacyl‐4′‐monophosphoryl lipid A (MPL) and 50 µg of <i>Quillaja saponaria</i> Molina, fraction 21 (QS21))<br/>SAEs: serious adverse events<br/>SC: subcutaneously or subcutaneous<br/>TDaPV: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine<br/>VZV: varicella zoster virus </p> </div> </div> <p>We analysed adverse events amongst participants aged 50 years or over because data for adverse events by specific age groups were not available. We performed ITT analyses for adverse events that did not include all randomised participants. In other words, we considered the worst‐case scenario for the intervention group (we assumed that participants with missing information had adverse events) and the best‐case scenario for the placebo group (we assumed that participants with missing information did not experience adverse events). We detected no differences between groups in this analysis, therefore we decided to present the results for adverse events as they were published. </p> <p>There were no significant differences between groups for death (RR 0.94, 95% CI 0.84 to 1.04; 29,311 participants; <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.1) (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>), or serious adverse events (RR 0.97, 95% CI 0.91 to 1.03; 29,311 participants; <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.3) (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>). </p> <p>Two studies (N = 29,311) compared RZV versus placebo (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>). The vaccinated group had a higher incidence of any symptom (RR 2.41, 95% CI 2.02 to 2.88; RD 0.47, 95% CI 0.45 to 0.49; NNTH 2.1, 95% CI 2.0 to 2.2; <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.6). </p> <p>Any systemic symptoms occurred more frequently in participants who received the vaccine (RR 2.23, 95% CI 2.12 to 2.34; RD 0.33, 95% CI 0.24 to 0.41; NNTH 3.0, 95% CI 2.4 to 4.2; 9762 participants; <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.9). </p> <p>There were no significant differences between groups for potential immune‐mediated disease (RR 0.88, 95% CI 0.71 to 1.08; 29,311 participants; <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.11) (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>) (<a href="./full#CD008858-tbl-0002">summary of findings Table 2</a>). </p> <p>The participants who received the vaccine had more gastrointestinal symptoms (RR 1.75, 95% CI 1.21 to 2.55; RD 0.06, 95% CI 0.00 to 0.12; 9762 participants; <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.17). </p> <p>Vaccinated participants had a higher frequency of any local symptom (RR 6.89, 95% CI 6.37 to 7.45; RD 0.67, 95% CI 0.62 to 0.73; NNTH 1.5, 95% CI 1.4 to 1.6; 9769 participants; <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.18). The most important difference between adverse events was for injection site events. The participants in the vaccinated group had a much higher incidence of injection site adverse events than those in the placebo group (absolute risk of 80.7% in the vaccinated group versus 11.7% in the placebo group). </p> <p>The most important adverse events (death, serious adverse events, any systemic symptom, potential immune‐mediated disease, and injection site adverse events) are presented in <a href="./full#CD008858-tbl-0002">summary of findings Table 2</a>. </p> <p>Heterogeneity was high in the following meta‐analyses: <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.6: any symptom (83%); <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.13: fatigue (73%); <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.17: gastrointestinal symptom (72%); and <a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.19: any local symptom (92%). </p> <p>The duration of adverse events was transient. Median duration was one to two days for systemic reactions and two to three days for injection site reactions. </p> <p>We judged the certainty of evidence as moderate due to insufficient information on allocation concealment and because the flow of participants was unclear (<a href="./full#CD008858-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> <section id="CD008858-sec-0075"> <h5 class="title">2. Dropouts</h5> <p>There were no significant differences between LZV and placebo for any reasons for dropouts (RR 0.99, 95% CI 0.91 to 1.08; 38,856 participants; <a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.1) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>), and also for participants with no follow‐up (RR 0.85, 95% CI 0.41 to 1.74; 50,627 participants; <a href="./references#CD008858-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> <p><a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a> and <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a> described four reasons for dropouts: "not receiving vaccine according to protocol" (no difference between groups) (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.1); "receiving the wrong vaccine" (no difference between groups) (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.2); "diagnosis of herpes zoster less than 30 days after the second dose" (RR 0.32, 95% CI 0.14 to 0.71 but no RD) (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.3); and "did not receive second dose" (the vaccinated group had higher dropout rates than the placebo group for this reason: RR 1.25, 95% CI 1.13 to 1.39; RD 0.01; NNTH 100) (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.4). </p> <p>Details of dropouts in the included studies for all comparisons are provided in <a href="#CD008858-tbl-0006">Table 4</a>. </p> <div class="table" id="CD008858-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Dropouts</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts (all included studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>LZV versus placebo</b> </p> <p>The pooled data from the studies that compared zoster vaccine and placebo showed no differences in reasons for dropout (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>): for any reason (RR 0.99, 95% CI 0.91 to 1.08) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.1) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); discontinued due to vaccine‐related adverse events (RR 5.05, 95% CI 0.25 to 103.88) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.2) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); for clinical AE (RR 1.34, 95% CI 0.72 to 2.52) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.3) (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); for physician decision (RR 0.20, 95% CI 0.01 to 4.17) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.4) (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>); for withdrawal of consent (RR 0.95, 95% CI 0.54 to 1.68) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.5) (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); for loss to follow‐up (RR 1.27, 95% CI 0.96 to 1.69) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.6) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); and for protocol deviation (RR 1.49, 95% CI 0.27 to 8.37) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.7) (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>). In <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>, <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>, and <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>, consent was withdrawn after the intervention. In <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>, some participants apparently withdrew consent after randomisation, but the exact number that withdrew consent after the intervention is not stated. </p> <p>The pooled data from the studies that compared zoster vaccine versus placebo showed no differences in reasons for participants with no follow‐up (RR 1.05, 95% CI 0.74 to 1.48) (<a href="./references#CD008858-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> <p><b>High‐potency versus low‐potency zoster vaccine:</b> there were no differences between groups (<a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>). </p> <p><b>NBP608 LZV versus LZV:</b> there were no differences between groups (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>). </p> <p><b>Refrigerated versus frozen zoster vaccine:</b> there were no differences between groups (<a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>). </p> <p><b>LZV IM route versus LZV SC route:</b> there were no withdrawals due to adverse events in either group (<a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>). </p> <p><b>LZV intradermal route versus LZV SC route:</b> there were no significant differences between full‐dose intradermal versus full‐dose SC; 1/3 dose intradermal versus full‐dose SC; 1/10 dose intradermal versus full‐dose SC; 1/27 dose intradermal versus full‐dose SC; 1/3 dose intradermal versus 1/3 dose SC. There were no dropouts for full‐dose intradermal versus 1/3 dose SC; 1/10 dose intradermal versus 1/3 dose SC; and 1/27 dose intradermal versus 1/3 dose SC (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>). </p> <p><b>2 doses of a zoster vaccine versus a single dose and 2 doses given at different intervals:</b> there were no differences between groups for participant withdrawals due to adverse events (<a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>). </p> <p><b>LZV AMP versus LZV:</b> there were no differences between groups (<a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>). </p> <p><b>LZV + IIV4 concomitant administration versus LZV + IIV4 sequential administration:</b> for this comparison there were no significant differences for dropouts between groups (<a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>) </p> <p>In all the comparisons of <a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>, there were no differences in dropouts between the groups. Similarly, in all the comparisons of <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>, there were no differences in dropouts between the groups. </p> <p><b>RZV versus placebo:</b><a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a> and <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a> described 4 reasons for dropout: did not receive vaccine according to protocol (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.1); received wrong vaccine (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.2); had diagnosis of HZ less than 30 days after dose 2 (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.3); and did not receive second dose (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.4). There were no differences between groups for the first 2 outcomes. The third outcome had an RR of 0.32 (95% CI 0.14 to 0.71) but no RD. For the fourth outcome, the vaccine group had a higher dropout rate than the placebo group: RR 1.25, 95% CI 1.13 to 1.39; RD 0.01, 95% CI 0.01 to 0.01; NNTH 100, 95% 100.0 to 100.0. </p> <p><b>RZV IM route versus RZV SC route</b>: there was no difference in participant withdrawal between groups (<a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> <p><b>RZV + TDaPV co‐administration group versus RZV + TDaPV not co‐administration group:</b> there was no difference in dropouts between groups (<a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>). </p> <p><b>Co‐administration RZV + IIV4 versus not co‐administration group RZV + IIV4:</b> there was no difference between groups for dropouts (<a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>). </p> <p><b>PCV13 vaccine + RZV concomitant administration versus PCV 13 vaccine + RZV sequential administration:</b> there was no difference between groups for dropouts (<a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>). </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse event or adverse experiences<br/>AMP: alternative manufacturing process<br/>AS01: liposome‐based adjuvant system containing the immunoenhancers 3‐O‐desacyl‐4′‐monophosphoryl lipid A (MPL) and the saponin QS‐21 (<i>Quillaja saponaria</i> Molina, fraction 21)<br/>Adjuvanted gE/AS01<sub>B</sub>: 50 μg purified gE with adjuvant B (1 mg dioleoyl phosphatidylcholine, 250 μg cholesterol, 50 μg MPL, and 50 μg QS‐21)<br/>Adjuvanted gE/AS01<sub>E</sub>: 50 μg purified gE with adjuvant E (500 μg dioleoyl phosphatidylcholine, 125 μg cholesterol, 25 μg MPL, and 25 μg QS‐21)<br/>AS01<sub>B</sub>: adjuvant B composed of 1 mg dioleoyl phosphatidylcholine, 250 μg cholesterol, 50 μg MPL, and 50 μg QS‐21<br/>AS01<sub>E</sub>: adjuvant E composed of 500 μg dioleoyl phosphatidylcholine, 125 μg cholesterol, 25 μg MPL, and 25 μg QS‐21<br/>Elderly or older adults: aged ≥ 60 years old<br/>Frozen: ‐15 °C or colder<br/>gE: recombinant subunit VZV composed of glycoprotein E<br/>gE/saline: unadjuvanted gE<br/>HZ: herpes zoster<br/>ID: identification<br/>IIV4: inactivated quadrivalent influenza vaccines<br/>IM: intramuscular<br/>LZV or ZV: live zoster vaccine (live attenuated Oka varicella zoster virus vaccine)<br/>MPL: immunoenhancer 3‐O‐desacyl‐4′‐monophosphoryl lipid A<br/>NBP608 LZV: live zoster vaccine (live attenuated Oka varicella zoster virus vaccine) with a minimum of 27,400 pfu (0,50 mL)<br/>NNTB: number needed to treat for an additional beneficial outcome<br/>NNTH: number needed to treat for an additional harmful outcome<br/>PCV13 vaccine: 13‐valent pneumococcal polysaccharide vaccine<br/>pneumo‐23 vaccine: 23–valent pneumococcal polysaccharide vaccine<br/>QS‐21: immunoenhancer saponin <i>Quillaja saponaria</i> Molina, fraction 21<br/>Refrigerated: 2 °C to 8 °C<br/>RR: risk ratio<br/>RZV: adjuvanted recombinant zoster vaccine (contains 50 µg of recombinant VZV glycoprotein E, and the liposome‐based AS01<sub>B</sub> adjuvant system contains 50 µg of 3‐O‐desacyl‐4′‐monophosphoryl lipid A (MPL) and 50 µg of <i>Quillaja saponaria</i> Molina, fraction 21 (QS21))<br/>SAEs: serious adverse events<br/>SC: subcutaneously or subcutaneous<br/>TDaPV: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine<br/>VZV: varicella zoster virus </p> </div> </div> <p>The overall certainty of evidence for dropouts up to three years of follow‐up was moderate for the comparison LZV versus placebo (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). The overall certainty of evidence was also moderate for the comparison RZV versus placebo for up to 3.2 years of follow‐up (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>). The reason for downgrading the evidence for the first comparison (LZV versus placebo) was insufficient information about random sequence generation (<a href="./full#CD008858-tbl-0001">summary of findings Table 1</a>). We downgraded the evidence for the second comparison (RZV versus placebo) due to insufficient information on allocation concealment and flow of participants (<a href="./full#CD008858-tbl-0002">summary of findings Table 2</a>). </p> <p><b>Observation:</b> the numbers of studies and participants for some analyses appear to be incorrect because some analyses include only safety subgroups, and not the total number of participants. Additionally, in some studies the flow of participants was not clear (attrition bias). We considered ITT analyses when these were possible or available. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008858-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008858-sec-0076"></div> <section id="CD008858-sec-0077"> <h3 class="title" id="CD008858-sec-0077">Summary of main results</h3> <section id="CD008858-sec-0078"> <h4 class="title">Live attenuated zoster vaccine (LZV)</h4> <p>We included a total of 16 clinical trials that reported prespecified outcomes for LZV (cumulative incidence of herpes zoster, adverse events, and dropouts) (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>; <a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>). </p> <p>Data from a major randomised controlled trial (RCT), the Shingles Prevention Study (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), which included 38,546 participants, confirmed the probable effectiveness of the intervention when compared to placebo in older adults for at least 3.1 years (moderate‐certainty evidence). The continuation of <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a> (<a href="./references#CD008858-bbs2-0116" title="SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]">Schmader 2012</a>) had the longest duration of follow‐up, reporting an average five years of herpes zoster surveillance in older adults (aged 60 years and over). The available data suggest that the vaccine probably works for an average of five years to prevent herpes zoster in adults aged 60 years and over. However, these long‐term effect estimates for cumulative incidence of herpes zoster should be interpreted with caution since they were derived from inferred data. </p> <p>The vaccinated group had more adverse events than the placebo group, but these effects were mild to moderate, compatible with a tolerable and safe vaccination profile. </p> <p>Although the rate of adverse events was higher in the LZV group (<a href="#CD008858-tbl-0004">Table 2</a>), dropout rates were similar in the vaccinated and placebo groups, suggesting that these adverse events did not have important repercussions (<a href="#CD008858-tbl-0006">Table 4</a>). </p> <p>With one exception (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>), all included studies received funding from the pharmaceutical industry. </p> <p>The US Food and Drug Administration (FDA) approved LZV for older adults (aged 60 years and over) in May 2006 (<a href="./references#CD008858-bbs2-0068" title="USA FDA approval letter - Zostavax, 25 May 2006. https://wayback.archive-it.org/7993/20170723093336/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm132873.htm accessed 24 October 2019.">FDA 2006</a>), and it was approved for individuals aged 50 years and over in March 2011 (<a href="./references#CD008858-bbs2-0120" title="SunW . Summary basis for regulatory action. http://wayback.archive-it.org/7993/20170723093318/https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM249230.pdf2011.">Sun 2011</a>). </p> </section> <section id="CD008858-sec-0079"> <h4 class="title">Adjuvanted recombinant varicella zoster virus (VZV) subunit zoster vaccine (RZV)</h4> <p>We included 10 trials that tested the effects of RZV on prespecified outcomes (cumulative incidence of herpes zoster, adverse events, and dropouts) (<a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). We assessed two of these studies as having a low risk of bias (<a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>). <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a> and <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a> evaluated the cumulative incidence of herpes zoster, adverse events, and dropouts using the final product of the vaccine composition, a vaccinated group versus a placebo group over an average of 3.2 years of follow‐up. There was a significant decrease in the cumulative incidence of herpes zoster in the vaccinated group (moderate‐certainty evidence), demonstrating that the vaccine probably works. </p> <p>The data on RZV suggest that the vaccine may be considered safe because there were no differences in serious adverse events between the vaccinated and placebo groups. Although systemic and injection sites adverse events (<a href="#CD008858-tbl-0005">Table 3</a>) occurred more frequently in the vaccinated group, these were transient. </p> <p><a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a> and <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a> reported more dropouts for the second dose in the vaccine group than in the placebo group (<a href="#CD008858-tbl-0006">Table 4</a>). </p> <p>There was high heterogeneity in the meta‐analyses that pooled the data of <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a> and <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a> for the following outcomes: cumulative incidence of herpes zoster, any symptom, fatigue, gastrointestinal symptom, and any local symptom. Since the two studies had the same design and type of randomisation, differences in the characteristics of the participants should be considered. <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a> included younger participants (60 years or older) than <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a> (70 years or older). Moreover, the flow of patients in the <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a> study was unclear, with inconsistencies between the data presented in the publication and the supplementary appendix. </p> <p>In the comparison of vaccinated versus placebo groups, it is worth mentioning that for the outcome "dropout did not receive the second dose" for every 100 vaccinated individuals, one will not receive the second dose and, consequently, may not be protected because the vaccination schedule is incomplete<b>.</b> </p> <p>All 10 studies received funding from the pharmaceutical industry.</p> <p>The FDA approved RZV for clinical use in October 2017 (<a href="./references#CD008858-bbs2-0069" title="USA FDA approval letter - zoster vaccine recombinant, adjuvanted. 20 October 2017. www.fda.gov/downloads/biologicsblood vaccines/vaccines/approvedproducts/ucm581750.pdf accessed 24 October 2019.">FDA 2017</a>). </p> </section> </section> <section id="CD008858-sec-0080"> <h3 class="title" id="CD008858-sec-0080">Overall completeness and applicability of evidence</h3> <p>We assessed the certainty of evidence presented in this systematic review, based on studies that included a large number of healthy participants aged 60 years or older, as moderate. The two available vaccines (one subcutaneous (SC) dose of LZV and two intramuscular (IM) doses two months apart of RZV) have been shown to produce a probable significant reduction in the cumulative incidence of herpes zoster over a period of at least three years. </p> <p>The vaccines were probably safe, as there was no difference between groups in deaths or serious adverse events. The cumulative incidence of systemic adverse events was significantly higher amongst participants receiving RZV than in controls, which was not observed amongst participants receiving attenuated LZV. Both vaccines produced a higher cumulative incidence of injection site adverse events than controls. </p> <p>There were no differences in withdrawals for any reason in the LZV group, but the number of participants not receiving the second dose of RZV was significantly higher in the vaccinated group than in the placebo group. </p> <p>In this update we had a small expansion of ethnicities with the inclusion of one study that was carried out in Korea. However, it is important to emphasise that readers should keep in mind that the majority of study participants were 60 years of age or older, Caucasian (understood to be white) (80%), and female (57%). </p> </section> <section id="CD008858-sec-0081"> <h3 class="title" id="CD008858-sec-0081">Certainty of the evidence</h3> <p>Using the GRADE approach (<a href="./references#CD008858-bbs2-0118" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Schünemann 2021</a>), we found the certainty of evidence for all outcomes as follows. </p> <p>The overall certainty of evidence for the primary effectiveness outcome (cumulative incidence of herpes zoster), for a follow‐up period of 3.1 years, was moderate for the comparison LZV versus placebo (<a href="./full#CD008858-tbl-0001">summary of findings Table 1</a>). The data for LZV come from a large study (38,546 participants), and we downgraded the certainty of the evidence because the method used for random sequence generation was not described (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). Because it is a large study with a low risk of bias for five of the eight risk of bias domains, it provides consistent results showing that the LZV probably decreases the cumulative incidence of herpes zoster for at least 3.1 years postvaccination. </p> <p>There is also moderate‐certainty evidence that RZV probably reduces the cumulative incidence of herpes zoster over a 3.2‐year follow‐up period (<a href="./full#CD008858-tbl-0002">summary of findings Table 2</a>). We downgraded the certainty of evidence because allocation concealment was not described and the flow of participants was unclear. These data came from two studies that included 22,022 participants (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>). One of these studies had a low risk of bias in four of the eight risk of bias domains (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>), and the other study had a low risk of bias in five of the eight domains, which strengthens the conclusion that this vaccine probably reduces the cumulative incidence of herpes zoster over a follow‐up period of 3.2 years (<a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>). </p> <p>We also judged the certainty of the evidence for adverse events for both LZV and RZV compared to placebo as moderate, for the same reasons as for the primary outcome. The certainty of evidence for this outcome is strengthened by the definitions of adverse events provided in the primary studies and the fact that systemic and injection site adverse events were collected prospectively. </p> <p>Participants who received LZV had a higher cumulative incidence of systemic adverse events (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; totalling 7059 participants) and injection site reactions (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; totalling 6980 participants). We downgraded the certainty of the evidence for this outcome to moderate due to insufficient information on random sequence generation. There were no differences between the vaccinated and placebo groups for death and serious adverse events. </p> <p>There was moderate‐certainty evidence (downgraded due to insufficient information on allocation concealment and attrition bias) based on two studies showing a higher cumulative incidence of adverse events in participants who received RZV versus placebo (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>). There was a higher cumulative incidence of participants with any systemic symptoms (2 studies, 9762 participants) and any local symptom (2 studies, 9769 participants). There was no difference between groups for death, serious adverse events, and potential immune‐mediated disease (2 studies, 29,311 participants). </p> <p>We found moderate‐certainty evidence for dropouts for both vaccines (LZV and RZV). For LZV, there was no difference in the rate of dropouts between the vaccine and placebo groups (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>, totalling 38,856 participants). We downgraded this evidence due to insufficient information on random sequence generation. For RZV, there was a higher rate of dropouts for the second dose in the vaccinated groups. We downgraded the certainty of the evidence to moderate due to insufficient information on allocation concealment and incomplete outcome data (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>, totalling 29,311 participants). </p> <p>Only the authors of <a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a> reported receiving grants not related to the conduct and results of the study. <a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a> and <a href="./references#CD008858-bbs2-0012" title="LevinMJ , EllisonMC , ZerbeGO , BarberD , ChanC , StinsonD , et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine2000;18(25):2915-20. [PMID: 10812235]">Levin 2000</a> did not describe any potential conflicts of interest. The following 12 studies described potential conflicts of interest: <a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>; <a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>; <a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>; <a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>. The authors of these 12 studies were either employees (and employees may hold stock or stock options, or both, in the company) or former employees, or shared intellectual property rights on Zostavax (zoster vaccine live), or received speaker fees or consultancy payments or grants from Merck &amp; Co Inc. The authors of nine studies were affiliated with GlaxoSmithKline Biologicals as employees (and employees may hold stock or stock options, or both, in the company), or former employees, or co‐inventor of a patent application related to the vaccine, or received lecture fees, or grant support, or owned GlaxoSmithKline stocks (<a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>; <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>; <a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>; <a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>; <a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>; <a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>; <a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>; <a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> </section> <section id="CD008858-sec-0082"> <h3 class="title" id="CD008858-sec-0082">Potential biases in the review process</h3> <p>We attempted to minimise the potential bias in the review process, within the control of the review authors. To do this, we searched all available databases using a highly sensitive search strategy without language restrictions. This led us to find a study published in Japanese (<a href="./references#CD008858-bbs2-0084" title="IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14.">Ikematsu 2018</a>), and the inclusion of a study conducted in the Republic of Korea (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>). We also conducted duplicate data extraction to ensure that no data were lost and that all relevant information was accurate. We contacted the lead authors of included studies to obtain additional information and to clarify any pending doubts. Finally, we extracted data from unpublished studies in the "Study Results" section in ClinicalTrials.gov. </p> <p>By including a cross‐over study in our meta‐analysis, risk of bias may have been introduced into the review process. However, this was a small study that assessed only adverse events and not effectiveness outcomes. </p> <p>A limitation of our review is that we could not evaluate reporting bias (funnel plot) because none of our meta‐analyses included at least 10 studies per outcome. Since studies with positive results are more likely to be published, it is possible that studies with negative effects of zoster vaccines in older adults were conducted but not published (<a href="./references#CD008858-bbs2-0091" title="KicinskiM . Publication bias in recent meta-analyses. PLOS One2013;8(11):e81823. [DOI: 10.1371/ journal.pone.0081823]">Kicinski 2013</a>). </p> </section> <section id="CD008858-sec-0083"> <h3 class="title" id="CD008858-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p>A cohort study followed 766,330 participants aged 65 years or over (a 5% random sample of Medicare patients) allocated according to whether or not they had received LZV between 1 January 2007 and 31 December 2009. Overall, the cumulative incidence rate of herpes zoster in vaccinated participants was 5.4 (95% CI 4.6 to 6.4) per 1000 person‐years compared to 10.0 (95% CI 9.8 to 10.2) per 1000 person‐years in those not vaccinated (<a href="./references#CD008858-bbs2-0092" title="LanganSM , SmeethL , MargolisDJ , ThomasSL . Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLOS Medicine2013;10(4):1-11. [PMID: 23585738]">Langan 2013</a>). </p> <p>A matched case‐control study that collected data from May 2006 to November 2014 was conducted by the Vaccine Adverse Event Reporting System (a national vaccine safety surveillance database maintained jointly by the US Centers for Disease Control and Prevention (CDC) and the FDA). The study aim was to clarify severe autoimmune adverse events after receiving LZV. The adverse events assessed were arthritis, vasculitis, systemic lupus erythematosus, thrombocytopenia, alopecia, Guillain‐Barré syndrome, optic neuritis, and multiple sclerosis. The study reported a higher incidence of arthritis and alopecia after vaccination. Compared to people who were unexposed, participants who received zoster vaccination had 2.2 and 2.7 times the odds of developing arthritis (P &lt; 0.001) and alopecia (P = 0.015) (<a href="./references#CD008858-bbs2-0094" title="LaiYC , YewYW . Severe autoimmune adverse events post herpes zoster vaccine: a case-control study of adverse events in a national database. Journal of Drugs in Dermatology2015;14(7):681-4. [PMID: 26151783]">Lay 2015</a>). </p> <p>Our main findings are similar to those reported by another review that also found a reduction in the cumulative incidence of herpes zoster and good tolerability of LZV (<a href="./references#CD008858-bbs2-0114" title="SanfordM , KeatingGM . Zoster vaccine (Zostavax®) a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs and Aging2010;27(2):159-76. [1170-229X/10/0002-0159/$49.95/0]">Sanford 2010</a>). </p> <p>Only one randomised study compared two vaccines (LZV versus RZV), but the only outcome reported was immunogenicity (<a href="./references#CD008858-bbs2-0039" title="WeinbergA , KroehlME , JohnsonMJ , HammesA , ReinholdD , LangN , et al. Comparative immune responses to licensed herpes zoster vaccines. Journal of Infectious Diseases2018;218(Suppl 2):81-7. [DOI: 10.1093/infdis/jiy383]">Weinberg 2018</a>). </p> <p><a href="./references#CD008858-bbs2-0060" title="BlomK , YinL , Arnheim-DahlströmL . Effectiveness of the herpes zoster vaccine Zostavax® in Stockholm County, Sweden. Vaccine2019;37(31):4401-6. [DOI: doi.org/10.1016/j.vaccine.2019.06.008]">Blom 2019</a> conducted a retrospective population‐based matched cohort study with data from healthcare registers in Stockholm county. Primary endpoints included new diagnosis of herpes zoster after administration of LZV. Individuals older than 50 years and living in Stockholm county between September 2013 to November 2014 were included in the study. Ten non‐vaccinated individuals for each vaccinated person were included in the cohort. The non‐vaccinated were matched for gender and age at index date. The conclusion was that LZV had an overall vaccine effectiveness (VE) of 34%. </p> <p>A phase III, open‐label, multicentre study conducted in the United States between March 2016 and August 2017 included 430 adults aged ≥ 65 years previously vaccinated with ZVL ≥ 5 years before RZV vaccination (HZ‐PreVac with 215 participants) matched with ZVL‐naive individuals (HZ‐NonVac with 215 participants). Study participants were to receive two RZV doses intramuscularly, two months apart (<a href="./references#CD008858-bbs2-0066" title="DagnewAF , KleinNP , HervéC , KalemaG , Di PaoloE , PetersonJ , et al. The adjuvanted recombinant zoster vaccine in adults aged ≥65 years previously vaccinated with a live attenuated herpes zoster vaccine. Journal of Infectious Diseases2021;224:1139-46. [DOI: DOI: 10.1093/infdis/jiaa083]">Dagnew 2021</a>). The authors concluded that RZV induced strong humoral and polyfunctional cell‐mediated immune responses that persisted above prevaccination levels through one year after dose two in adults aged ≥ 65 years, irrespective of previous ZVL vaccination. The RZV safety profile was not affected. </p> <p>Our findings about the effectiveness and safety of HZ vaccines are concordant with those of a more recent review that included randomised controlled trials, post‐marketing and post‐licensing observational studies, a meta‐analysis of observational studies, and a prospective cohort study (<a href="./references#CD008858-bbs2-0101" title="MarraY , LaljiF . Prevention of herpes zoster: a focus on the effectiveness and safety of herpes zoster vaccines. Viruses2022;14:2667. [DOI: doi.org/10.3390/v14122667]">Marra 2022</a>). </p> <p>Since no trial compared the effects of the two available vaccines on clinical outcomes (cumulative incidence of herpes zoster, adverse events, or dropouts), <a href="./references#CD008858-bbs2-0122" title="TriccoAC , ZarinW , CardosoR , VeronikA , KhanPA , NincicV , et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ2018;363(8173):k4029. [DOI: 10.1136/bmj.k4029]">Tricco 2018</a> used the pairwise meta‐analysis methodology that is used when at least two studies examine the same intervention and comparator for a particular outcome and conducted a network meta‐analysis to compare the different shingles vaccines using the comparator placebo (<a href="./references#CD008858-bbs2-0085" title="JansenJP , NaciH . Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BioMed Central Medicine2013;11:159. [DOI: 10.1186/1741-7015-11-159]">Jansen 2013</a>). In situations when both direct and indirect comparisons are available in a review, any use of multiple‐treatments meta‐analyses should be to supplement, rather than to replace, the direct comparisons. Direct evidence from good‐quality RCTs should be used wherever possible. Without this evidence, it may be necessary to look for indirect comparisons from RCTs (<a href="./references#CD008858-bbs2-0073" title="GlennyAM , AltmanDG , SakarovitchC , DeeksJJ , D'AmicoR , BradburnM , et al. Indirect comparisons of competing interventions. Health Technology Assessment2005;9(26):1-134. [PMID: 16014203]">Glenny 2005</a>). The conclusion of the systematic review and network meta‐analysis reached by <a href="./references#CD008858-bbs2-0122" title="TriccoAC , ZarinW , CardosoR , VeronikA , KhanPA , NincicV , et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ2018;363(8173):k4029. [DOI: 10.1136/bmj.k4029]">Tricco 2018</a> that RZV is likely to be superior to LZV in reducing the cumulative incidence of herpes zoster should be interpreted with caution, since it comes from indirectly obtained data, and did not include all the aspects of the two vaccines. We should therefore take into consideration the balance between the benefits and harms of each vaccine. </p> <p>Another network meta‐analysis highlights the greater effectiveness of RZV in relation to LZV (<a href="./references#CD008858-bbs2-0102" title="McGirrA , WidenmaierR , CurranD , EspiéE , MrkvanT , OostvogelsL , et al. The comparative efficacy and safety of herpes zoster vaccines: a network meta-analysis. Vaccine2019;37:2896-909. [DOI: doi.org/10.1016/j.vaccine.2019.04.014]">McGirr 2019</a>). The authors concluded that "RZV is significantly more effective in reducing herpes zoster and incidence in adults ≥60 YOA [years of age], compared with LZV. As anticipated with an adjuvanted vaccine, RZV results in more reactogenicity following immunization. No differences in SAEs [serious adverse events] were found between RZV and LZV". However, as previously mentioned, we need to be very careful in interpreting these findings because they are derived from indirect data. Moreover, in this network meta‐analysis the authors disregard the participants who did not receive the second dose, limiting themselves to commenting that RZV is more reactogenic and that there was no difference in SAEs (<a href="./references#CD008858-bbs2-0102" title="McGirrA , WidenmaierR , CurranD , EspiéE , MrkvanT , OostvogelsL , et al. The comparative efficacy and safety of herpes zoster vaccines: a network meta-analysis. Vaccine2019;37:2896-909. [DOI: doi.org/10.1016/j.vaccine.2019.04.014]">McGirr 2019</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008858-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram 2022 update." data-id="CD008858-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram 2022 update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008858-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008858-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Live zoster vaccine versus placebo, Outcome 1: Cumulative incidence of herpes zoster" data-id="CD008858-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Live zoster vaccine versus placebo, Outcome 1: Cumulative incidence of herpes zoster </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Live zoster vaccine versus placebo, Outcome 2: Participants with adverse events" data-id="CD008858-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Live zoster vaccine versus placebo, Outcome 2: Participants with adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Live zoster vaccine versus placebo, Outcome 3: Duration in days of adverse events" data-id="CD008858-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Live zoster vaccine versus placebo, Outcome 3: Duration in days of adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Live zoster vaccine versus placebo, Outcome 4: Dropouts" data-id="CD008858-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Live zoster vaccine versus placebo, Outcome 4: Dropouts</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Live zoster vaccine versus placebo, Outcome 5: Participants with no follow‐up" data-id="CD008858-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Live zoster vaccine versus placebo, Outcome 5: Participants with no follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Recombinant zoster vaccine versus placebo, Outcome 1: Cumulative incidence of herpes zoster at least 3.2 years follow‐up" data-id="CD008858-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Recombinant zoster vaccine versus placebo, Outcome 1: Cumulative incidence of herpes zoster at least 3.2 years follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Recombinant zoster vaccine versus placebo, Outcome 2: Incidence of herpes zoster at least 4 years follow‐up" data-id="CD008858-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Recombinant zoster vaccine versus placebo, Outcome 2: Incidence of herpes zoster at least 4 years follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Recombinant zoster vaccine versus placebo, Outcome 3: Participants with adverse events" data-id="CD008858-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Recombinant zoster vaccine versus placebo, Outcome 3: Participants with adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008858-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/urn:x-wiley:14651858:media:CD008858:CD008858-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Recombinant zoster vaccine versus placebo, Outcome 4: Dropouts" data-id="CD008858-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_t/tCD008858-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Recombinant zoster vaccine versus placebo, Outcome 4: Dropouts</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/media/CDSR/CD008858/image_n/nCD008858-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008858-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Live zoster vaccine versus placebo for preventing herpes zoster in older adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Live zoster vaccine versus placebo for preventing herpes zoster in older adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> healthy older adults aged ≥ 60 years<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> live zoster vaccine versus placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Live zoster vaccine versus placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cumulative incidence of herpes zoster, 3.1 years follow‐up (Incidence per 1000 person‐years at risk)</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/>(14 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b> <br/>(0.43 to 0.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,546<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB = 50</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>584 per 1000</b><br/>(553 to 615) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b> <br/>(1.38 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7119<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH = 4.3</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b><br/>Clinical criteria<br/>Follow‐up: mean 3.1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b><br/>(29 to 35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/>(0.92 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50,820<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(21 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/>(0.95 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51,029<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ systemic adverse events</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 42 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b><br/>(222 to 263) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b> (0.82 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7119<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ injection site adverse events</b><br/>Clinical criteria<br/>Follow‐up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>161 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b><br/>(441 to 522) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.73</b> (1.93 to 7.21<b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7040<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH = 3.6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b><br/>(43 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> <br/>(0.90 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,916<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Most data came from a large study, and we downgraded the certainty of the evidence because the trial did not describe the method used for random sequence generation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Live zoster vaccine versus placebo for preventing herpes zoster in older adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008858-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Recombinant zoster vaccine versus placebo for preventing herpes zoster in older adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Recombinant zoster vaccine versus placebo for preventing herpes zoster in older adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> healthy older adults aged ≥ 60 years<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> recombinant zoster vaccine<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Recombinant zoster vaccine versus placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cumulative incidence of herpes zoster at least 3.2 years follow‐up</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/>(2 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.08</b> <br/>(0.03 to 0.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,022<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB = 33</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ death</b><br/>Clinical criteria<br/>Follow‐up: mean 3.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b><br/>(36 to 45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.84 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,311<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ serious adverse events</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b><br/>(118 to 133) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> <br/>(0.91 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,311<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ any systemic symptom</b><br/>Clinical criteria<br/>Follow‐up: mean 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>291 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>648 per 1000</b><br/>(617 to 680) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.23</b> <br/>(2.12 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9762<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH = 3.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ potential immune‐mediated disease</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b><br/>(9 to 14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/>(0.71 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,311<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events ‐ any local symptom</b><br/>Clinical criteria<br/>Follow‐up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>807 per 1000</b><br/>(746 to 873) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 6.89</b> <br/>(6.37 to 7.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9769<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH = 1.5</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts ‐ did not receive second dose</b><br/>Clinical or laboratory criteria<br/>Follow‐up: mean 3.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b><br/>(50 to 50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> <br/>(1.13 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,311<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH = 100</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Both studies had limitations in study design or execution (allocation concealment, attrition, or detection bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Recombinant zoster vaccine versus placebo for preventing herpes zoster in older adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008858-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of adverse events for LZV versus placebo and RZV versus placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Summary of adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The incidence of the following AEs did not differ significantly between the groups receiving LZV or placebo: 1 or more SAEs (including death), vaccine‐related SAEs, systemic AEs, AEs not related to vaccine, and haematoma at inoculation site. </p> <p>Participants of the vaccinated group had a higher incidence of vaccine‐related AEs and vaccine‐related systemic AEs beyond AEs at the injection site (erythema, pain, swelling, warmth, pruritus, rash, mass, and varicella‐like rash). </p> <p>The injection site AEs were erythema, pruritus, swelling, which lasted longer in the LZV group, and duration of rash, which lasted longer in the placebo group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The incidence of the following AEs did not differ significantly between the groups receiving RZV or placebo: SAEs (including death), SAEs (including death) related to vaccination, and potential immune‐mediated disease. </p> <p>Systemic AEs (myalgia, fatigue, headache, fever, shivering, and gastrointestinal symptom) as well as local AEs (redness, pain, and swelling) occurred more frequently in the RZV group than in the placebo group. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>AEs: adverse events<br/>LZV: live zoster vaccine<br/>RZV: recombinant zoster vaccine<br/>SAEs: serious adverse events </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of adverse events for LZV versus placebo and RZV versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008858-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events live zoster vaccine (LZV)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV versus placebo</b> </p> <p>(<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The following adverse events did not differ significantly between groups receiving LZV or placebo: death (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), 1 or more SAE regardless of type of storage of the vaccine (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), vaccine‐related serious adverse events (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), hospitalisation (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), hospitalisation related to HZ (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), systemic adverse events (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>), systemic pruritus (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>), general malaise (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>), headache (<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>), varicella‐like rash not at injection site (from day of vaccination to day 42) (<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>), rash unrelated to HZ (from day of vaccination to day 42) (<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), haematoma at inoculation site (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>), and adverse events not related to vaccine (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>). </p> <p>Participants in the vaccinated group had a higher incidence of the following: 1 or more adverse events (RR 1.71, 95% CI 1.38 to 2.11; RD 0.23, 95% CI 0.14 to 0.32; NNTH 4.3, 95% CI 3.1 to 7.1) (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.6) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); vaccine‐related adverse events (RR 2.64, 95% CI 1.21 to 5.75; RD 0.26, 95% CI 0.03 to 0.55; NNTH 3.8, 95% CI 1.8 to 33.3) (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.7) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); and vaccine‐related systemic adverse events (RR 1.30, 95% CI 1.07 to 1.58; RD 0.01, 95% CI 0.00 to 0.03; NNTH 100.0 95% CI 33.3 to 100.00) (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.9) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> <p>The vaccinated group had a higher incidence of adverse events at the injection site (RR 3.73, 95% CI 1.93 to 7.21; RD 0.28, 95% CI 0.15 to 0.41; NNTH 3.6, 95% CI 2.4 to 6.7) (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.15) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>). </p> <p>Specific injection site adverse events also occurred more frequently in the vaccinated group: </p> <p> <ul id="CD008858-list-0011"> <li> <p>participants with erythema: RR 4.30, 95% CI 2.66 to 6.94; RD 0.22, 95% CI 0.05 to 0.38; NNTH 4.5, 95% CI 2.6 to 20.0 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.16) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); </p> </li> <li> <p>participants with pain: RR 6.47, 95% CI 2.67 to 15.68; RD 0.27, 95% CI 0.15 to 0.40; NNTH 3.7, 95% CI 2.5 to 6.7 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.17) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); </p> </li> <li> <p>participants with pruritus: RR 4.32, 95% CI 1.49 to 12.48; RD 0.05, 95% CI 0.01 to 0.09; NNTH 20.0, 95% CI 11.1 to 100.0 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.18) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); </p> </li> <li> <p>participants with swelling: RR 5.84, 95% CI 4.95 to 6.89; RD 0.18, 95% CI 0.07 to 0.29; NNTH 5.6, 95% CI 3.4 to 14.3 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.19) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); </p> </li> <li> <p>participants with warmth: RR 4.73, 95% CI 2.57 to 8.74; RD 0.01, 95% CI 0.01 to 0.02; NNTH 100.0, 95% CI 50.0 to 100.0 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.20) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); </p> </li> <li> <p>participants with rash: RR 3.26, 95% CI 1.31 to 8.11, but no significant RD (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.21) (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>); </p> </li> <li> <p>participants with mass: RR 7.05, 95% CI 1.91 to 26.05; RD 0.15, 95% CI −0.20 to 0.50; NNTH 6.7 (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.23) (<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> </li> </ul> </p> <p>Varicella‐like rash at injection site (up to day 42) also occurred more frequently in the vaccinated group: RR 2.86, 95% CI 1.21 to 6.76, but without a significant RD due to the small number of events (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.24) (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> <p>The risk of herpes zoster‐like rash up to 42 days postvaccination was lower in the vaccinated group (RR 0.47, 95% CI 0.27 to 0.84) than in the placebo group, but without a significant RD (<a href="./references#CD008858-fig-0005" title="">Analysis 1.2</a>.26) (<a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> <p><b>Duration of injection site adverse events</b> </p> <p>Injection site adverse events generally lasted longer in the zoster vaccine group. There were significant differences with respect to the duration of the following local adverse events: erythema MD 2.40 days (95% CI 1.56 to 3.24) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.1); pruritus MD 2.40 days (95% CI 1.32 to 3.48) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.3); and swelling MD 1.90 days (95% CI 1.35 to 2.45) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.4). </p> <p>The duration of pain and haematoma did not differ significantly between the groups: MD 1.00 (95% CI −0.10 to 2.10) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.2) and MD −0.50 (95% CI −5.52 to 4.52) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.6), respectively. </p> <p>The duration of rash was longer in the placebo group than in the vaccine group: RR −16.60 (95% CI −33.68 to 0.48) (<a href="./references#CD008858-fig-0006" title="">Analysis 1.3</a>.5). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High‐potency (∼207,000 pfu/0.65 mL) versus low‐potency (∼58,000 pfu/0.65 mL) zoster vaccine</b> (<a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The comparison of high‐ versus low‐potency zoster vaccine yielded no significant differences between groups for the following adverse events: vaccine‐related adverse events, systemic vaccine‐related adverse events, and vaccine‐related serious adverse events (death). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NBP608 (minimum 27,400 pfu/0.5 ml) versus LZV (minimum 19,400 pfu/0.65 ml)</b> (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For the AEs evaluated, there were no statistical significances. The AEs were: solicited local AEs, pain, redness/erythema, induration/swelling, solicited systemic AEs, fever, fatigue/malaise, myalgia, headache, vomiting, diarrhoea, unsolicited AEs infections and infestations, musculoskeletal and connective tissue disorders, gastrointestinal disorders, skin and subcutaneous tissue disorders, nervous system disorders, immune system disorders, injury, poisoning, and procedural complications, other disorders, SAE within 6 weeks postvaccination, SAE within 26 weeks postvaccination. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Refrigerated versus frozen zoster vaccine</b> </p> <p>(<a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between the refrigerated versus the frozen zoster vaccine for the following adverse events: 1 or more adverse events, vaccine‐related adverse events, systemic adverse events, systemic vaccine‐related adverse events, serious adverse events, vaccine‐related serious adverse events or death. However, there were more injection site adverse events in the group receiving frozen vaccines (RR 0.77, 95% CI 0.60 to 0.98). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 doses versus a single dose of LZV and 2 doses given at different intervals</b> </p> <p>(<a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zoster vaccine 1‐month schedule versus zoster vaccine 3‐month schedule</b> </p> <p>There was no statistical difference between participants who received the doses of zoster vaccine 2 months apart compared to those receiving them 3 months apart: SAE (RR 0.95, 0.14 to 6.70); withdrawal due to AE (RR 2.86, 95% CI 0.12 to 69.80); AE (RR 1.10, 95% CI 0.91 to 1.31); vaccine‐related AE (RR 1.00, 95% CI 0.81 to 1.24); systemic AE (RR 1.34, 95% CI 0.90 to 2.00); vaccine‐related systemic AE (RR 1.27, 95% CI 0.45 to 3.60); rash of interest non‐injection site rashes (RR 0.95, 95% CI 0.06 to 15.14); varicella/varicella‐like rash (RR 0.95, 95% CI 0.06 to 15.14); injection site reaction (RR 0.99, 95% CI 0.80 to 1.23); solicited injection site reaction (RR 1.00, 95% CI 0.81 to 1.25); unsolicited injection site reaction (RR 0.41, 95% CI 0.11 to 1.56); erythema injection site (RR 1.01, 95% CI 0.80 to 1.27); pain injection site (RR 0.84, 95% CI 0.57 to 1.25); swelling injection site (RR 1.05, 95% CI 0.75 to 1.47). </p> <p>No participants from either group reported the following AEs: vaccine‐related SAE; vaccine‐related withdrawal due to AE; non‐serious vaccine‐related withdrawal due to AE; and herpes zoster/zoster‐like rash. </p> <p><b>Zoster vaccine 1‐month schedule versus zoster vaccine single dose</b> </p> <p>Only participants with systemic AE: there were significant differences in favour of the 2 doses 1 month apart, with a higher incidence in the single‐dose group: RR 0.74, 95% CI 0.56 to 0.97; RD −0.07, 95% CI −0.13 to −0.01; NNTH 14.3, 95% CI 7.6 to 100. </p> <p>There was no statistical difference for most adverse events: SAE (RR 0.72, 95% CI 0.16 to 3.30); withdrawal due to AE (RR 0.36, 95% CI 0.05 to 2.82); vaccine‐related withdrawal due to AE (RR 0.21, 95% CI 0.01 to 3.74); non‐serious vaccine‐related withdrawal due to AE (RR 0.21, 95% CI 0.01 to 3.74); AE (RR 0.92, 95% CI 0.80 to 1.05); vaccine‐related AE (RR 0.91, 95% CI 0.77 to 1.08); vaccine‐related systemic AE (RR 0.54, 95% CI 0.26 to 1.12); rash of interest non‐injection site rashes (RR 1.61, 95% CI 0.15 to 17.72); varicella/varicella‐like rash (RR 9.66, 95% CI 0.39 to 236.25); herpes zoster/zoster‐like rash (RR 0.64, 95% CI 0.03 to 13.36); injection site reaction (RR 0.93, 95% CI 0.78 to 1.10); solicited injection site reaction (RR 0.94, 95% CI 0.79 to 1.11); unsolicited injection site reaction (RR 0.35, 95% CI 0.11 to 1.13); injection site erythema (RR 0.98, 95% CI 0.81 to 1.17); injection site pain (RR 0.74, 95% CI 0.54 to 1.01); injection site swelling (RR 1.08, 95% CI 0.82 to 1.41). </p> <p>There were no participants with vaccine‐related SAEs in either group.</p> <p><b>Zoster vaccine 3‐month schedule versus zoster vaccine single dose</b> </p> <p>Participants in the single‐dose group had a higher incidence of the following AEs in comparison to the group that received 2 doses, 3 months apart: AE (RR 0.84, 95% CI 0.72 to 0.97; RD −0.09; 95% CI −0.17 to −0.02; NNTH 11.1, 95% CI 5.9 to 50); systemic AE (RR 0.55, 95% CI 0.39 to 0.76; RD −0.13, 95% CI −0.18 to −0.07; NNTH 7.6, 95% CI 5.6 to 14.3); vaccine‐related systemic AE (RR 0.42, 95% CI 0.18 to 0.98; RD −0.04, 95% CI −0.06 to −0.01; NNTH 25.0, 95% CI 16.6 to 100). There were no significant differences between groups for the following adverse events: SAE (RR 0.75, 95% CI 0.16 to 3.46); withdrawal due to AE (RR 0.18, 95% CI 0.01 to 3.04); vaccine‐related withdrawal due to AE (RR 0.23, 95% CI 0.01 to 3.93); non‐serious vaccine‐related withdrawal due to AE (RR 0.23, 95% CI 0.01 to 3.93); vaccine‐related AE (RR 0.91, 95% CI 0.77 to 1.08); rash of interest non‐injection site rashes (RR 1.69, 95% CI 0.15 to 18.60); varicella/varicella‐like rash (RR 10.14, 95% CI 0.41 to 247.92); herpes zoster/zoster‐like rash (RR 0.68, 95% CI 0.03 to 14.02); injection site reaction (RR 0.93, 95% CI 0.79 to 1.11); solicited injection site reaction (RR 0.93, 95% CI 0.78 to 1.11); unsolicited injection site reaction (RR 0.85, 95% CI 0.38 to 1.91); injection site erythema (RR 0.97, 95% CI 0.80 to 1.17); injection site pain (RR 0.87, 95% CI 0.65 to 1.17); injection site swelling (RR 1.03, 95% CI 0.77 to 1.36). </p> <p>There were no participants with vaccine‐related SAE in either group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV AMP versus LZV</b> (<a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between LZV AMP versus LZV for the following adverse events: participants with 1 or more adverse events; injection site adverse events; injection site erythema; injection site pain; injection site pruritus; and injection site swelling. It is important to note that there was a significant difference for participants with 1 or more serious adverse events (RR 0.25, 95% CI 0.08 to 0.82; RD −0.04, 95% CI −0.07 to −0.00; NNTH 25.0, and no RD favourable to LZV). There were no deaths in this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heat‐treated LZV versus LZV or placebo</b> </p> <p>(<a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heat LZV versus LZV</b> </p> <p>There was no SAE in this comparison. There were no significant differences between groups for the following adverse events: 1 or more AE, 1 or more vaccine‐related AE, 1 or more systemic AE, 1 or more vaccine‐related systemic AE, headache, injection site erythema, and injection site pruritus. On the other hand, for 1 or more injection site AE (RR 0.40, 95% CI 0.23 to 0.70; RD −0.40, 95% CI −0.60 to −0.20; NNTH 2.5, 95% CI 1.17 to 5.0); vaccine‐related 1 or more injection site AE (RR 0.48, 95% CI 0.27 to 0.85; RD −0.30, 95% CI −0.50 to −0.09; NNTH 3.3, 95% CI 2 to 11.1); injection site induration (RR 0.36, 95% CI 0.16 to 0.82; RD −0.26, 95% CI −0.45 to −0.08; NNTH 3.8, 95% CI 2.2 to 12.5); injection site pain (RR 0.18, 95% CI 0.07 to 0.48; RD −0.44, 95% CI −0.62 to −0.26; NNTH 2.3, 95% CI 1.6 to 3.8). All significant differences were favourable to heat LZV. </p> <p><b>Heat LZV versus placebo</b> </p> <p>There was no SAE in this comparison. There was no significant difference between heat LZV and placebo for all adverse events reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV IM route versus LZV SC route</b> </p> <p>(<a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The participants who received SC vaccines had a significantly higher incidence of the following adverse events: </p> <p> <ul id="CD008858-list-0012"> <li> <p>at least 1 AE: RR 0.68, 95% CI 0.56 to 0.82; RD −0.22, 95% CI −0.32 to −0.12; NNTH 4.5, 95% CI 3.1 to 8.33; </p> </li> <li> <p>vaccine‐related AE: RR 0.58, 95% CI 0.47 to 0.72; RD −0.28, 95% CI −0.38 to −0.18; NNTH 3.6, 95% CI 2.6 to 5.55; </p> </li> <li> <p>solicited injection site reaction: RR 0.53, 95% CI 0.42 to 0.67; RD −0.30, 95% CI −0.40 to −0.20; NNTH 1.8, 95% CI 2.5 to 5; </p> </li> <li> <p>injection site erythema: RR 0.30, 95% CI 0.21 to 0.44; RD −0.37, 95% CI −0.46 to −0.28; NNTH 2.7, 95% CI 2.1 to 3.5; </p> </li> <li> <p>injection site pain: RR 0.65, 95% CI 0.47 to 0.88; RD −0.14, 95% CI −0.24 to −0.04; NNTH 7.1, 95% CI 4.2 to 25; </p> </li> <li> <p>injection site swelling: RR 0.37, 95% CI 0.24 to 0.56; RD −0.24, 95% CI −0.32 to −0.15; NNTH 4.2, 95% CI 3.1 to 6.7; </p> </li> <li> <p>injection site pruritus: RR 0.27, 95% CI 0.08 to 0.97; RD −0.05, 95% CI −0.09 to −0.00; NNTH 20.0, 95% CI 0 to 11.0. </p> </li> </ul> </p> <p>There were no significant differences between groups for the following adverse events: all systemic adverse events: RR 1.03, 95% CI 0.70 to 1.51; vaccine‐related systemic AE: RR 0.93, 95% CI 0.44 to 1.98; headache considered as vaccine‐related by the investigator: RR 0.75, 95% CI 0.17 to 3.32; unsolicited injection site reaction: RR 0.65, 95% CI 0.29 to 1.45; severe injection site erythema (&gt; 10 cm): RR 0.67, 95% CI 0.11 to 3.96; severe injection site pain (inability to work or perform usual activity): RR 1.01, 95% CI 0.14 to 7.06; severe injection site swelling (&gt; 10 cm): RR 0.25, 95% CI 0.03 to 2.23. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV intradermal route versus LZV SC route</b> (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Full‐dose intradermal versus full‐dose subcutaneous</b> </p> <p>There were significant differences in favour of LZV SC for 2 AEs: 1 or more injection site AEs (RR 1.53, 95% CI 1.12 to 2.09; RD 0.27, 95% CI 0.08 to 0.47; NNTH 3.7, 95% CI 2.1 to 12.5) and erythema (RR 2.49, 95% CI 1.59 to 3.89; RD 0.46, 95% CI 0.27 to 0.65; NNTH 2.2, 95% CI 1.5 to 3.7). There were no significant differences between groups for the following adverse events: pain, swelling, induration, pruritus, haematoma, anaesthesia, or rash. </p> <p><b>1/3 dose intradermal versus full‐dose subcutaneous</b> </p> <p>There were significant differences in favour of full‐dose LZV SC for the following AEs: erythema (RR 1.95, 95% CI 1.20 to 3.18; RD 0.29, 95% CI 0.09 to 0.50; NNTH 3.4, 95% CI 2.0 to 11.1) and induration (RR 3.57, 95% CI 1.38 to 9.23; RD 0.25, 95% CI 0.07 to 0.42; NNTH 4.0, 95% CI 2.4 to 14.3). There was no significant difference between groups for the other adverse events. </p> <p><b>1/10 dose intradermal versus full‐dose subcutaneous</b> </p> <p>There was no significant difference between groups for any adverse events.</p> <p><b>1/27 dose intradermal versus full‐dose subcutaneous</b> </p> <p>Erythema (RR 1.72, 95% CI 1.03 to 2.88; RD 0.22, 95% CI 0.01 to 0.43; NNTH 4.5, 95% CI 2.30 to 100.0) and induration (RR 3.06, 95% CI 1.14 to 8.17; RD 0.20, 95% CI 0.03 to 0.37; NNTH 5.0, 95% CI 2.7.0 to 3.3). There was no significant difference between groups for the other adverse events. </p> <p><b>Full‐dose intradermal versus 1/3 dose subcutaneous</b> </p> <p>There was a difference between the groups favourable to the subcutaneous 1/3 dose group, which had a significantly lower incidence of the following AEs: 1 or more injection site adverse events (RR 3.86, 95% CI 1.95 to 7.63; RD 0.59, 95% CI 0.40 to 0.77; NNTH 1.7, 95% CI 1.3 to 2.5); erythema (RR 5.20, 95% CI 2.27 to 11.93; RD 0.62, 95% CI 0.43 to 0.80; NNTH 1.6, 95% CI 1.2 to 2.3); and induration (RR 6.00, 95% CI 1.45 to 24.81; RD 0.29, 95% CI 0.12 to 0.47; NNTH 3.4, 95% CI 2.1 to 8.3). There was no significant difference between groups for the other adverse events. </p> <p><b>1/3 dose intradermal versus 1/3 dose subcutaneous</b> </p> <p>There was no significant difference between groups for all adverse events reported.</p> <p><b>1/10 dose intradermal versus 1/3 dose subcutaneous</b> </p> <p>There were significant differences in favour of 1/3 dose SC for the following AEs: 1 or more injection site adverse events (RR 2.71, 95% CI 1.32 to 5.60; RD 0.35, 95% CI 0.14 to 0.57; NNTH 2.9, 95% CI 1.8 to 7.1); erythema (RR 3.20, 95% CI 1.32 to 7.75; RD 0.32, 95% CI 0.12 to 0.53; NNTH 3.1, 95% CI 1.9 to 8.3); and induration (RR 5.50, 95% CI 1.32 to 22.98; RD 0.26, 95% CI 0.09 to 0.44; NNTH 3.8, 95% CI 2.3 to 11.1). There was no significant difference between groups for the other adverse events. </p> <p><b>1/27 dose intradermal versus 1/3 dose subcutaneous</b> </p> <p>There were significant differences in favour of 1/3 dose SC for the following AEs: 1 or more injection site adverse events (RR 2.71, 95% CI 1.32 to 5.60; RD 0.35, 95% CI 0.14 to 0.57; NNTH 2.9, 95% CI 1.8 to 7.1); erythema (RR 3.60, 95% CI 1.51 to 8.59; RD 0.38, 95% CI 0.18 to 0.59; NNTH 2.6, 95% CI 1.7 to 5.6); and induration (RR 5.00, 95% CI 1.18 to 21.14; RD 0.24, 95% CI 0.06 to 0.41; NNTH 4.2, 95% CI 2.4 to 16.7). There was no significant difference between groups for the other adverse events. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV versus pneumo‐23 vaccine</b> </p> <p>(<a href="./references#CD008858-bbs2-0002" title="BergerR , TrannoyE , HolländerG , BailleuxF , RudinC , CreusvauxH . A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]TrannoyE , BergerR , HolländerG , BailleuxF , HeimendingerP , VuillierD , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine2000;18(16):1700-6. [PII: S0264-410X (99) 00510-1]">Berger 1998</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study compared 3 different concentrations of plaque‐forming units (pfu) of live attenuated VZV and reported the following adverse events: </p> <p><b>3200 pfu VZV/dose versus pneumo‐23</b> </p> <p>There was a lower incidence of 1 or more injection site reactions in the group vaccinated with the 3200 pfu/dose zoster vaccine (RR 0.61, 95% CI 0.41 to 0.91) as well as pain at the injection site (RR 0.49, 95% CI 0.30 to 0.81). </p> <p>There were no significant differences between the 3200 pfu/dose zoster vaccine and the pneumo‐23 vaccine for the following local adverse events: induration (≥ 2 cm diameter injection site), probably vaccine‐related injection site pain, redness (≥ 2 cm diameter injection site), pruritus or vesicles (no patients had vesicles in the 3200 pfu/dose zoster vaccine nor the pneumo‐23 groups). </p> <p><b>8500 pfu VZV/dose versus pneumo‐23</b> </p> <p>There was a lower incidence of 1 or more injection site reaction in the group vaccinated with the 8500 pfu/dose zoster vaccine (RR 0.63, 95% CI 0.43 to 0.93). </p> <p>There were no significant differences for the following injection site adverse events between participants who received the 8500 pfu/dose VZV vaccine and those who received the pneumo‐23 vaccine: induration (≥ 2 cm diameter injection site), pain (injection site), probably vaccine‐related injection site pain, redness, pruritus, and vesicles. </p> <p><b>41,650 pfu VZV/dose VZV versus pneumo‐23</b> </p> <p>Participants receiving the 41,650 pfu/dose zoster vaccine had significantly lower rates of one or more injection site reaction (RR 0.41, 95% CI 0.24 to 0.68) and pain at injection site (RR 0.43, 95% CI 0.25 to 0.74) than those receiving the pneumo‐23 vaccine. </p> <p>There were no significant differences between the groups for the following injection site adverse events: induration (≥ 2 cm diameter injection site), probably vaccine‐related injection site pain, redness (≥ 2 cm diameter injection site), pruritus, and vesicles (no patients had vesicles in the 41,650 pfu/dose zoster vaccine nor the pneumo‐23 vaccine groups). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LZV + IIV4 concomitant administration versus LZV + IIV4 sequential administration</b> (<a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between groups for the following: death, serious adverse events, one or more adverse events, non injection‐site adverse events, non injection site vaccine‐related AE, injection‐site adverse events. </p> <p>There were no vaccine‐related adverse events.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>AE: adverse event or adverse experiences<br/>AMP: alternative manufacturing process<br/>CI: confidence interval<br/>Elderly or older adults: aged ≥ 60 years old<br/>Frozen: −15 °C or colder<br/>gE: recombinant subunit VZV composed of glycoprotein E<br/>gE/saline: unadjuvanted gE<br/>Heat LZV: heat‐treated LZV<br/>HZ: herpes zoster<br/>ID: identification<br/>IIV4: inactivated quadrivalent influenza vaccines<br/>IM: intramuscular<br/>ISRs: injection site adverse reactions<br/>ITT: intention‐to‐treat<br/>LZV or ZV: live zoster vaccine (live attenuated Oka varicella zoster virus vaccine) minimum of 19,400 pfu (0.65 mL)<br/>MD: mean difference<br/>mL: millilitres<br/>NBP608 LZV: live zoster vaccine (live attenuated Oka varicella zoster virus vaccine) with a minimum of 27,400 pfu (0.50 mL)<br/>NNTB: number needed to treat for an additional beneficial outcome<br/>NNTH: number needed to treat for an additional harmful outcome<br/>pfu: plaque‐forming units<br/>pIMDs: potential immune‐mediated diseases<br/>pneumo‐23 vaccine: 23–valent pneumococcal polysaccharide vaccine<br/>RD: risk difference<br/>Refrigerated: 2 °C to 8 °C<br/>RR: risk ratio<br/>SAEs: serious adverse events<br/>SC: subcutaneously or subcutaneous<br/>VZV: varicella zoster virus </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events live zoster vaccine (LZV)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008858-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: adjuvanted recombinant varicella zoster virus subunit zoster vaccine (RZV)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV versus placebo</b> (<a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a>; <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The adverse events related to RZV versus placebo were:</p> <p> <ul id="CD008858-list-0013"> <li> <p>deaths: RR 0.94, 95% CI 0.84 to 1.04 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.1); </p> </li> <li> <p>deaths within 30 days after vaccination: RR 1.15, 95% CI 0.42 to 3.16 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.2); </p> </li> <li> <p>serious adverse events: RR 0.97, 95% CI 0.91 to 1.03 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.3); </p> </li> <li> <p>with serious adverse events within 30 days after vaccination: RR 0.90, 95% CI 0.67 to 1.20 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.4); </p> </li> <li> <p>serious adverse events within 30 days after vaccination related to vaccination: RR 0.33, 95% CI 0.03 to 3.21 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.5); </p> </li> <li> <p>any symptom: RR 2.41, 95% CI 2.02 to 2.88; RD 0.47, 95% CI 0.45 to 0.49; NNTH 2.1, 95% CI 2.0 to 2.2 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.6); </p> </li> <li> <p>any symptom grade 3: RR 5.29, 95% CI 4.48 to 6.26; RD 0.12, 95% CI 0.08 to 0.16; NNTH 8.3, 95% CI 6.3 to 12.5 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.7); </p> </li> <li> <p>any symptom grade 3 related to vaccination: RR 8.37, 95% CI 6.69 to 10.47; RD 0.14, 95% CI 0.13 to 0.15; NNTH 7.1, 95% CI 6.7 to 7.7 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.8); </p> </li> <li> <p>any systemic symptom: RR 2.23, 95% CI 2.12 to 2.34; RD 0.33, 95% CI 0.24 to 0.41; NNTH 3.0, 95% CI 2.4 to 4.2 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.9); </p> </li> <li> <p>any systemic symptom grade 3: RR 4.29, 95% CI 3.01 to 6.11; RD 0.07, 95% CI 0.02 to 0.12; NNTH 14.3, 95% CI 8.3.0 to 50.0 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.10); </p> </li> <li> <p>potential immune‐mediated disease: RR 0.88, 95% CI 0.71 to 1.08 and no RD (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.11); </p> </li> <li> <p>myalgia: RR 3.82, 95% CI 3.52 to 4.16; RD 0.33, 95% CI 0.31 to 0.35; NNTH 3.0, 95% CI 2.9 to 3.3 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.12); </p> </li> <li> <p>fatigue: RR 2.51, 95% CI 1.99 to 3.17; RD 0.24, 95% CI 0.12 to 0.35; NNTH 4.2, 95% CI 2.9 to 8.3 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.13); </p> </li> <li> <p>headache: RR 2.44, 95% CI 2.26 to 2.63; RD 0.22, 95% CI 0.21 to 0.24; NNTH 4.5, 95% CI 4.1 to 4.8 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.14); </p> </li> <li> <p>fever: RR 6.45, 95% CI 4.61 to 9.04; RD 0.14, 95% CI 0.06 to 0.23; NNTH 7.1, 95% CI 4.3 to 16.7 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.15); </p> </li> <li> <p>shivering: RR 4.35, 95% CI 3.26 to 5.81; RD 0.16, 95% CI 0.05 to 0.28; NNTH 6.3, 95% CI 3.6 to 20.0 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.16); </p> </li> <li> <p>gastrointestinal symptom: RR 1.75, 95% CI 1.21 to 2.55; RD 0.06, 95% CI 0.00 to 0.12 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.17); </p> </li> <li> <p>any local symptom: RR 6.89, 95% CI 6.37 to 7.45; RD 0.67, 95% CI 0.62 to 0.73; NNTH 1.5, 95% CI 1.4 to 1.6 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.18); </p> </li> <li> <p>any local symptom grade 3: RR 12.69, 95% CI 2.87 to 56.06; RD 0.09, 95% CI 0.08 to 0.10; NNTH 11.1, 95% CI 10 to 12.5 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.19); </p> </li> <li> <p>local redness: RR 28.93, 95% CI 22.62 to 37.00; RD 0.37, 95% CI 0.35 to 0.38; NNTH 2.7, 95% CI 2.6 to 2.9 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.20); </p> </li> <li> <p>local pain: RR 7.14, 95% CI 6.58 to 7.74; RD 0.64, 95% CI 0.57 to 0.72; NNTH 1.6, 95% CI 1.4 to 1.8 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.21); </p> </li> <li> <p>local swelling: RR 28.26, 95% CI 15.91 to 50.20; RD 0.24, 95% CI 0.21 to 0.27; NNTH 4.2, 95% CI 3.7 to 4.8 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.22); </p> </li> <li> <p>unsolicited report of adverse events: RR 1.07, 95% CI 1.00 to 1.14; RD 0.02, 95% CI 0.00 to 0.04 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.23); </p> </li> <li> <p>unsolicited report of adverse events grade 3: RR 1.38, 95% CI 1.12 to 1.69; RD 0.01, 95% CI 0.00 to 0.02 (<a href="./references#CD008858-fig-0011" title="">Analysis 2.3</a>.24). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV: lower or higher quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline</b> </p> <p>(<a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The incidence of adverse events in participants randomised to 4 different groups was compared as follows: </p> <p> <ol id="CD008858-list-0014"> <li> <p>Participants who received smaller amounts of adjuvant (AS01E) plus gE subunit VZV injection </p> </li> <li> <p>Participants who received larger amounts of adjuvant (AS01B) plus gE subunit VZV injection</p> </li> <li> <p>Participants who received unadjuvanted gE subunit VZV injection</p> </li> <li> <p>Participants who received saline injections</p> </li> </ol> </p> <p>We compared each of the groups with all of the other groups (total of 6 comparisons) as follows: </p> <p><b>50 μg gE/AS01<sub>E</sub> versus 50 μg gE/AS01<sub>B</sub> </b> </p> <p>There was a significantly higher incidence of adverse events in participants who received a higher quantity of adjuvant (AS01<sub>B</sub>): </p> <p> <ul id="CD008858-list-0015"> <li> <p>any symptom: RR 0.89, 95% CI 0.80 to 0.99; RD −0.09, 95% CI −0.18 to −0.01; NNTH 11.1, 95% CI 5.6 to 100.0; </p> </li> <li> <p>fatigue: RR 0.73, 95% CI 0.55 to 0.96; RD −0.13, 95% CI −0.24 to −0.02; NNTH 7.7, 95% CI 4.2 to 50.0; </p> </li> <li> <p>headache: RR 0.67, 95% CI 0.47 to 0.94; RD −0.13, 95% CI −0.23 to −0.02; NNTH 7.7, 95% CI 4.3 to 50.0; </p> </li> <li> <p>any local symptom: RR 0.85, 95% CI 0.75 to 0.96; RD −0.13, 95% CI −0.22 to −0.04; NNTH 7.7, 95% CI 4.5 to 25.0; </p> </li> <li> <p>local redness: RR 0.59, 95% CI 0.39 to 0.91; RD −0.12, 95% CI −0.21 to −0.02; NNTH 8.3, 95% CI 4.7 to 50.0; </p> </li> <li> <p>local pain: RR 0.84, 95% CI 0.74 to 0.95; RD −0.14, 95% CI −0.23 to −0.04; NNTH 7.1, 95% CI 4.3 to 25.0. </p> </li> </ul> </p> <p>There were no significant differences between groups for all other adverse events: any grade 3 symptom, any general symptom, any general grade 3 symptom, grade 3 fatigue, fever, gastrointestinal symptoms, grade 3 gastrointestinal symptoms, grade 3 headache, myalgia, grade 3 myalgia, any grade 3 local symptom, local grade 3 pain, local grade 3 redness, local swelling and local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>50 μg gE/AS01<sub>E</sub> versus 50 μg gE/saline (unadjuvanted)</b> </p> <p> <ul id="CD008858-list-0016"> <li> <p>any symptom: RR 1.76, 95% CI 1.34 to 2.32; RD 0.33, 95% CI 0.20 to 0.47; NNTH 3.0, 95% CI 2.1 to 5.0; </p> </li> <li> <p>any general symptom: RR 1.67, 95% CI 1.17 to 2.40; RD 0.22, 95% CI 0.09 to 0.36; NNTH 4.5, 95% CI 2.7 to 11.1; </p> </li> <li> <p>myalgia: RR 2.00, 95% CI 1.14 to 3.52; RD 0.16, 95% CI 0.05 to 0.28; NNTH 6.25, 95% CI 3.5 to 20.0; </p> </li> <li> <p>fever: RR 18.25, 95% CI 1.12 to 298.73; RD 0.12, 95% CI 0.06 to 0.18; NNTH 8.3, 95% CI 5.5 to 16.6; </p> </li> <li> <p>any local symptom: RR 3.05, 95% CI 1.99 to 4.69; RD 0.48, 95% CI 0.36 to 0.60; NNTH 2.0, 95% CI 1.6 to 2.7; </p> </li> <li> <p>local redness: RR 4.25, 95% CI 1.33 to 13.57; RD 0.13, 95% CI 0.06 to 0.21; NNTH 7.6, 95% CI 4.7 to 16.6; </p> </li> <li> <p>local pain: RR 3.64, 95% CI 2.25 to 5.90; RD 0.51, 95% CI 0.39 to 0.62; NNTH 1.9, 95% CI 1.6 to 2.5; </p> </li> <li> <p>local swelling: RR 4.08, 95% CI 1.27 to 13.08; RD 0.13, 95% CI 0.05 to 0.20; NNTH 7.6, 95% CI 5.0 to 20. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured the unadjuvanted gE group. </p> <p>There were no significant differences between groups for the following adverse events: any grade 3 symptom, any general grade 3 symptom, fatigue, grade 3 fatigue, gastrointestinal symptoms, grade 3 gastrointestinal symptoms, headache, grade 3 myalgia, any local grade 3 symptom, local grade 3 pain, local grade 3 redness and local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever or grade 3 headache in either group.</p> <p><b>50 μg gE/AS01<sub>B</sub> versus 50 μg gE/saline (unadjuvanted)</b> </p> <p> <ul id="CD008858-list-0017"> <li> <p>any symptom: RR 1.98, 95% CI 1.51 to 2.58; RD 0.43, 95% CI 0.30 to 0.55; NNTH 2.3, 95% CI 1.8 to 3.3; </p> </li> <li> <p>any general symptom: RR 1.93, 95% CI 1.36 to 2.73; RD 0.30, 95% CI 0.17 to 0.44; NNTH 3.3, 95% CI 2.2 to 5.8; </p> </li> <li> <p>myalgia: RR 2.51, 95% CI 1.45 to 4.36; RD 0.25, 95% CI 0.13 to 0.36; NNTH 4.0, 95% CI 2.7 to 7.6; </p> </li> <li> <p>fatigue: RR 2.19, 95% CI 1.38 to 3.48; RD 0.26, 95% CI 0.14 to 0.38; NNTH 3.8, 95% CI 2.6 to 7.1; </p> </li> <li> <p>headache: RR 2.73, 95% CI 1.48 to 5.03; RD 0.24, 95% CI 0.13 to 0.35; NNTH 4.1, 95% CI 2.8 to 7.6; </p> </li> <li> <p>fever: RR 24.99, 95% CI 1.54 to 404.89; RD 0.17, 95% CI 0.10 to 0.23; NNTH 5.8, 95% CI 4.3 to 10.0; </p> </li> <li> <p>any local symptom: RR 3.61, 95% CI 2.36 to 5.50; RD 0.61, 95% CI 0.49 to 0.72; NNTH 1.6, 95% CI 1.3 to 2.0; </p> </li> <li> <p>local redness: RR 7.14, 95% CI 2.29 to 22.22; RD 0.25, 95% CI 0.17 to 0.34; NNTH 4.0, 95% CI 2.9 to 5.8; </p> </li> <li> <p>local pain: RR 4.35, 95% CI 2.70 to 7.00; RD 0.64, 95% CI 0.53 to 0.75; NNTH 1.5, 95% CI 1.3 to 1.8; </p> </li> <li> <p>local swelling: RR 3.73, 95% CI 1.16 to 12.02; RD 0.11, 95% CI 0.04 to 0.19; NNTH 9.0, 95% CI 5.2 to 25. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured unadjuvanted gE.</p> <p>There were no significant differences between groups for the following adverse events: any grade 3 symptom, any general grade 3 symptom, grade 3 fatigue, gastrointestinal symptoms, grade 3 headache, grade 3 myalgia, any local grade 3 symptom, local grade 3 pain, local grade 3 redness and local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever or grade 3 gastrointestinal symptoms in either group.</p> <p><b>50 μg gE/AS01<sub>E</sub> versus saline</b> </p> <p> <ul id="CD008858-list-0018"> <li> <p>any symptom: RR 3.67, 95% CI 1.97 to 6.83; RD 0.56, 95% CI 0.42 to 0.71; NNTH 1.7, 95% CI 1.4 to 2.3; </p> </li> <li> <p>any general symptom: RR 2.99, 95% CI 1.51 to 5.92; RD 0.37, 95% CI 0.22 to 0.51; NNTH 9.1, 95% CI 1.9 to 4.5; </p> </li> <li> <p>myalgia: RR 6.25, 95% CI 1.59 to 24.55; RD 0.28, 95% CI 0.17 to 0.38; NNTH 3.5, 95% CI 2.6 to 5.8; </p> </li> <li> <p>any local symptom: RR 9.01, 95% CI 3.03 to 26.82; RD 0.63, 95% CI 0.52 to 0.74; NNTH 1.5, 95% CI 1.3 to 1.9; </p> </li> <li> <p>local pain: RR 8.84, 95% CI 2.97 to 26.33; RD 0.62, 95% CI 0.51 to 0.73; NNTH 1.6, 95% CI 1.3 to 1.9. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured the saline group.</p> <p>There were no significant differences between groups for the following adverse events: any grade 3 symptom, any general grade 3 symptom, fatigue, grade 3 fatigue, fever, gastrointestinal symptoms, grade 3 gastrointestinal symptoms, headache, grade 3 headache, grade 3 myalgia, any local grade 3 symptom, local grade 3 pain, local redness, local grade 3 redness, local swelling and local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever or grade 3 headache in either group.</p> <p><b>50 μg gE/AS01<sub>B</sub> versus saline</b> </p> <p> <ul id="CD008858-list-0019"> <li> <p>any symptom: RR 4.12, 95% CI 2.22 to 7.64; RD 0.66, 95% CI 0.52 to 0.80; NNTH 1.5, 95% CI 1.2 to 1.9; </p> </li> <li> <p>any general symptom: RR 3.44, 95% CI 1.74 to 6.79; RD 0.45, 95% CI 0.30 to 0.59; NNTH 2.2, 95% CI 1.6 to 3.3; </p> </li> <li> <p>myalgia: RR 7.85, 95% CI 2.01 to 30.67; RD 0.36, 95% CI 0.25 to 0.47; NNTH 2.7, 95% CI 2.1 to 4.0; </p> </li> <li> <p>fatigue: RR 2.61, 95% CI 1.31 to 5.19; RD 0.30, 95% CI 0.15 to 0.44; NNTH 1.3, 95% CI 2.2 to 6.6; </p> </li> <li> <p>headache: RR 3.55, 95% CI 1.37 to 9.17; RD 0.27, 95% CI 0.14 to 0.39; NNTH 3.7, 95% CI 2.5 to 7.1; </p> </li> <li> <p>any local symptom: RR 10.64, 95% CI 3.58 to 31.59; RD 0.76, 95% CI 0.66 to 0.86; NNTH 1.3, 95% CI 1.1 to 1.5; </p> </li> <li> <p>local redness: RR 22.99, 95% CI 1.45 to 365.01; RD 0.29, 95% CI 0.21 to 0.37; NNTH 3.4, 95% CI 2.7 to 4.7; </p> </li> <li> <p>local pain: RR 10.56, 95% CI 3.55 to 31.34; RD 0.75, 95% CI 0.65 to 0.86; NNTH 1.3, 95% CI 1.1 to 1.5. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured the saline group.</p> <p>There were no significant differences between groups for the following adverse events: any grade 3 symptom, any general grade 3 symptom, grade 3 fatigue, fever, gastrointestinal symptoms, grade 3 gastrointestinal symptoms, grade 3 headache, grade 3 myalgia, any local grade 3 symptom, local grade 3 pain, local grade 3 redness, local swelling and local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>50 μg gE/saline (unadjuvanted) versus saline</b> </p> <p> <ul id="CD008858-list-0020"> <li> <p>any symptom: RR 2.08, 95% CI 1.07 to 4.06; RD 0.23, 95% CI 0.06 to 0.40; NNTH 4.3, 95% CI 2.5 to 16.6 (favouring saline). </p> </li> </ul> </p> <p>There were no significant differences between groups for the following adverse events: any grade 3 symptom, any general symptom, any general grade 3 symptom, fatigue, grade 3 fatigue, fever, gastrointestinal symptoms, grade 3 gastrointestinal symptoms, headache, myalgia, grade 3 myalgia, any local symptom, local pain, local redness and local swelling, or consent withdrawal. </p> <p>No participants in either group had grade 3 fever, grade 3 headache, any local grade 3 symptom, local grade 3 pain, local grade 3 redness, local grade 3 swelling, loss to follow‐up, and serious adverse events. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline</b> (<a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The incidence of adverse events in participants randomised to 5 different groups was compared as follows: </p> <p> <ol id="CD008858-list-0021"> <li> <p>Participants receiving 25 µg adjuvanted gE/AS01<sub>B</sub> injection </p> </li> <li> <p>Participants receiving 50 µg adjuvanted gE/AS01<sub>B</sub> injection </p> </li> <li> <p>Participants receiving 100 µg adjuvanted gE/AS01<sub>B</sub> injection </p> </li> <li> <p>Participants receiving 1 dose saline injection + 1 dose 100 µg gE 2 months later injection</p> </li> <li> <p>Participants receiving 100 µg gE/saline</p> </li> </ol> </p> <p>We compared each of the groups to all other groups (total of 10 comparisons) as follows:</p> <p><b>25 µg gE/AS01<sub>B</sub> versus 50 µg gE/AS01<sub>B</sub> </b> </p> <p>There were no differences between groups in the incidence of the following adverse events: any fatigue, grade 3 fatigue, any fever, grade 3 fever, any headache, grade 3 headache, any myalgia, grade 3 myalgia, local pain, local grade 3 pain, local redness, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p><b>25 µg gE/AS01<sub>B</sub> versus 100 µg gE/AS01<sub>B</sub> </b> </p> <p>There were no differences between groups in the incidence of the following adverse events: any fatigue, grade 3 fatigue, any fever, any headache, grade 3 headache, any myalgia, grade 3 myalgia, local pain, grade 3 local pain, local redness, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p><b>50 µg gE/AS01<sub>B</sub> versus 100 µg gE/AS01<sub>B</sub> </b> </p> <p> <ul id="CD008858-list-0022"> <li> <p>any myalgia: RR 1.26, 95% CI 1.01 to 1.59; RD 0.11, 95% CI 0.00 to 0.22; NNTH 9.0, 95% CI 0 to 4.5 (favouring 100 µg gE/AS01<sub>B</sub>). </p> </li> </ul> </p> <p>There were no differences between groups in the incidence of other adverse events: any fatigue, grade 3 fatigue, any fever, grade 3 fever, any headache, grade 3 headache, grade 3 myalgia, local pain, local grade 3 pain, local redness, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, and serious adverse events. </p> <p><b>25 µg gE/AS01<sub>B</sub> versus 100 µg gE/saline (unadjuvanted gE)</b> </p> <p> <ul id="CD008858-list-0023"> <li> <p>any myalgia: RR 2.71, 95% CI 1.46 to 5.03; RD 0.28, 95% CI 0.16 to 0.41; NNTH 3.5, 95% CI 2.4 to 6.2; </p> </li> <li> <p>any fatigue: RR 1.89, 95% CI 1.11 to 3.22; RD 0.20, 95% CI 0.06 to 0.33; NNTH 5.0, 95% CI 3.0 to 16.6; </p> </li> <li> <p>local redness: RR 11.20, 95% CI 2.84 to 44.15; RD 0.38, 95% CI 0.29 to 0.47; NNTH 2.6, 95% CI 2.1 to 3.4; </p> </li> <li> <p>local pain: RR 4.21, 95% CI 2.30 to 7.70; RD 0.53, 95% CI 0.41 to 0.66; NNTH 1.8, 95% CI 1.5 to 2.4; </p> </li> <li> <p>local swelling: RR 14.49, 95% CI 2.04 to 102.66; RD 0.25, 95% CI 0.17 to 0.33; NNTH 4.0, 95% CI 3.0 to 5.8. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured unadjuvanted gE.</p> <p>There were no differences in the incidence of the following adverse events: grade 3 fatigue, any fever, any headache, grade 3 headache, grade 3 myalgia, local grade 3 pain, local grade 3 redness, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>50 µg gE/AS01<sub>B</sub> versus 100 µg gE/saline (unadjuvanted gE)</b> </p> <p> <ul id="CD008858-list-0024"> <li> <p>any myalgia: RR 3.22, 95% CI 1.74 to 5.94; RD 0.37, 95% CI 0.24 to 0.49; NNTH 2.7, 95% CI 2.0 to 4.1; </p> </li> <li> <p>any fatigue: RR 2.30, 95% CI 1.37 to 3.88; RD 0.29, 95% CI 0.16 to 0.42; NNTH 3.4, 95% CI 2.3 to 6.2; </p> </li> <li> <p>any headache: RR 2.13, 95% CI 1.14 to 4.01; RD 0.19, 95% CI 0.07 to 0.31; NNTH 5.2, 95% CI 3.2 to 14.2; </p> </li> <li> <p>local redness: RR 10.73, 95% CI 2.72 to 42.37; RD 0.36, 95% CI 0.27 to 0.45; NNTH 2.7, 95% CI 2.2 to 3.7; </p> </li> <li> <p>local pain: RR 4.37, 95% CI 2.39 to 8.00; RD 0.56, 95% CI 0.44 to 0.68; NNTH 1.7, 95% CI 1.4 to 2.2; </p> </li> <li> <p>local swelling: RR 10.73, 95% CI 1.50 to 76.64; RD 0.18, 95% CI 0.11 to 0.25; NNTH 5.5, 95% CI 4.0 to 9.0. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured unadjuvanted gE.</p> <p>There were no differences in the incidence of the following adverse events: grade 3 fatigue, any fever, grade 3 headache, grade 3 myalgia, local grade 3 pain, local grade 3 redness, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>100 µg gE/AS01<sub>B</sub> versus 100 µg gE/saline (unadjuvanted gE)</b> </p> <p> <ul id="CD008858-list-0025"> <li> <p>any myalgia: RR 2.55, 95% CI 1.37 to 4.74; RD 0.26, 95% CI 0.13 to 0.38; NNTH 3.8, 95% CI 2.6 to 7.6; </p> </li> <li> <p>any fatigue: RR 1.99, 95% CI 1.17 to 3.37; RD 0.22, 95% CI 0.09 to 0.35; NNTH 4.5, 95% CI 2.8 to 11.1; </p> </li> <li> <p>any headache: RR 1.85, 95% CI 0.98 to 3.51; RD 0.14, 95% CI 0.02 to 0.26; NNTH 7.1, 95% CI 3.8 to 50.0; </p> </li> <li> <p>local redness: RR 11.13, 95% CI 2.82 to 43.88; RD 0.38, 95% CI 0.28 to 0.47; NNTH 2.6, 95% CI 2.1 to 3.5; </p> </li> <li> <p>local pain: RR 4.44, 95% CI 2.43 to 8.11; RD 0.57, 95% CI 0.45 to 0.69; NNTH 1.7, 95% CI 1.4 to 2.2; </p> </li> <li> <p>local swelling: RR 14.73, 95% CI 2.08 to 104.31; RD 0.25, 95% CI 0.18 to 0.33; NNTH 4.0, 95% CI 3.0 to 5.5. </p> </li> </ul> </p> <p>All these differences in incidence of adverse events favoured unadjuvanted gE.</p> <p>There were no differences in the incidence of the following adverse events: grade 3 fatigue, any fever, grade 3 headache, grade 3 myalgia, local grade 3 pain, local grade 3 redness, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>25 µg gE/AS01<sub>B</sub> versus saline + 100 µg gE/AS01<sub>B</sub> </b> </p> <p> <ul id="CD008858-list-0026"> <li> <p>any myalgia: RR 1.52, 95% CI 1.14 to 2.03; RD 0.15, 95% CI 0.05 to 0.26; NNTH 6.6, 95% CI 3.8 to 20; </p> </li> <li> <p>any fatigue: RR 1.48, 95% CI 1.09 to 2.00; RD 0.14, 95% CI 0.03 to 0.24; NNTH 7.1, 95% CI 4.1 to 33.3; </p> </li> <li> <p>local redness: RR 1.40, 95% CI 1.04 to 1.88; RD 0.12, 95% CI 0.01 to 0.22; NNTH 8.3, 95% CI 4.5 to 100.0; </p> </li> <li> <p>local pain: RR 1.24, 95% CI 1.05 to 1.47; RD 0.14, 95% CI 0.03 to 0.24; NNTH 7.1, 95% CI 4.1 to 33.3. </p> </li> </ul> </p> <p>All differences in incidence of adverse events favoured saline + 100 µg gE/AS01<sub>B</sub>. </p> <p>There were no differences in the incidence of the following adverse events: any fatigue, grade 3 fever, any headache, grade 3 headache, grade 3 myalgia, local grade 3 pain, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>50 µg gE/AS01<sub>B</sub> versus saline + 100 µg gE/AS01<sub>B</sub> </b> </p> <p> <ul id="CD008858-list-0027"> <li> <p>any myalgia: RR 1.81, 95% CI 1.37 to 2.37; RD 0.24, 95% CI 0.14 to 0.34; NNTH 4.1, 95% CI 2.9 to 7.1; </p> </li> <li> <p>any fatigue: RR 1.80, 95% CI 1.35 to 2.39; RD 0.23, 95% CI 0.12 to 0.33; NNTH 4.3, 95% CI 3.0 to 8.3; </p> </li> <li> <p>any headache: RR 1.63, 95% CI 1.14 to 2.32; RD 0.14, 95% CI 0.04 to 0.23; NNTH 7.1, 95% CI 4.3 to 25; </p> </li> <li> <p>local pain: RR 1.29, 95% CI 1.10 to 1.52; RD 0.17, 95% CI 0.06 to 0.27; NNTH 5.8, 95% CI 3.7 to 16.6. </p> </li> </ul> </p> <p>All differences in incidence of adverse events favoured saline + 100 µg gE/AS01<sub>B</sub>. </p> <p>There were no differences in the incidence of the following adverse events: grade 3 fatigue, any fever, grade 3 fever, grade 3 headache, grade 3 myalgia, local grade 3 pain, local redness, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p><b>100 µg gE/AS01<sub>B</sub> versus saline + 100 µg gE/AS01<sub>B</sub> </b> </p> <p> <ul id="CD008858-list-0028"> <li> <p>any myalgia: RR 1.43, 95% CI 1.06 to 1.92; RD 0.13, 95% CI 0.02 to 0.23; NNTH 7.6, 95% CI 4.3 to 50.0; </p> </li> <li> <p>any fatigue: RR 1.55, 95% CI 1.15 to 2.09; RD 0.16, 95% CI 0.06 to 0.26; NNTH 6.2, 95% CI 3.8 to 16.6; </p> </li> <li> <p>any fever: RR 2.44, 95% CI 1.16 to 5.15; RD 0.08, 95% CI 0.02 to 0.14; NNTH 12.5, 95% CI 7.1 to 50; </p> </li> <li> <p>local redness: RR 1.39, 95% CI 1.03 to 1.87; RD 0.12, 95% CI 0.01 to 0.22; NNTH 8.3, 95% CI 4.5 to 100.0; </p> </li> <li> <p>local pain: RR 1.31, 95% CI 1.12 to 1.54; RD 0.18, 95% CI 0.07 to 0.28; NNTH 5.5, 95% CI 3.5 to 14.2. </p> </li> </ul> </p> <p>All differences in incidence of adverse events favoured saline + 100 µg gE/AS01<sub>B</sub>. </p> <p>There were no differences in the incidence of the following adverse events: grade 3 fatigue, headache, grade 3 headache, grade 3 myalgia, local grade 3 pain, local grade 3 redness, local swelling, local grade 3 swelling, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever in either group.</p> <p><b>Saline + 100 µg gE/AS01<sub>B</sub> versus 100 µg gE/saline (unadjuvanted gE)</b> </p> <p> <ul id="CD008858-list-0029"> <li> <p>local redness: RR 8.02, 95% CI 2.02 to 31.88; RD 0.26, 95% CI 0.17 to 0.35; NNTH 3.8, 95% CI 2.8 to 5.8; </p> </li> <li> <p>local pain: RR 3.38, 95% CI 1.84 to 6.23; RD 0.40, 95% CI 0.27 to 0.52; NNTH 2.5, 95% CI 1.9 to 3.7; </p> </li> <li> <p>local swelling: RR 9.82, 95% CI 1.37 to 70.30; RD 0.16, 95% CI 0.09 to 0.23; NNTH 6.2, 95% CI 4.3 to 11.1. </p> </li> </ul> </p> <p>All differences in incidence of adverse events favoured 100 µg gE/saline.</p> <p>There were no differences in the incidence of the following adverse events: any fatigue, grade 3 fatigue, any fever, any headache, any myalgia, grade 3 myalgia, local grade 3 pain, local grade 3 redness, consent withdrawal, loss to follow‐up, and serious adverse events. </p> <p>No participants had grade 3 fever, grade 3 headache, or local grade 3 swelling in either group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV: 2 doses given at 3 different intervals</b> (<a href="./references#CD008858-bbs2-0011" title="LalH , PoderA , CamporaL , GeeraertsB , OostvogelsL , AbeeleCV , et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine2018;36(1):148-54. [DOI: 10.1016/j.vaccine.2017.11.019]">Lal 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no statistically significant differences between groups for any of the 3 comparisons (<b>RZV 2 doses 2 months apart versus RZV 2 doses 6 months apart; RZV 2 doses 2 months apart versus RZV 2 doses 12 months apart; and RZV 2 doses 6 months apart versus RZV 2 doses 12 months apart</b>) in incidence of the following adverse events: at least 1 unsolicited AE symptom, at least 1 unsolicited AE symptom related to vaccination. </p> <p>There were no significant differences between groups for the following general symptoms: fatigue, grade 3 fatigue, fever, grade 3 fever, headache, grade 3 headache, myalgia, grade 3 myalgia, gastrointestinal symptom, grade 3 gastrointestinal symptom. The average duration of solicited general symptoms was ≤ 2 days. </p> <p>There were no significant differences between groups for the following local symptoms: local pain, grade 3 local pain, local redness, grade 3 redness, local swelling, grade 3 local swelling. The average duration of local symptoms was ≤ 3 days. There were no significant differences between groups for the following: SAE, withdrawn due to an SAE, consent withdrawal, lost to follow‐up. There were no cases of suspected zoster or autoimmune disease throughout the study in any of the groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV IM route versus RZV SC route</b> (<a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a significant difference between groups favouring the IM route for the following adverse events: injection site redness (RR 1.73, 95% CI 1.18 to 2.55; RD 0.37, 95% CI 0.15 to 0.58; NNTH 2.7, 95% CI 1.7 to 6.7); injection site swelling (RR 2.00, 95% CI 1.25 to 3.21; RD 0.40, 95% CI 0.17 to 0.63; NNTH 2.5, 95% CI 1.6 to 5.9); grade 3 injection site swelling (RR 5.00, 95% CI 1.19 to 20.92; RD 0.27, 95% CI 0.08 to 0.46; NNTH 3.7, 95% CI 2.2 to 12.5); injection site pruritus (RR 2.10, 95% CI 1.20 to 3.67; RD 0.37, 95% CI 0.13 to 0.60; NNTH 2.7, 95% CI 1.7 to 7.7). There were no differences between groups for all other adverse events. </p> <p>There were no deaths or autoimmune diseases.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV versus pneumo‐23</b> (<a href="./references#CD008858-bbs2-0014" title="MaréchalC , LalH , PoderA , FergusonM , EnweonyeI , HeinemanTC , et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: randomized trial. Vaccine2018;36(29):4278-86. [DOI: 10.1016/j.vaccine.2018.05.110]">Maréchal 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events within 30 days after vaccination</b> </p> <p> <ul id="CD008858-list-0030"> <li> <p>any serious adverse event: RR 0.78, 95% CI 0.29 to 2.07 and no RD;</p> </li> <li> <p>potential immune‐mediated disease: RR 0.33, 95% CI 0.01 to 8.18 and no RD;</p> </li> </ul> </p> <p>There were no serious adverse events or pIMDs that were considered vaccine‐related.</p> <p><b>Serious adverse events from 30 days after last vaccination up to the end of study</b> </p> <p> <ul id="CD008858-list-0031"> <li> <p>any serious adverse event: RR 1.00, 95% CI 0.32 to 2.38 and no RD;</p> </li> <li> <p>potential immune‐mediated disease: RR 3.01, 95% CI 0.12 to 73.71 and no RD;</p> </li> </ul> </p> <p>There were no serious adverse events or pIMDs that were considered vaccine‐related.</p> <p>When comparing the group that received RZV + pneumo‐23 versus the group that received only pneumo‐23, the following systemic adverse events occurred within 7 days after vaccination: </p> <p> <ul id="CD008858-list-0032"> <li> <p>any general symptom: RR 1.74, 95% CI 1.51 to 2.01; RD 0.27, 95% CI 0.21 to 0.34; NNTH 3.7, 95% CI 2.9 to 4.8; </p> </li> <li> <p>any general symptom grade 3: RR 5.90, 95% CI 2.95 to 11.81; RD 0.10, 95% CI 0.07 to 0.14; NNTH 10.0, 95% CI 7.1 to 14.3; </p> </li> <li> <p>myalgia: RR 2.18, 95% CI 1.75 to 2.70; RD 0.24, 95% CI 0.18 to 0.30; NNTH 4.2, 95% CI 3.3 to 5.6; </p> </li> <li> <p>myalgia grade 3: RR 2.78, 95% CI 1.31 to 5.90; RD 0.04, 95% CI 0.01 to 0.06; NNTH 25.0, 95% CI 16.7 to 100.0; </p> </li> <li> <p>pain local: RR 1.93, 95% CI 1.70 to 2.19; RD 0.37, 95% CI 0.31 to 0.43; NNTH 2.7, 95% CI 2.3 to 3.2; </p> </li> <li> <p>fatigue grade 3: RR 7.52, 95% CI 2.67 to 21.16; RD 0.06, 95% CI 0.03 to 0.09; NNTH 16.7, 95% CI 11.1 to 33.3; </p> </li> <li> <p>headache: RR 2.23, 95% CI 1.74 to 2.85; RD 0.20, 95% CI 0.14 to 0.26; NNTH 5.0, 95% CI 3.8 to 7.1; </p> </li> <li> <p>headache grade 3: RR 4.26, 95% CI 1.45 to 12.56; RD 0.03, 95% CI 0.01 to 0.05; NNTH 33.3, 95% CI 20.0 to 100.0; </p> </li> <li> <p>fever: RR 5.32, 95% CI 2.99 to 9.48; RD 0.13, 95% CI 0.09 to 0.17; NNTH 7.7, 95% CI 5.9 to 11.1; </p> </li> <li> <p>fever grade 3: RR 2.00, 95% CI 0.37 to 10.89; RD 0.00, 95% CI −0.01 to 0.02;</p> </li> <li> <p>shivering: RR 3.17, 95% CI 2.15 to 4.68; RD 0.02, 95% CI 0.00 to 0.04; NNTH 50.0; and no RD; </p> </li> <li> <p>shivering grade 3: RR 3.26, 95% CI 1.07 to 9.91; RD 0.32, 95% CI 0.30 to 0.34; NNTH 3.1, 95% CI 2.9 to 3.3; </p> </li> <li> <p>gastrointestinal symptom: RR 2.54, 95% CI 1.70 to 3.79; RD 0.11, 95% CI 0.06 to 0.15; NNTH 9.0, 95% CI 6.7 to 16.7; </p> </li> <li> <p>gastrointestinal symptom grade 3: RR 3.01, 95% CI 0.61 to 14.82; RD 0.01, 95% CI −0.00 to 0.02; and no RD. </p> </li> </ul> </p> <p><b>Injection site AE</b> </p> <p> <ul id="CD008858-list-0033"> <li> <p>any local symptom: RR 1.05, 95% CI 1.00 to 1.11; and no RD;</p> </li> <li> <p>any local symptom grade 3: RR 1.49, 95% CI 1.10 to 2.03; RD 0.07, 95% CI 0.02 to 0.11; NNTH 14.3, 95% CI 9.1 to 50.0; </p> </li> <li> <p>redness local: RR 5.61, 95% CI 3.90 to 8.08; RD 0.32, 95% CI 0.27 to 0.37; NNTH 3.1, 95% CI 2.7 to 3.7; </p> </li> <li> <p>redness local grade 3: RR 6.52, 95% CI 1.48 to 28.70; RD 0.03, 95% CI 0.01 to 0.04; NNTH 33.3, 95% CI 25.0 to 100.0; </p> </li> <li> <p>pain local: RR 1.93, 95% CI 1.70 to 2.19; RD 0.37, 95% CI 0.31 to 0.43; NNTH 2.7, 95% CI 2.3 to 3.2; </p> </li> <li> <p>pain local grade 3: RR 10.77, 95% CI 3.90 to 29.76; RD 0.09, 95% CI 0.06 to 0.12; NNTH 11.1, 95% CI 8.3 to 16.7; </p> </li> <li> <p>swelling local: RR 4.15, 95% CI 2.65 to 6.48; RD 0.16, 95% CI 0.12 to 0.20; NNTH 6.25, 95% CI 5.0 to 8.3; </p> </li> <li> <p>swelling local grade 3: RR 2.00, 95% CI 0.18 to 22.03; and no RD.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV + TDaPV co‐administration group versus RZV + TDaPV not co‐administration group</b> (<a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between groups for the following: death, serious adverse events, systemic adverse events, injection site adverse events, unsolicited vaccine‐related adverse events. There were no pIMDs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RZV + IIV4 co‐administration group versus not co‐administration group</b> (<a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no deaths.</p> <p>There were no significant differences between groups except for the following AEs:</p> <p> <ul id="CD008858-list-0034"> <li> <p>fatigue: RR 1.21, 95% CI 1.05 to 1.39; RD 0.09, 95% CI 0.03 to 0.16; NNTH 11.1, 95% CI 6.3 to 33.3; </p> </li> <li> <p>pain local: RR 1.09, 95% CI 1.02 to 1.16; RD 0.07, 95% CI 0.01 to 0.12; NNTH 14.3, 95% CI 8.3 to 100.0. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PCV13 vaccine + RZV concomitant administration (Co‐Ad) versus PCV13 vaccine + RZV sequential administration (Se‐Ad)</b> (<a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between groups for the following: death, serious adverse events, systemic adverse events, injection site adverse events, unsolicited vaccine‐related adverse events and pIMDs. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>AE: adverse event or adverse experiences<br/>AS01: liposome‐based adjuvant system containing the immunoenhancers 3‐O‐desacyl‐4′‐monophosphoryl lipid A (MPL) and the saponin QS‐21 (<i>Quillaja saponaria</i> Molina, fraction 21)<br/>Adjuvanted gE/AS01<sub>B</sub>: 50 μg purified gE with adjuvant B (1 mg dioleoyl phosphatidylcholine, 250 μg cholesterol, 50 μg MPL, and 50 μg QS‐21)<br/>Adjuvanted gE/AS01<sub>E</sub>: 50 μg purified gE with adjuvant E (500 μg dioleoyl phosphatidylcholine, 125 μg cholesterol, 25 μg MPL, and 25 μg QS‐21)<br/>AS01<sub>B</sub>: adjuvant B composed of 1 mg dioleoyl phosphatidylcholine, 250 μg cholesterol, 50 μg MPL, and 50 μg QS‐21<br/>AS01<sub>E</sub>: adjuvant E composed of 500 μg dioleoyl phosphatidylcholine, 125 μg cholesterol, 25 μg MPL, and 25 μg QS‐21<br/>CI: confidence interval<br/>Elderly or older adults: aged ≥ 60 years old<br/>gE: recombinant subunit VZV composed of glycoprotein E<br/>gE/saline: unadjuvanted gE<br/>ID: identification<br/>IIV4: inactivated quadrivalent influenza vaccines<br/>IM: intramuscular<br/>MPL: immunoenhancer 3‐O‐desacyl‐4′‐monophosphoryl lipid A<br/>NNTB: number needed to treat for an additional beneficial outcome<br/>NNTH: number needed to treat for an additional harmful outcome<br/>pIMDs: potential immune‐mediated diseases<br/>PCV13 vaccine: 13‐valent pneumococcal polysaccharide vaccine<br/>pneumo‐23 vaccine: 23–valent pneumococcal polysaccharide vaccine<br/>QS‐21: immunoenhancer saponin <i>Quillaja saponaria</i> Molina, fraction 21<br/>RD: risk difference<br/>RR: risk ratio<br/>RZV: adjuvanted recombinant zoster vaccine (contains 50 µg of recombinant VZV glycoprotein E, and the liposome‐based AS01<sub>B</sub> adjuvant system contains 50 µg of 3‐O‐desacyl‐4′‐monophosphoryl lipid A (MPL) and 50 µg of <i>Quillaja saponaria</i> Molina, fraction 21 (QS21))<br/>SAEs: serious adverse events<br/>SC: subcutaneously or subcutaneous<br/>TDaPV: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine<br/>VZV: varicella zoster virus </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: adjuvanted recombinant varicella zoster virus subunit zoster vaccine (RZV)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008858-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Dropouts</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts (all included studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>LZV versus placebo</b> </p> <p>The pooled data from the studies that compared zoster vaccine and placebo showed no differences in reasons for dropout (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>): for any reason (RR 0.99, 95% CI 0.91 to 1.08) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.1) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); discontinued due to vaccine‐related adverse events (RR 5.05, 95% CI 0.25 to 103.88) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.2) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); for clinical AE (RR 1.34, 95% CI 0.72 to 2.52) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.3) (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); for physician decision (RR 0.20, 95% CI 0.01 to 4.17) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.4) (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>); for withdrawal of consent (RR 0.95, 95% CI 0.54 to 1.68) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.5) (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); for loss to follow‐up (RR 1.27, 95% CI 0.96 to 1.69) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.6) (<a href="./references#CD008858-bbs2-0009" title="HataA , InoueF , HamamotoY , YamasakiM , FujikawaJ , KawaharaH , et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes and Metabolism2016;33(8):1094–101. [DOI: 10.1111/dme.13038]">Hata 2016</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0018" title="NCT00886613. A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) [A double-blind, randomized, placebo controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT00886613 (first received 22 April 2009). ">NCT00886613</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>); and for protocol deviation (RR 1.49, 95% CI 0.27 to 8.37) (<a href="./references#CD008858-fig-0007" title="">Analysis 1.4</a>.7) (<a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>). In <a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>, <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>, and <a href="./references#CD008858-bbs2-0024" title="VermeulenJN , LangeJM , TyringSK , PetersPH , NunezM , PolandG , et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥ 60 years of age. Vaccine2012;30(5):904-10. [DOI: 10.1016/j.vaccine.2011.11.096]">Vermeulen 2012</a>, consent was withdrawn after the intervention. In <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>, some participants apparently withdrew consent after randomisation, but the exact number that withdrew consent after the intervention is not stated. </p> <p>The pooled data from the studies that compared zoster vaccine versus placebo showed no differences in reasons for participants with no follow‐up (RR 1.05, 95% CI 0.74 to 1.48) (<a href="./references#CD008858-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD008858-bbs2-0015" title="MillsR , TyringSK , LevinMJ , ParrinoJ , LiX , CollKE , et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]">Mills 2010</a>; <a href="./references#CD008858-bbs2-0017" title="MurrayAV , ReisingerKS , KerznerB , StekJE , SausserTA , XuJ , et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines2011;7(11):1130-6. [DOI: 104161/hv.7.11.17982]">Murray 2011</a>; <a href="./references#CD008858-bbs2-0020" title="LevinMJ , OxmanMN , ZhangJH , JohnsonGR , StanleyH , HaywardAR , et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases2008;197:825-35. [DOI: 10.1086/528696]OxmanMN , LevinMJ , JohnsonGR , SchmaderKE , StrausSE , GelbLD , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine2005;352(22):2271-84. [PMID: 15930418]SchmaderKE , JohnsonGR , SaddierP , CiarleglioM , WangWWB , ZhangJH , et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of the American Geriatrics Society2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]SchmaderKE , OxmanMN , LevinMJ , JohnsonG , ZhangJH , BettsR , et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases2012;55(10):1320–8. [DOI: 10.1093/cid/cis638]SimberkoffMS , ArbeitRD , JohnsonGR , OxmanMN , BoardmanKD , WilliamsHM , et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine2010;152(9):545-54. [PMID: 20439572]WeinbergA , ZhangJH , OxmanMN , JohnsonGR , HaywardAR , CaufieldMJ , et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases2009;200(7):1068-77. [DOI: 10.1086/605611]">Oxman 2005</a>). </p> <p><b>High‐potency versus low‐potency zoster vaccine:</b> there were no differences between groups (<a href="./references#CD008858-bbs2-0023" title="TyringSK , Diaz-MitomaF , PadgetLG , NunezM , PolandG , CassidyWM , et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine2007;25(10):1877-83. [DOI: 10.1016/j.vaccine.2006.10.027]">Tyring 2007</a>). </p> <p><b>NBP608 LZV versus LZV:</b> there were no differences between groups (<a href="./references#CD008858-bbs2-0005" title="ChoiWS , ChoiJH , JungDS , ChoiHJ , KimYS , LeeJ , et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. Vaccine2019;37(27):3605–10. ">Choi 2019</a>). </p> <p><b>Refrigerated versus frozen zoster vaccine:</b> there were no differences between groups (<a href="./references#CD008858-bbs2-0008" title="GildermanLI , LawlessJF , NolenTM , SterlingT , RutledgeRZ , FernslerDA , et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]">Gilderman 2008</a>). </p> <p><b>LZV IM route versus LZV SC route:</b> there were no withdrawals due to adverse events in either group (<a href="./references#CD008858-bbs2-0007" title="Diez-DomingoJ , WeinkeT , Garcia de LomasJ , MeyerCU , BertrandI , EyminC , et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: a randomised non-inferiority clinical trial. Vaccine2015;33(6):789-95. [MEDLINE: 25555381]Diez-DomingoJ , WeinkeT , Kieninger-BaumD , EyminC , ThomasS , SadorgedC . A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine2013;4(Suppl):81–141. ">Diez‐Domingo 2015</a>). </p> <p><b>LZV intradermal route versus LZV SC route:</b> there were no significant differences between full‐dose intradermal versus full‐dose SC; 1/3 dose intradermal versus full‐dose SC; 1/10 dose intradermal versus full‐dose SC; 1/27 dose intradermal versus full‐dose SC; 1/3 dose intradermal versus 1/3 dose SC. There were no dropouts for full‐dose intradermal versus 1/3 dose SC; 1/10 dose intradermal versus 1/3 dose SC; and 1/27 dose intradermal versus 1/3 dose SC (<a href="./references#CD008858-bbs2-0001" title="BealsCR , RailkarRA , SchaefferAK , LevinY , KochbaE , MeyerBK , et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases2016;16(8):915-22. ">Beals 2016</a>). </p> <p><b>2 doses of a zoster vaccine versus a single dose and 2 doses given at different intervals:</b> there were no differences between groups for participant withdrawals due to adverse events (<a href="./references#CD008858-bbs2-0025" title="VesikariT , HardtR , RümkeHC , IcardiG , MonteroJ , ThomasS , et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines and Immunotherapeutics2013;9(4):1–7. ">Vesikari 2013</a>). </p> <p><b>LZV AMP versus LZV:</b> there were no differences between groups (<a href="./references#CD008858-bbs2-0019" title="NCT01505647. Safety and immunogenicity of zoster vaccine (ZOSTAVAX™) made with an alternative manufacturing process (AMP) (V211-042 AM1) [A phase III double-blinded, randomized, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)]. clinicaltrials.gov/ct2/show/study/NCT01505647 (first received 4 January 2012). ">NCT01505647</a>). </p> <p><b>LZV + IIV4 concomitant administration versus LZV + IIV4 sequential administration:</b> for this comparison there were no significant differences for dropouts between groups (<a href="./references#CD008858-bbs2-0013" title="LevinMJ , BuchwaldUK , GardnerJ , MartinJ , StekJE , BrownE , et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine2018;36(1):179-85. [DOI: 10.1016/j.vaccine.2017.08.029]">Levin 2018</a>) </p> <p>In all the comparisons of <a href="./references#CD008858-bbs2-0003" title="ChlibekR , BayasJM , CollinsH , PintaMLR , LedentE , JohannF , et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases2013;208:1953–61. ">Chlibek 2013</a>, there were no differences in dropouts between the groups. Similarly, in all the comparisons of <a href="./references#CD008858-bbs2-0004" title="ChlibekR , SmetanaJ , PauksensK , RomboL , Van den HoekJA , RichardusJH , et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine2014;32(15):1745-53. ">Chlibek 2014</a>, there were no differences in dropouts between the groups. </p> <p><b>RZV versus placebo:</b><a href="./references#CD008858-bbs2-0006" title="CunninghamAL , LalH , KovacM , ChlibekR , HwangSJ , Díez-DomingoJ , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine2016;375(11):1019-32. IkematsuH , YamashitaN , OgawaM , HiranoM , KovacM , WatanabeD . Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi2018;92(2):103-14. ">Cunningham 2016</a> and <a href="./references#CD008858-bbs2-0010" title="LalH , CunninghamAL , GodeauxO , ChlibekR , Diez-DomingoJ , HwangSJ , et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]">Lal 2015</a> described 4 reasons for dropout: did not receive vaccine according to protocol (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.1); received wrong vaccine (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.2); had diagnosis of HZ less than 30 days after dose 2 (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.3); and did not receive second dose (<a href="./references#CD008858-fig-0012" title="">Analysis 2.4</a>.4). There were no differences between groups for the first 2 outcomes. The third outcome had an RR of 0.32 (95% CI 0.14 to 0.71) but no RD. For the fourth outcome, the vaccine group had a higher dropout rate than the placebo group: RR 1.25, 95% CI 1.13 to 1.39; RD 0.01, 95% CI 0.01 to 0.01; NNTH 100, 95% 100.0 to 100.0. </p> <p><b>RZV IM route versus RZV SC route</b>: there was no difference in participant withdrawal between groups (<a href="./references#CD008858-bbs2-0026" title="VinkP , ShiramotoM , OgawaM , EdaM , DouhaM , HeinemanT . Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Human Vaccines and Immunotherapeutics2017;13(3):574-8. [DOI: 10.1080/21645515.2016.1232787]">Vink 2017</a>). </p> <p><b>RZV + TDaPV co‐administration group versus RZV + TDaPV not co‐administration group:</b> there was no difference in dropouts between groups (<a href="./references#CD008858-bbs2-0022" title="StrezovaA , LalH , EnweonyeI , CamporaL , BeukelaersP , SegallN , et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged &gt;50 years: a randomized trial [Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' herpes zoster subunit (HZ/su) vaccine (GSK1437173A) when co-administered with GSK Biologicals' diphtheria, tetanus and pertussis vaccine (Boostrix®) in adults aged 50 years and older]. Vaccine2019;37(39):5877–85. ">Strezova 2019</a>). </p> <p><b>Co‐administration RZV + IIV4 versus not co‐administration group RZV + IIV4:</b> there was no difference between groups for dropouts (<a href="./references#CD008858-bbs2-0021" title="SchwarzTF , AggarwalN , MoeckeschB , SchenkenbergerI , ClaeysC , DouhaM , et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older. Journal of Infectious Diseases2017;216(11):1352-61. [DOI: 10.1093/infdis/jix481]">Schwarz 2017</a>). </p> <p><b>PCV13 vaccine + RZV concomitant administration versus PCV 13 vaccine + RZV sequential administration:</b> there was no difference between groups for dropouts (<a href="./references#CD008858-bbs2-0016" title="MinJY , Mwakingwe-OmariA , RileyM , MoloLY , SoniJ , GirardG , et al. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. Journal of Infection2022;84:490-8. ">Min 2022</a>). </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>AE: adverse event or adverse experiences<br/>AMP: alternative manufacturing process<br/>AS01: liposome‐based adjuvant system containing the immunoenhancers 3‐O‐desacyl‐4′‐monophosphoryl lipid A (MPL) and the saponin QS‐21 (<i>Quillaja saponaria</i> Molina, fraction 21)<br/>Adjuvanted gE/AS01<sub>B</sub>: 50 μg purified gE with adjuvant B (1 mg dioleoyl phosphatidylcholine, 250 μg cholesterol, 50 μg MPL, and 50 μg QS‐21)<br/>Adjuvanted gE/AS01<sub>E</sub>: 50 μg purified gE with adjuvant E (500 μg dioleoyl phosphatidylcholine, 125 μg cholesterol, 25 μg MPL, and 25 μg QS‐21)<br/>AS01<sub>B</sub>: adjuvant B composed of 1 mg dioleoyl phosphatidylcholine, 250 μg cholesterol, 50 μg MPL, and 50 μg QS‐21<br/>AS01<sub>E</sub>: adjuvant E composed of 500 μg dioleoyl phosphatidylcholine, 125 μg cholesterol, 25 μg MPL, and 25 μg QS‐21<br/>Elderly or older adults: aged ≥ 60 years old<br/>Frozen: ‐15 °C or colder<br/>gE: recombinant subunit VZV composed of glycoprotein E<br/>gE/saline: unadjuvanted gE<br/>HZ: herpes zoster<br/>ID: identification<br/>IIV4: inactivated quadrivalent influenza vaccines<br/>IM: intramuscular<br/>LZV or ZV: live zoster vaccine (live attenuated Oka varicella zoster virus vaccine)<br/>MPL: immunoenhancer 3‐O‐desacyl‐4′‐monophosphoryl lipid A<br/>NBP608 LZV: live zoster vaccine (live attenuated Oka varicella zoster virus vaccine) with a minimum of 27,400 pfu (0,50 mL)<br/>NNTB: number needed to treat for an additional beneficial outcome<br/>NNTH: number needed to treat for an additional harmful outcome<br/>PCV13 vaccine: 13‐valent pneumococcal polysaccharide vaccine<br/>pneumo‐23 vaccine: 23–valent pneumococcal polysaccharide vaccine<br/>QS‐21: immunoenhancer saponin <i>Quillaja saponaria</i> Molina, fraction 21<br/>Refrigerated: 2 °C to 8 °C<br/>RR: risk ratio<br/>RZV: adjuvanted recombinant zoster vaccine (contains 50 µg of recombinant VZV glycoprotein E, and the liposome‐based AS01<sub>B</sub> adjuvant system contains 50 µg of 3‐O‐desacyl‐4′‐monophosphoryl lipid A (MPL) and 50 µg of <i>Quillaja saponaria</i> Molina, fraction 21 (QS21))<br/>SAEs: serious adverse events<br/>SC: subcutaneously or subcutaneous<br/>TDaPV: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine<br/>VZV: varicella zoster virus </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Dropouts</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/full#CD008858-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008858-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Live zoster vaccine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Cumulative incidence of herpes zoster <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 3.1 years follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 30 days of vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 42 days of vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 3.3 to 7.8 years after vaccination substudy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 Mean 5 years follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.92, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 1 or more serious adverse events regardless of type of storage of the vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.95, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Vaccine‐related serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.24, 4.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Hospitalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 Hospitalisation related to herpes zoster</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.25, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.6 1 or more adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.38, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.7 Vaccine‐related adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [1.21, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.8 Systemic adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.82, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.9 Vaccine‐related systemic adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.07, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.10 Systemic pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.12, 22.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.11 General malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.07, 15.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.12 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.15, 6.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.13 Varicella‐like rash not at injection site (day of vaccination to day 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.57, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.14 Rash unrelated to herpes zoster (day of vaccination to day 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.80, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.15 Injection site adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7040</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.73 [1.93, 7.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.16 Erythema inoculation site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.30 [2.66, 6.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.17 Pain inoculation site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.47 [2.67, 15.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.18 Pruritus inoculation site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.32 [1.49, 12.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.19 Swelling inoculation site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6879</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.84 [4.95, 6.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.20 Warmth inoculation site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6879</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.73 [2.57, 8.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.21 Rash inoculation site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [1.31, 8.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.22 Haematoma inoculation site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.76, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.23 Mass inoculation or induration site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.05 [1.91, 26.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.24 Varicella‐like rash at injection site (day of vaccination to day 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [1.21, 6.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.25 Vaccine‐unrelated adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.26 Herpes zoster‐like rash (day of vaccination to day 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.27, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Duration in days of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 Haematoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 For any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Discontinued due to vaccine‐related adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.05 [0.25, 103.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Clinical adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.72, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Physician decision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 Withdrew consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50814</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.54, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.6 Lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.96, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.7 Protocol deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.27, 8.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Participants with no follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.41, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Live zoster vaccine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008858-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Recombinant zoster vaccine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Cumulative incidence of herpes zoster at least 3.2 years follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.03, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Incidence of herpes zoster at least 4 years follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.35 [2.68, 4.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Death within 30 days after vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.42, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.91, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 Serious adverse events within 30 days after vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.67, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.5 Serious adverse events within 30 days after vaccination related to vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.6 Any symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [2.02, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.7 Grade 3 any symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.29 [4.48, 6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.8 Grade 3 any symptom related to vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.37 [6.69, 10.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.9 Any systemic symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [2.12, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.10 Grade 3 any systemic adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.29 [3.01, 6.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.11 Potential immune‐mediated disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.71, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.12 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.82 [3.52, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.13 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [1.99, 3.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.14 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [2.26, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.15 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.45 [4.61, 9.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.16 Shivering</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.35 [3.26, 5.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.17 Gastrointestinal symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.21, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.18 Any local symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.89 [6.37, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.19 Grade 3 any local symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.69 [2.87, 56.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.20 Local redness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.93 [22.62, 37.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.21 Local pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.14 [6.58, 7.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.22 Local swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.26 [15.91, 50.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.23 Unsolicited report of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [1.00, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.24 Grade 3 unsolicited report of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.12, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Did not receive vaccine according to protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.38, 3.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Received wrong vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.81, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Diagnosis of herpes zoster &lt; 30 days after dose 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.14, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.4 Did not receive second dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.13, 1.39]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Recombinant zoster vaccine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008858.pub5/references#CD008858-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008858.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008858-note-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008858-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008858-note-0023">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008858-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008858-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD008858-note-0022">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008858-note-0014">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008858-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008858-note-0024">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD008858-note-0013">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD008858-note-0012">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD008858-note-0021">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008858-note-0019">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008858-note-0020">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008858\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008858\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008858\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008858\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008858\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008858.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008858.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008858.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008858.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008858.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715410233"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008858.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715410237"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008858.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8667fee89374',t:'MTc0MDcxNTQxMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 